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ABSTRACT
 The elderly are at increased risk for developing psychiatric 
diseases, which include Alzheimer’s disease, depression, anxiety and 
suicide. The probability of multiple disease comorbidity is also 
increased in the elderly. At the cellular level, the loss of protein 
homeostasis is often at the root of disease emergence, and thus the 
scientific community is searching for ways to help maintain this 
balance. A vast group of proteins that are paramount to balancing and 
counterbalancing protein levels is the molecular chaperone protein 
group, which has evolved a tremendous variety of functions in the cell. 
They aid in protein trafficking, folding, receptor signaling, 
neurotransmission, vesicle forming and fusion, protein degradation, 
and apoptosis, among other activities. Despite their best efforts, 
disease still ensues, but because of their vast number and multiple 
abilities, it may be possible to modulate these proteins as a way to 
treat and prevent disease. Chaperones are of particular interest in 
diseases of aging, because chaperone induction and effectiveness is 
reduced with age. In addition, many diseases of the elderly are 
xi
brought on by aberrant protein accumulation, like Alzheimer’s disease. 
As a result, the hypothesis of this dissertation is whether the 
modulation of molecular chaperones changes disease pathology. A 
molecular chaperone family that is important to protein degradation is 
the Hsp70 chaperone complex. Hsp70 proteins have specialized 
function depending on cell type and cellular compartment, but Hsp70 
proteins are very important for protein synthesis and degradation. As a 
result, they are in a position to contribute to the regulation of proteins 
that become aberrant. 
In recent years scientific literature has indicated that compounds 
that inhibit the enzymatic ATP hydrolysis of these proteins promote tau 
degradation, which accumulates in Alzheimer’s disease. Alzheimer's 
disease is the sixth leading cause of death in the U.S., it is a 
progressive neurodegenerative disease, and is caused by the aberrant 
accumulation of the amyloid beta and tau proteins. Here, we show that 
treatment with the Hsp70 inhibitor methylene blue, reduces tau, saves 
neurons, and restores cognition, in a mouse model of tau accumulation 
(rTg4510). Cognitive rescue occurred despite a severe tangle load, 
equal to control treated tau transgenic mice. This study shows that 
reducing soluble tau can restore cognition, reducing tangles is not 
necessarily to ameliorate cognition, and saving neurons is not 
xii
sufficient to increase cognition if they are burdened with soluble tau. 
This work shows that methylene blue does not affect the the number 
of tau tangles in this model, as suggested by in vitro data. It also 
suggests that further work into the development of Hsp70 ATPase 
inhibitors may find success in alleviating the soluble tau burden found 
in Alzheimer’s disease. 
 The co-chaperone FKBP5 is also of extreme importance, 
not because it is essential, but because research has implicated this 
protein with a host of psychiatric diseases. Single nucleotide 
polymorphisms in this gene, which increase the levels of FKBP5, 
interact with averse traumatic events to enhance the likelihood of 
developing mood and anxiety disorders, including major depressive 
disorder, post-traumatic stress disorder, bipolar disorder, and suicide. 
Moreover, we have found that FKBP5 protein levels increase with age 
in the human brain, increasing the risk for the elderly of developing 
disease if exposed to traumatic stress. Here, we tested the hypothesis 
that FKBP5 negatively regulates resilient behavior. We found that 
FKBP5 levels increase with age in the wild type mouse brain, and that 
wild type mice display reduced resiliency with age. FKBP5-/- mice, on 
the other hand, show enhanced resiliency to stress at all ages tested, 
and are protected from aging-induced despair. At the molecular level, 
xiii
FKBP5 is a robust inhibitor of the glucocorticoid receptor, which is 
responsible for the shut-off of the hypothalamic-pituitary-adrenal axis. 
In addition, excess glucocorticoid levels in the blood is a robust marker 
of psychiatric disease. Consequently, FKBP5 may be causing disease 
through enhanced levels of glucocorticoids. FKBP5-/- mice display 
reduced corticosterone after stress. Moreover, corticosterone 
production increases with age, and FKBP5-/- mice are protected from 
this increase. These studies are the first to show that reducing the 
levels of FKBP5 is a promising therapeutic option for the treatment of 
mood disorders in the elderly, resiliency naturally declines with age 
due to FKBP5, corticosterone levels after stress rise due to FKBP5, and 
that the ablation of this gene increases resiliency and prevents aging-
induced despair. 
As a whole, these data show that the modulation of chaperone 
proteins has the potential for developing new therapies for the 
treatment of psychiatric diseases of the elderly.
xiv
CHAPTER ONE:
Introduction
 The explosion in medical research, discovery, and access to 
medicine that occurred in the 20th century, dramatically increased the 
lifespan of people all over the world. There was considerable growth in 
the number of individuals reaching the age of 65 in the United States, 
from 4.1% in 1900 to 12.4% in 2000 (Daccache et al., 2011). 
Notwithstanding this increase of life expectancy, aging increases 
susceptibility to psychiatric diseases (Sibille, 2013). And in spite of the 
growing accumulation of medical knowledge, relatively minuscule 
advancement has occurred in the development of hypothesis-driven 
therapeutic approaches. As a result of this, this dissertation is focused 
on the testing of hypotheses aimed at discovering novel methods to 
treat psychiatric disorders that affect the elderly. 
1
Alzheimer’s Disease
 Alzheimer’s as a psychiatric disease
 Alzheimer’s disease (AD), is traditionally considered a 
neurological disorder. However, it is also officially sanctioned as a 
psychiatric disorder in the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV-TR). From the perspective of the mind, AD is 
characterized by the loss of learning and episodic memory (Citron, 
2010), personality changes (Robins Wahlin and Byrne, 2011), and the 
loss of general cognitive and intellectual ability. Often, the loss of 
motivation, anhedonia, and the overlap of symptoms with depression 
can lead to a misdiagnosis(Landes et al., 2001; Landes et al., 2005). 
In the later stages AD can produce aphasia (Weintraub et al., 2012), 
and complete loss of the performance of basic human activities, like 
eating, dressing, bathing, and even going to the bathroom (Desai and 
Grossberg, 2001). As of the date of this writing, AD can only be 
medically diagnosed postmortem, by the paired presence of amyloid 
beta plaques and neurofibrillary tangles in the brain (Ittner and Gotz, 
2011). AD was first recognized by Alois Alzheimer in 1907, and has 
been researched ever since, marking this year as the 105th year since 
its discovery (Hippius and Neundorfer, 2003). Notwithstanding, there is 
currently no cure, preventative method, or disease-modulating agent. 
2
 What should we target?
 There is some debate in the AD field as to what biological target 
will yield a cure. As a whole, the answer to the question “what should 
we target” is “everything.” We need to target all the different problems 
in AD, like amyloid beta, tau, inflammation, blood brain barrier 
deterioration, etc. Each one is likely to contribute to the extension of 
life of the patient. Here, however, we have taken the route of exploring 
the therapeutic options to reduce the tau burden.
 Historically there has been an overrepresentation in the scientific 
community of scientists and clinical trials that searched for therapeutic 
avenues that reduce amyloid beta (Lee et al., 2007). This was due to 
the strong evidence that amyloid beta is the initiator of the AD 
cascade, including mutations that cause early onset (St George-Hyslop 
et al., 1987), and, recently, the discovery of SNPs in the APP gene that 
protect against Alzheimer’s (Jonsson et al., 2012). However, key 
discoveries have shown that tau is of equal importance in AD research. 
 Mutations have been found in the tau gene that are responsible 
for causing frontotemporal dementia with Parkinsonism linked to 
chromosome 17. These mutations produce neurodegeneration and 
neurofibrillary tangles that are very similar to those in AD. Thus, the 
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logical conjecture arose that tau, like in FTDP-17, may be capable of 
producing neurodegeneration in AD. Mice transgenic for the human 
APP gene do not develop tau tangles, but displayed robust cognitive 
deficits (Spires and Hyman, 2005). The role of tau in AD was 
subsequently diminished, as it was presumed that tau was not playing 
as much of a role. A study from Lennart Mucke’s lab, on the other 
hand, showed that when the tau gene is knocked out in mice 
transgenic for the human APP gene, cognition is improved dramatically 
(Roberson et al., 2007). The improvement of these mice ensued, 
despite robust amyloid beta pathology. Additionally, evidence from the 
human brain also shows that amyloid beta pathology is not the sole 
source of AD, since there are people with a heavy amyloid burden in 
the brain who do not develop AD (Crystal et al., 1988). 
 What kind of tau should we target?
 In healthy individuals, the microtubule associated protein tau, 
referred to herein as tau, is responsible for stabilizing microtubules, 
which allow for the transport of materials throughout the cell (Brunden 
et al., 2009). Tau, though, is the main component of the neurofibrillary 
tangles found in AD (Brunden et al., 2009). Tau tangles are also called 
tombstone tangles, since they are so insoluble they are often found at 
the place of death of neurons. Because of this, the hypothesis was 
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formed that the formation of tau tangles is toxic for neurons and 
causes them to die. The current scientific thought about tau, though, is 
shifting due to research in the last decade that suggests otherwise.
 In the publication describing the making of the rTg4510 tau 
transgenic mouse, the authors utilized the model to test if suppression 
of tau transgene expression would suppress tau pathology, memory 
loss, and neuron loss (Santacruz et al., 2005). Tau transgene 
suppression, via doxycycline, alleviated memory and neuron loss, but 
neurofibrillary tangles continued to form. Thus, separating tau tangle 
pathology from memory and neuron loss. This was the first indication 
that excess soluble tau may be the culprit of acute, deadly 
neurotoxicity, and not the tau tangles themselves. It also showed that 
a reduction in soluble tau can be therapeutic, despite the increased 
presence of tau tangles. Previous to this study it was thought that 
without a reduction in tangle pathology, cognitive improvement was 
not possible.
 The work of Bradley Hyman shows that the emergence of tangles 
in the rTg4510 mice does not cause the cell to die acutely, as they can 
monitor the same neuron for up to 5 days (de Calignon et al., 2010). 
Further examination of tangle bearing neurons in the cortex of 7-8 
5
month old rTg4510 mice showed intact nuclei. Additionally, histological 
sections of mice with six weeks of suppressed tau transgene 
expression shows a large number of tangles, suggesting that tau 
tangles are long lived and relatively stable. These data suggest that 
tau tangles are not responsible for acute neuronal death experienced 
in AD, and that tau neurofibrillary tangles are an atypical or later-stage 
cause of neuron loss. Neurofibrillary tangles correlate with neuronal 
death, but fall short in number to account for the size of the neuron 
loss experienced (Gomez-Isla et al., 1997). In support of this notion 
that soluble tau is the most toxic tau to neurons it was found that mice 
overexpressing human wild type tau develop memory deficits, despite 
the absence of neurofibrillary tangle formation in this model. 
 These data, as a whole, indicate that the depletion of soluble tau 
could be a successful therapeutic strategy in the treatment of AD. Tau 
knockout animals are also functionally intact (Ke et al., 2012), 
although they do develop motor deficits with age. This may be due to 
changes in development, since the gene is absent at this critical 
period. The development and testing of conditional tau knockout mice 
has yet to be determined. However, considering the vast majority of 
AD patients are older than 65 it is not unreasonable to think that a 
tau-reducing therapy may be suitable for the treatment of AD. 
6
 How should we target soluble tau?
 One possibility for tau reduction is the modulation of the 
degradation of the tau protein (Jinwal et al., 2009; Abisambra et al., 
2010; Jinwal et al., 2010). Molecular chaperones offer this possibility 
because they are responsible, among other things, for the proper 
degradation of proteins through many of the cells degratory pathways, 
including proteasomal and autophagic protein degradation.
Molecular Chaperones 
 What are molecular chaperones?
 Molecular chaperones are a family of proteins that are dedicated 
to maintaining the proper function of proteins in the intercellular milieu 
(Muchowski and Wacker, 2005). They assist in de novo protein folding, 
and in protein refolding after a cellular stressor has caused protein 
misfolding to occur (e.g. heat shock) (Barral et al., 2004). Apart from 
protein folding, molecular chaperones are also necessary in protein 
transport, targeting, degradation, signal transduction, apoptosis, and 
vesicle fusion, among other things (Muchowski and Wacker, 2005).
 
 During a cellular stress event all the major families of heat shock 
proteins get transcribed, including Hsp90, Hsp70, Hsp60, Hsp40, and 
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Hsp20 families (Lindquist, 1986). However, chaperone proteins cannot 
always fix the misfolded protein. As a result, the cell has evolved 
chaperone-mediated targeting of proteins to the degratory pathways. 
This occurs through the coordinated crosstalk between Hsp70, Hsp90 
and representative proteins of the different degradation pathways, like 
E3 ubiquitin ligases, and lysosome-associated membrane proteins 
(Ballinger et al., 1999; Massey et al., 2006). 
 
 Protein misfolding occurs despite chaperones
 It is thought that the induction and function of molecular 
chaperones decrease with age (Muchowski, 2002; Soti and Csermely, 
2002). Moreover, loss of Hsp70 chaperone function, via the 
overexpression of a dominant negative form, has been shown to 
produce neurodegeneration in a fruit fly. In addition, there is a 
reduction in autophagy and proteasomal degradation with age. 
Accordingly, there may be a reduction in the ability of neurons to 
handle cellular stressors that require the protein activity of molecular 
chaperones. This would lead one to the hypothesis that increasing the 
activity of chaperones would reduce the aggregation of proteins, and 
the subsequent neurodegeneration this produces, at least for tau. 
 
8
 Molecular chaperone levels or activity?
 Despite the fact that chaperones decrease with age, research 
has shown that chaperone stimulation is not always effective in the 
management of aberrant tau accumulation (Jinwal et al., 2009). In 
2009, the use of a high throughput screening system identified 
chemical compounds that modulate the ATPase activity of Hsp70. 
Oppositely of what the literature was suggesting, Hsp70 ATPase 
activating compounds promoted tau accumulation, and Hsp70 ATPase 
inhibiting compounds promoted tau degradation in cell models of 
tauopathy (Jinwal et al., 2009). 
 The co-chaperone CHIP, C-terminus of Hsc70 interacting protein, 
is an E3 ligase that works with Hsp70 and Hsp90 to promote tau 
degradation. CHIP reduces the ATPase activity of Hsp70, and helps 
ubiquitinate misfolded proteins that are beyond the repair that 
chaperones can provide (Xu et al., 2002). Congruent with the idea that 
chaperones help misfolded proteins, CHIP levels are reduced in the 
rTg4510 tau mouse model (Dickey et al., 2009). Moreover, knockout of 
CHIP exacerbates tau accumulation (Dickey et al., 2006). However, 
overexpression of CHIP enhances folding activity, not degratory 
activity of Hsp70. On the other hand, Hsp72 overexpression was found 
9
to reduce the levels of tau in a cell model (Jinwal et al., 2013), and a 
mouse model (Petrucelli et al., 2004). 
 These studies demonstrate that all chaperones are not made 
equal, and the exact circumstance that may lead to tau degradation 
has to be worked out.
FKBP5 and Psychiatric Diseases
 Mood and anxiety disorders in the elderly
 The percentage of people with major depressive disorder and 
other mood disorders does not increase with age. In fact, 
approximately 1% of older adults meet the DSM-IV criteria for major 
depression (Weissman et al., 1988). This is substantially lower than in 
younger individuals. Generally, mood and anxiety disorders tend to 
decrease with age, despite the brain having less regenerative power, 
and a general decline in health (Byers et al., 2010). Nonetheless, 
15-25% of the elderly population experience depressive symptoms 
that interfere with their quality of life (Koenig and Blazer, 1992). 
Depression is the most common disease in the elderly, according to 
the American Psychiatric Association. This phenomenon can also be 
attributed to different factors, like the cohort effect, survivor bias, 
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sampling methods, and epidemiological and diagnostic issues in the 
proper diagnosis of disease in the elderly (Byers et al., 2010). There is 
also a tendency to underreport mood and anxiety disorders in the 
elderly (Wiener et al., 1997). This is evident in the suicide statistics; 
suicide rates increase steadily and culminates in old age . The general 
decline of the body with age gives these individuals reduced ability to 
recover if extreme trauma is experienced; 71-97% of older adult 
suicide victims suffer from a psychiatric illness. In terms of population 
growth, the giant baby boomer generation is quickly coming to a head, 
as they are beginning to age past 65 years, a critical barrier for the 
onset of age-related disorders. And although the percentage of ill 
individuals may drop with age, the number of people with psychiatric 
disorders aged 65 and older is only going to increase. 
 FKBP5
 FKBP5 is a co-chaperone of the Hsp90 chaperone complex. The 
Hsp90 machinery is part of all hormone receptors, including androgen, 
estrogen, mineralocorticoid, and glucocorticoid receptor (GR). The 
glucocorticoid receptor is of great importance because glucocorticoid 
resistance is one of the most commonly observed irregularities in 
mood disorders (Pariante and Miller, 2001). FKBP5 is a potent inhibitor 
of GR, and is the cause of a naturally existing form of glucocorticoid 
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receptor insensitivity in several species of new world monkeys 
(Reynolds et al., 1999; Denny et al., 2000; Scammell et al., 2001; 
Wochnik et al., 2005; Westberry et al., 2006). In addition, there are 
single nucleotide polymorphisms in the GR gene, NR3C1, that are 
associated with major depression (van Rossum et al., 2006). 
 
 Discovery of SNPs in the FKBP5 gene
 GR activity in the hypothalamus and pituitary is responsible for 
the inhibition of the hypothalamic-pituitary-adrenal (HPA) axis that 
produces glucocorticoids in response to a stressor (de Kloet et al., 
2005), creat ing a negat ive feedback loop. S ince basa l 
hypercortisolemia is common in depression, Binder et al., 2004, 
hypothesized that genes that regulate the HPA axis, especially those 
modulating GR sensitivity, could contribute to the susceptibility of 
developing depression. They performed a search for SNPs in the 
NR3C1, BAG1, STUB1, TEBP, FKBP4, FKBP5, CRH, and AVP genes, and 
found that although none of the SNPs were statistically significant, 
they found that FKBP5 SNPs significantly associated with a faster 
response to antidepressant treatment. In particular, they looked at the 
SNP rs1360780. They genotyped depressed patients at this location in 
the FKBP5 gene and found an overrepresentation of the TT genotype, 
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which corresponds to people that inherited a thymidine at this location 
from both parents, hence “TT.” Although a quicker response to an 
antidepressant treatment is definitely a positive phenotype, these 
patients also develop a staggering number of depressive episodes 
throughout their life, as compared to other depressed individuals that 
have the CT or CC genotypes. The TT individuals also produce excess 
FKBP5. 
 After this initial discovery other studies began to emerge looking 
at SNPs in the FKBP5 gene, and several more have been discovered 
and found to be overrepresented in people who experience trauma and 
develop major depressive disorder (Zimmermann et al., 2011), post-
traumatic stress disorder (Binder et al., 2008), commit suicide (Roy et 
al., 2010; Roy et al., 2012), display aggressive behavior (Bevilacqua et 
al., 2012), and develop bipolar disorder (Willour et al., 2009). 
 Interestingly, the experience of trauma is highly important for 
the development of psychiatric disease, as the majority of these 
require it for the associations with the SNPs to be significant, as was 
the case for depression. In fact, the mechanism for this has recently 
been found (Klengel et al., 2012).
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 Gene x environment in FKBP5
 Gene times environment is the emergence of a phenotype based 
on the combination of a predisposing genotype in an environment that 
allows the phenotype to express (Meaney, 2010). SNPs that promote 
smoking behavior, for example, require an environment where an 
introduction to smoking is possible (Duncan and Keller, 2011). Due to 
the ability of this interaction to apply a context to the otherwise 
isolated genome, and its ability to explain natural phenomena, this 
approach to research has become very popular in the last decade. This 
applies to FKBP5 and GR, since they are stress reactive proteins. As a 
result, the combination of stressful environments and genetics may 
help explain why the same stressor produces disease in some but not 
others. 
 Gene x environment works with FKBP5 and GR in the following 
way. GR produces its effects by the combination of the transactivation 
and transrepression of ~100 genes (de Kloet et al., 2005). One of the 
genes that is transactivated is FKBP5 (Scharf et al., 2011). FKBP5 
contains several hormone responsive element sequences, which allow 
it to be activated by hormone receptor complexes, including the 
progesterone and androgen receptor, in addition to GR (Barik, 2006). 
As a result, GR activity has a built-in attenuation. In this way, FKBP5 
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serves as a GR activity rheostat. People who hare homozygous for the 
T allele of the FKBP5 SNP rs1360780, display greater FKBP5 
expression (Binder et al., 2004). This single nucleotide change 
increases the binding between the RNA polymerase II and the TATA 
box, yielding higher FKBP5 transcription (Klengel et al., 2012). FKBP5 
levels are further increased by stress. This increased level of FKBP5 
protein allows for the increased production of glucocorticoids after 
stress. However, glucocorticoids promote the demethylation of genes, 
one of which is FKBP5. This, in turn, is a positive feedback loop that 
begins with an SNP, which is small, and in combination with extended 
traumatic stress starts a snowball effect that results in a epigenetic 
change in the FKBP5 gene that may be permanent. 
 Why is FKBP5 relevant to aging
 The risk that FKBP5 poses is even greater with age, because the 
basal expression levels of FKBP5 increase in the human brain with age 
(Blair et al., In Press). In fact, they increase age-dependently due to 
the natural demethylation of the FKBP5 gene (Figure 1.2). As a result 
of this, elderly people in general, even those without predisposing 
SNPs, may be at greater risk for developing disease if they are 
exposed to environments that are extremely traumatic. Elderly 
individuals who are carriers of the risk alleles are at even greater risk 
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of developing disease from traumatic stress. As a result, it is 
extremely important to better understand the role of FKBP5 in the 
development of mood and anxiety disorders.
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CHAPTER TWO1:
Phenothiazine-Mediated Rescue of Cognition in Tau Transgenic 
Mice Requires Neuroprotection and Reduced Soluble Tau 
Burden
Abstract
 Background
 It has traditionally been thought that the pathological 
accumulation of tau in Alzheimer's disease and other tauopathies 
facilitates neurodegeneration, which in turn leads to cognitive 
impairment. However, recent evidence suggests that tau tangles are 
not the entity responsible for memory loss, rather it is an intermediate 
tau species that disrupts neuronal function. Thus, efforts to discover 
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 1This work was previously published in the journal Molecular 
Neurodegeneration (O'Leary III, John C., et al. "Phenothiazine-
mediated rescue of cognition in tau transgenic mice requires 
neuroprotection and reduced soluble tau burden." Molecular 
neurodegeneration 5.1 (2010): 1-11), and is used here with 
permission of the publisher. The permissions are available in Appendix 
F.
therapeutics for tauopathies emphasize soluble tau reductions as well 
as neuroprotection.
 Results
 Here, we found that neuroprotection alone caused by methylene 
blue (MB), the parent compound of the anti-tau phenothiaziazine drug, 
Rember™, was insufficient to rescue cognition in a mouse model of the 
human tauopathy, progressive supranuclear palsy (PSP) and fronto-
temporal dementia with parkinsonism linked to chromosome 17 
(FTDP17): Only when levels of soluble tau protein were concomitantly 
reduced by a very high concentration of MB, was cognitive 
improvement observed. Thus, neurodegeneration can be decoupled 
from tau accumulation, but phenotypic improvement is only possible 
when soluble tau levels are also reduced.
 
 Conclusions
 Neuroprotection alone is not sufficient to rescue tau-induced 
memory loss in a transgenic mouse model. Development of 
neuroprotective agents is an area of intense investigation in the 
tauopathy drug discovery field. This may ultimately be an unsuccessful 
approach if soluble toxic tau intermediates are not also reduced. Thus, 
MB and related compounds, despite their pleiotropic nature, may be 
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the proverbial "magic bullet" because they not only are 
neuroprotective, but are also able to facilitate soluble tau clearance. 
Moreover, this shows that neuroprotection is possible without reducing 
tau levels. This indicates that there is a definitive molecular link 
between tau and cell death cascades that can be disrupted.
Introduction
 The current clinically available options for treating Alzheimer’s 
disease (AD) are limited to acetylcholinesterase inhibitors and NMDA 
receptor antagonists (Doody, 1999; Reisberg et al., 2003). For 
tauopathies like PSP and FTDP17, treatment is restricted to supportive 
therapies. Thus the demand to identify compounds that can remove 
the microtubule associated protein tau is extremely high.
 Modifying tau pathophysiology has been the primary goal of 
first-generation tau therapeutics. For example, kinase inhibitors 
(Mazanetz and Fischer, 2007), microtubule stabilizers (Zhang et al., 
2005), tau aggregation inhibitors , immunotherapy (Sigurdsson, 
2009), and chaperone-based drugs targeting disease-specific tau 
species (Dickey et al., 2007), have all been proposed based largely on 
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in vitro data. However, their efficacy for ameliorating cognitive deficits 
in mouse models of tauopathy have not been tested, primarily due to 
the fact that few models of tau accumulation are available that develop 
memory loss. One of the more controversial tau modifying compounds, 
to recently emerge as a potentially clinically relevant drug, is the 
phenothiazine methylthionium chloride better known as methylene 
blue (MB). MB is best known for its function in the laboratory as a 
redox indicator and as an antiseptic (Oz et al., 2009); however, it, 
along with other phenothiazine derivatives, have been used 
extensively in the clinic since the 1950’s to treat a number of different 
conditions, including schizophrenia, mania, anxiety, emesis, cancer, 
high blood pressure, allergies and even parasitic infections (Mosnaim 
et al., 2006). These compounds are generally well tolerated and have 
minimal side effects, including discoloration of urine and ocular 
vitreous. 
 More recently MB has been shown to inhibit the aggregation 
propensity of proteins that can adopt a ß-sheet conformation in vitro 
(Medina et al.; Taniguchi et al., 2005; Necula et al., 2007), and it was 
this property that critically linked MB to AD as a possible plaque or 
tangle buster. However, the propensity of the phenothiazines to 
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liberally bind to proteins and donate electrons has resulted in a 
number of other mechanisms being ascribed to them. For example, MB 
can regulate mitochondrial function (Hassan and Fridovich, 1979; 
Visarius et al., 1997) and inhibit Hsp70 ATPase activity (Deiana et al., 
2009; Jinwal et al., 2009). Interestingly, these pleiotropic mechanisms 
and clinical applications combined with its relatively innocuous side 
effects and high bioavailability are what make the phenothiazines such 
an interesting therapeutic option for tauopathies. Most of the outcomes 
ascribed to MB could converge to ameliorate symptoms associated 
with tau accumulation. Here, we sought to determine whether MB 
could potentially be beneficial as a therapeutic option for tauopathies, 
based on its pleiotropic anti-tau efficacy, we investigated how its 
chronic administration might impact the rTg4510 tau transgenic mice. 
We show that MB is capable of protecting neurons, however, only high 
dose MB treatment was able to reduce tau and also improve cognition. 
However, pathology was unaffected. This shows that MB does not 
reduce tau pathology, but reduces soluble tau levels. Also, it shows 
that neuroprotection alone is not sufficient to improve behavior, but 
only when MB levels are sufficiently high to reduce soluble tau levels 
can memory be improved.
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Materials & Methods 
 Mice
  The rTg4510 mice and parental mutant tau and tTA lines were 
generated and maintained for this study as previously described 
(Santacruz et al., 2005).
 Central administration
 A concentration of 1 mM MB in saline was infused by pump into 
the CA3 of the right hippocampus of rTg4510 mice. Alzet pumps 
(Model 1004, 100µL, 0.11 µl/hr; Alzet Osmotic Pumps) were filled with 
100 µl of 1 mM MB or with saline 0.9% . The pumps were incubated in 
0.9% saline at 37°C for 48 hr. Mice were operated in a stereotaxic 
apparatus (51725D, Stoelting, Wood Dale, IL). A mid-sagittal incision 
was made to expose the cranium and a small aperture was drilled with 
a dental tool over the right hippocampus to the following coordinates 
from bregma: anterior-posterior, -2.7 mm; lateral, -2.5 mm. The 
osmotic pump was inserted into a subcutaneous pocket on the back of 
the mouse, leading the catheter to the site of cannula (Brain infusion 
kit 3, Alzet) placement. The cannula, with a thin layer of cyanoacrylate 
(Loctite 454, Alzet), was attached to the stereotaxic cannula holder 
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(Cannula holder 51636, Stoelting) and then lowered 3 mm ventral 
through the midline aperture. The incision was cleaned with saline and 
closed with surgical sutures. After surgery, the mice were housed 
individually. Infusion lasted for 28 days. Six mice were administered 
with MB and 7 with Saline. The mice were 7 months old at the time of 
surgery and they were 7 months and three weeks old at the time of 
water maze testing. 
 Peripheral administration 
 Ten age and gender-matched rTg4510 mice and ten wild type 
littermates were administered MB (Sigma) and saccharine (Acros 
Organics, Geel, Belgium) in their drinking water, while another ten 
rTg4510 mice and ten wild type littermates received drinking water 
with saccharine only. A treatment of 650 mg/day in a 70 kg human 
equates to 9.3 mg/kg/day. Based on a 4.5 ml of water/day rate of 
consumption of a 30 g mouse, ad libitum, we estimated mice to 
receive 9.3 mg/kg/day (0.062 mg/ml). MB or vehicle administration 
was initiated in 12 week-old rTg4510 and wild type mice using drinking 
water supplemented with 2mM saccharine. Treatment was maintained 
for four months and the supplemented water was replaced three times 
per week. Mice were 6 months old at the time of initial behavioral 
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assessment and they were 6.5 months old at the time of the water 
maze analysis. During the course of the study one mouse died of 
unknown circumstances and drug, tau levels and stereological 
analyses were not able to measured. 
 Determination of methylene blue concentrations in the 
cerebellum
 Frozen brain tissue was thawed on ice and homogenized for 2 
minutes at a concentration of 100 mg/ml in homogenizing solution 
(ACN:PBS = 9:1). A 30 µL aliquot of the brain homogenate was added 
to a 1.5 mL polypropylene microcentrifuge tube and spiked with 30 µL 
of the internal standard solution (Methylene Violet 3RAX, 250 ng/ml). 
Analytical grade acetonitrile was then added (90 µL) and the sample 
was vortexed again for 30 s. Following high speed centrifugation at 
13,200 rpm for 10 minutes at 4°C, the supernatant was transferred to 
a glass vial and subjected to LC-MS analysis. The LC-MS system used 
for these studies was a Shimadzu (Columbia, MD) series 2010EV 
instrument equipped with an APCI probe to minimize ion suppression. 
Quantification was performed using LCMSolution Version 2.05 and a 
set of external standards.
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 Open field 
 The open field is used as a standard test of general activity. 
Animals are monitored for 15 minutes in a 40 cm square open field 
with a video tracking software (ANY-Maze, Stoelting, Illinois), under 
moderate lighting. General activity levels were evaluated by 
measurements of horizontal and vertical activity.
 Rotorod test
  This test was performed on an accelerating rotorod apparatus 
(Ugo Basile, Italy) with a 3cm diameter rod starting at an initial 
rotation of 4 RPM accelerating to 40 RPM over 5 minutes. Mice were 
tested for the time spent on the rod during each of four trials with a 
thirty-minute inter-trial interval. Each trial was completed when the 
mouse fell off the rod (distance of 12 cm) onto a spring-cushioned 
lever.
 Elevated plus maze. 
 Anxiety can be assessed through the elevated plus maze 
(EPM).The EPM consists of two well-lit open arms (35 cm) facing each 
other and two enclosed arms (30.5 cm) also facing each other. Each 
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arm is attached to a common center platform (4.5 cm square) and 
elevated 40 cm off the floor. The mouse is placed in the center 
platform and allowed to explore for 5 min. Video tracking software 
measures movement in each section (ANY-Maze, Stoelting, Illinois).
MWM. A circular pool (1.38-m diameter) filled with opaque water at 
room temperature with an escape platform (15 cm x 15 cm) hidden 
beneath the water level (3 cm) was used. Each mouse was given four 
trials per day with an intertribal interval of 1 hour for 6 consecutive 
days. The time to find the platform (escape latency), the total distance 
traveled and the swim speed of the animals was recorded. Each animal 
was given a maximum of 60 seconds to find the platform. During 
training, if the mice failed to find the platform after 60 seconds, they 
were placed on the platform for 30 seconds. They were then towel-
dried and placed in a cage with a heating pad underneath until dry and 
returned to their home cage. On day 7 the mice were subject to one 
probe trial in which the platform was removed and each animal had 60 
seconds to search the training pool for the platform.
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 Brain tissue fractionation and western blot analysis
 Brain tissue was homogenized as previously described (Dickey et 
al., 2006). Measurements of tau levels were performed by western blot 
analysis.
 Immunohistochemistry 
 Fixed mouse brains were cryoprotected in successive 24 hours 
incubations of 10%, 20%, and 30% solutions of sucrose and then 
sectioned as previously described [Gordon, 2002]. Stained sections 
were imaged using an Olympus BX51 microscope at original 40x, 
100x, or 200x final magnification. For quantification, images (original 
100x magnification) of cornu ammonis (CA)1, CA3, entorhinal cortex, 
cortex and dentate gyrus were taken using spatial orientation cues. 
Quantification of positive staining product was determined using 
Image-Pro Plus (Media Cybernetics, Silver Springs, MD). Nissl staining 
was done in 0.05% cresyl violet for 5 minutes followed by 
differentiation in acidic water until desired color. Tissue was 
dehydrated through a graded series of ethanol (75%, 95% and 
100%). Slides were cleared in Histoclear (xylene substitute) and cover 
slipped with DPX. Silver stain was performed as previously described 
(Lewis et al., 2000).
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 Stereological analysis 
 Neurons that were stained with cresyl violet were counted in the 
the cornu ammonis 1 (CA1), the cornu ammonis 2 and 3 (CA2+3), the 
dentate gyrus (DG), the cerebral cortex (CX) and the striatum (STR) 
using the optical fractionator method of stereological counting (West et 
al., 1991) with commercially available stereological software 
(StereoInvestigator, MBF Bioscience, Williston, VT). A systematic 
random sampling of sections throughout the left hemibrain were 
stained as described above and coded to ensure blinding. The regions 
of interests (ROI) were defined using specific landmarks within the 
brain to maintain consistency. A grid was placed randomly over the 
region of interest slated for counting. At regularly predetermined 
positions of the grid, cells were counted within three-dimensional 
optical dissectors. Within each dissector, a 1µm guard distance from 
the top and bottom of the section surface was excluded. Section 
thickness was measured regularly on all collected sections to estimate 
the mean section thickness for each animal after tissue processing and 
averaged 35.24 µm ± 0.46 µm for all sections analyzed. The total 
number of neurons was calculated using the equation: 
N = Q- x 1/ssf x 1/asf x 1/hsf
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where N is total neuron number, Q- is the number of neurons counted, 
ssf is section sampling fraction, asf is the area sampling fraction and 
hsf is the height sampling fraction. Tissue from one mouse in the MB-
treated rTg4510 cohort was unusable for this study. Therefore, n=8 for 
this group.
 Antibodies 
 Tau antibodies S202/T205 and MC1 were provided by Dr. Peter 
Davies, Albert Einstein College of Medicine; total tau antibody was 
purchased from Stantacruz Biotech, Stantacruz, CA. Horseradish 
peroxidase conjugated secondary antibodies were obtained from 
Southern Biotech, Birmingham, AL. Glyceraldehyde-3-phosphate 
dehydrogenase antibody was obtained from Meridian Life Science, 
Saco, ME.
 Statistical analysis 
 Statistical analysis comparing 2 groups was done using an 
unpaired, two tailed t-test. Analysis comparing more than 2 groups 
was done using a one-way analysis of variance (ANOVA) with the 
Tukey-Kramer post-hoc test.  Analysis of three or more groups during 
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different time points (water maze learning and rotorod) was done 
using repeated measures 2-way ANOVA with the Bonferroni post-hoc 
test. Statistical analysis was done in the GraphPad Prism software.
Results & Discussion
 Previously, biochemical analyses of hippocampal tissue from tau 
transgenic mice [rTg4510; (Santacruz et al., 2005)] injected with MB 
showed reduced tau levels after 24 hours (Jinwal et al., 2009). 
Hippocampi of wild type mice were then injected with either 1mM or 
0.1mM MB [based on a recent study in Zebrafish (van Bebber et al., 
2010)] to determine its effective therapeutic window for reducing tau 
levels. Only 1mM MB reduced tau levels (Figure 2.1 A). Based on these 
results, 1mM MB (1mM; n=6) or saline (n=7) was administered to the 
right hippocampi (Smith and Milner, 1981) of 7-month old rTg4510 
mice for 1 month using mini-osmotic pump implantation (Figure 2.1 
B). The accumulation of soluble mutant human tau in the forebrain of 
this model causes spatial memory deficits as early as 3 months of age, 
which precede neuronal loss (Santacruz et al., 2005). Morris water 
maze (MWM) during the final week of treatment revealed that MB-
treated mice showed significant improvements in learning the location 
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of the escape platform compared to those receiving saline (Figure 2.1 
C). Probe trial analysis using target quadrant discrimination, number of 
platform crossings and search strategy imaging showed significantly 
improved cognitive recall in MB-treated mice compared to those 
treated with saline (Figure 2.1 D-F). Biochemical analysis of 
hippocampal lysates showed that both phosphorylated (S202/T205) 
and total tau levels were significantly reduced (Figure 2.2 A&B). Thus, 
despite the focal distribution of osmotic pump administration and the 
age of the mice, MB was still able to improve cognitive function; an 
effect that was concomitant with reductions in hippocampal tau levels. 
Contrastingly, pathology was unaffected (Figure 2.2 C&D). 
Furthermore, nissl staining was done in order to determine if any 
damage was done to the hippocampus due to pump implantation. No 
such damage was found (Figure 2.2 E&F). 
 Based on this evidence, a new trial was initiated in rTg4510 mice 
to test the effects of long-term MB administration not only on behavior 
and tau biochemistry, but also on neuronal survival and tau pathology. 
Practical limitations with osmotic pump applications required that this 
study be done using non-invasive peripheral administration. Dose 
selection for this study was based on two factors: 1) FDA conversion 
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tables show that a 10 mg/kg dose in a mouse is equivalent to ~1 mg/
kg in humans, which is within the range of current MB clinical 
applications (FDA, 2005; Walter-Sack et al., 2009), and 2) 
pharmacokinetic analyses showed that MB could concentrate in the 
brain 500-fold, making the effective concentration (>100µM) possible 
(Figure 2.3 A&B).
 Thus, two groups (n=10) of 3 month-old rTg4510 mice and two 
groups of 10 wild type littermates received either ~10 mg/kg (165µM; 
5x maximum recommended dose) of MB via drinking water 
supplemented with 2mM saccharine or saccharine water alone (Figure 
2.4 A). Following 12 weeks of treatment, behavioral assessment 
showed no overt alterations in motor coordination or task acquisition 
(See Appendix A: Figure A1). MWM was then used to assess cognitive 
function. Probe trial analysis and search strategy imaging showed that 
MB, but not saccharine, prevented the significant progressive 
impairment in target quadrant discrimination that is a hallmark of the 
rTg4510 phenotype (Figure 2.4 B&C). Furthermore, wild type 
littermates showed normal spatial memory recall irrespective of MB 
treatment (for visible trial and swim speed see Figure A3). Biochemical 
analyses of half-brain homogenates (excluding cerebellum) showed a 
42
reduction in soluble tau levels in some mice, but not others (Fig. 
5A,B). Histochemical analyses revealed no change in tau pathology in 
any mice (Figure 2.5 C&D).
 Given the variability in behavioral performance as well as 
reductions in tau levels, we hypothesized that the MB concentration in 
the brain may have also varied due to the ad libitum administration 
strategy. To test this idea, brain concentrations of MB were assessed 
using LC-MS analysis of the cerebellar tissue from these mice. Indeed, 
MB concentration was positively correlated with MWM performance 
(p<0.05) and was inversely correlated with soluble tau levels (p<0.05) 
(Figure 2.6 A&B). The differences in brain MB concentration between 
mice could not be attributed to body weight or gender (See Appendix 
A: Figure A2). Moreover, mice with >470µM MB brain concentration 
accounted for a preponderance of the effects on memory function and 
tau reductions, consistent with our previous results showing that very 
high concentrations of MB were required for anti-tau efficacy (Figure 
2.1 A). Surprisingly, stereological assessment of five different brain 
regions from these mice showed that MB treatment significantly 
delayed neurodegeneration by ~30% in all forebrain regions of all 
rTg4510 mice (Figure 2.6 C), but neuronal number failed to correlate 
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with memory performance or soluble tau levels (Figure 2.6 D, and data 
not shown).
 Post-hoc analysis of the behavioral performances of rTg4510 
mice with brain MB concentrations above or below ~470µM (High [MB] 
or Low [MB], respectively), elucidated that the High [MB] cohort 
performed equivalent to wild type mice, while the Low [MB] cohort was 
significantly impaired (Figure 2.7 A). We again used the camera-
tracking software to map the areas of the pool most traversed by each 
cohort (Figure 2.7 B). High [MB] rTg4510 mice were predominantly 
found in the target quadrant, while the Low [MB] cohort displayed an 
unguided search strategy. Furthermore, we wanted to see if MB 
treatment in the High [MB] mice had an effect on motor learning. The 
mice were subjected to the rotorod task for two days and the latency 
to fall onto a spring-cushioned lever was measured. We found that 
motor learning from day 1 to day 2 of MB treated rTg4510 was 
significantly improved, dissimilar to the saccharine treated rTg4510 
analogs (Figure 2.7 C). 
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Conclusion
 In conclusion, these findings are consistent with recent evidence 
showing that reducing tangle burden does not beget functional 
recover(de Calignon et al.; Santacruz et al., 2005; Spires-Jones et al., 
2008); however, the unexpected result that neuroprotection is 
insufficient to preserve cognitive function suggests that preventing 
neuronal loss may not be enough to alter cognitive deficits in 
tauopathies either. In fact, it was only when soluble tau levels are 
reduced in the brain that functional recovery was observed. Moreover, 
these data show that there is a link between tau and cell death 
signaling cascades that can be altered with therapeutics since 
neurodegeneration can be decoupled from tau accumulation with MB.
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Figure 2.1. Direct hippocampal infusion of methylene blue by 
mini-osmotic pump reverses spatial navigation related learning 
and memory deficits by reducing tau levels in rTg4510 mice. (A) 
Four groups of wild type mice (n=3) were injected with 100 µM MB, 1 
mM MB, or saline into the hippocampus for 24 hours. Western blot 
from hippocampal lysates show reductions in tau at 1 mM MB in 
phospho- and total tau. (B) Experimental design of central 
administration of MB (MB central n=6, saline central n=7). (C) Infusion 
of MB increased ability of rTg4510 mice to learn the location of the 
hidden platform in the MWM, **p<0.01). (D) Probe trial of Morris 
water maze shows that MB treated rTg4510 mice were able to 
recognize the target from the opposite quadrant, unlike saline treated 
rTg4510 mice, (F(3,20)=8.202, p=0.0009), ***p<0.001. (E) Number 
of crossing across the area where the hidden platform was located 
during training. (F (7, 44) = 2.757, p=0.0183), p<0.05. (F) Search 
strategy imaging using a camera tracking system shows that MB 
treated rTg4510 mice have a more focused strategy than saline treated 
rTg4510 mice.
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Figure 2.2. MB treatment reduces tau levels, but does not affect 
pathology in mice with pre-existing tangle formation and 
neurodegeneration. (A) Western blot analysis of tau protein levels 
from hippocampal lysates. (B) Quantitation of the optical density as a 
percentage of saline treated rTg4510 mice shows a significant 
difference in pS202/T205 and total tau levels, *p<0.05. (C) 
Representative images of the Gallyas silver stain. (D) Percentage of 
area of silver positive staining shows no statistical difference between 
the means (n=2 per group). (E) Representative images of the staining 
of neuronal nissl substance in the ipsilateral side of drug infusion (right 
hippocampus). (F) Quantitation of the percent area positive for nissl 
staining of ipsilateral versus the contralateral brain side of each group 
of mice shows that there is no detectable neuron loss due to pump 
implantation.
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Figure 2.3. Pharmacokinetic analysis of MB following peripheral 
administration. (A) A single intravenous (I.V.) administration of 20 
mg/kg MB was given to wild type mice at different time points (n=3 
per time point), and cerebellar and plasma concentrations were 
measured through LC-MS. (B) A single 200 mg/kg oral gavage bolus of 
MB was given to wild type mice at different time points (n=3 per time 
point) and also measured by LC-MS.  Cerebellar brain concentrations 
of MB are higher than plasma.
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Figure 2.4
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Figure 2.4. Chronic treatment with methylene blue has 
moderate effect in behavior. (A) Experimental design, n=10. (B) 
Percent of time spent in each quadrant during the probe trial of MWM 
(F (15,144) = 8.781, p<0.0001). MB rTg4510 recognize target versus 
opposite quadrant (F (3,36) = 3.38, p = 0.0286) (* p<0.05,). (C) 
Search strategy imaging using a camera tracking system. 
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Figure 2.5. Chronic dosing of methylene blue leads to 
reductions in soluble tau but pathology is unaffected. (A) Half-
brain lysates (no cerebellum) were analyzed for tau protein levels by 
Western blot. (B) Optical density of tau levels is shown as a 
percentage of control (saccharine treated rTg4510), (* p<0.05). (C) 
Representative images of immunoreactivity to a phosphorylated tau 
epitope (pS202/T205), the MC1 epitope (early tangles), and reactivity 
to the gallyas silver stain (late tangles) are shown. (D) Quantitation of 
the percent area of positive staining shows no statistical significance 
between the means of all stains.
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Figure 2.6
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Figure 2.6. Chronic dosing of methylene blue enhances 
neuronal survival. (A) Parenchymal drug concentrations correlated 
significantly with memory retention in the probe trial of MWM 
p=0.016, Pearson r=0.766, r2=0.587. (B) Tau levels inversely 
correlate significantly with parenchymal drug concentration, p<0.05, 
Pearson r=-0.6724, r2=0.452. (C) Number of neurons counted in five 
regions as a percentage of sacc treated rTg4510 (MB treated rTg4510 
n=8, sacc treated rTg4510 n=10) (DG stands for dentate gyrus, CX 
stands for cortex and STR stands for striatum). (D) Number of neurons 
does not correlate significantly with time spent in the target quadrant.
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Figure 2.7
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Figure 2.7. High concentrations of MB repair spatial and motor 
memory deficits. (A) Post-hoc analyses reveal that High [MB] 
rTg4510 mice (n=5) perform similar to wild-type MB treated mice, 
while Low [MB] rTg4510 mice (n=4) did not display memory retention. 
Wild type mice performed similarly regardless of MB (F (7,30) = 
10.64, p<0.0001) (**p<0.01, ***p<0.001). (B) Camera tracking 
software imaging of MB treated rTg4510 mice divided by low and high 
parenchymal MB concentrations. (C) Motor learning was assessed by 
comparing the average latency to fall from the rotorod apparatus of 
day 1 with the average of day 2. High [MB] rTg4510 mice (n=5) learn 
better than saccharine treated rTg4510 (n=10). Wild Type groups, 
n=10 (**p<0.01, ***p<0.001).
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CHAPTER THREE2:
A New Anti-Depressive Strategy for the Elderly: Ablation of 
FKBP5/FKBP51
Abstract
 The gene FKBP5 codes for FKBP51, a co-chaperone protein of the 
Hsp90 complex that increases with age. Through its association with 
Hsp90, FKBP51 regulates the glucocorticoid receptor (GR). Single 
nucleotide polymorphisms (SNPs) in the FKBP5 gene associate with 
increased recurrence of depressive episodes, increased susceptibility to 
post-traumatic stress disorder, bipolar disorder, attempt of suicide, and 
major depressive disorder in HIV patients. Variation in one of these 
SNPs correlates with increased levels of FKBP51. FKBP51 is also 
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 2This work was previously published in the journal PLoS One 
(O'Leary III, John C., et al. "A new anti-depressive strategy for the 
elderly: ablation of FKBP5/FKBP51." PloS one 6.9 (2011): e24840), 
and is used here with permission of the publisher. The permissions are 
available in Appendix F.
increased in HIV patients. Moreover, increases in FKBP51 in the 
amygdala produce an anxiety phenotype in mice. Therefore, we tested 
the behavioral consequences of FKBP5 deletion in aged mice. Similar 
to that of naïve animals treated with classical antidepressants FKBP5−/
− mice showed antidepressant behavior without affecting cognition 
and other basic motor functions. Reduced corticosterone levels 
following stress accompanied these observed effects on depression. 
Age-dependent anxiety was also modulated by FKBP5 deletion. 
Therefore, drug discovery efforts focused on depleting FKBP51 levels 
may yield novel antidepressant therapies.
Introduction
 Genes regulating the hypothalamus-pituitary-adrenal (HPA) axis 
are associated with susceptibility to depression as well as 
antidepressant efficacy (Binder et al., 2004; Liu et al., 2006; van 
Rossum et al., 2006). The HPA axis has a well-characterized role as a 
regulator of the neuroendocrine stress response (Lupien et al., 2009). 
Its activation leads to the production of glucocorticoids in the adrenal 
axis, of which the major constituent in humans is cortisol and in 
rodents is corticosterone. Over the past decade, genome wide 
association studies for single nucleotide polymorphisms (SNPs) 
67
revealed significant associations between susceptibility to depressive 
episodes and variants in both the NR3C1, that encodes the 
glucocorticoid receptor (GR), and FKBP5, that encodes a GR binding 
protein thought to attenuate GR activity (Lahti et al.; Binder et al., 
2004). While most studies have focused on the variants in GR because 
of its role as a transcriptional regulator (Derijk et al., 2008), the 
involvement of FKBP5 and its gene product, FKBP51, have received 
little attention.  This is largely due to uncertainty about how to 
approach this relatively unknown protein. In fact, it remains to be 
proven whether FKBP51 is a valid therapeutic target for treating 
depression, despite its clear genetic link. 
 Since the initial discovery of the association between FKBP5 
SNPs and depression, other psychiatric disorders have been found to 
be associated with FKBP5 SNPs including PTSD (Xie et al., 2010), 
bipolar disorder (Willour et al., 2009), anxiety (Binder, 2009), 
peritraumatic dissociation (Koenen et al., 2005), and major depression 
in HIV patients (Tatro et al., 2010). The TT variant of the rs1360780 
SNP was associated with both an increased incidence of depressive 
episodes throughout a carrier’s lifetime, and increased sensitivity to 
common neurotransmitter-based anti-depressants (Binder et al., 
2004). Interestingly, individuals with the rs1360780 TT SNP had 
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significantly higher FKBP51 protein levels in their lymphocytes. FKBP51 
levels are also elevated in patients with HIV infection, perhaps playing 
a role in the depression that commonly occurs with chronic highly 
active antiretroviral therapies (HAART)(Tatro et al., 2009). Recently, 
stress was shown to induce neuropsin activity in the amygdala, 
inducing anxiety in mice through an FKBP51-dependent mechanism 
(Attwood et al., 2011). How FKBP51 directly modulates GR has been 
investigated in vitro. In these systems, increases in FKBP51 levels 
decreased GR activation by lowering GR affinity for glucocorticoid 
(Binder, 2009). In new world monkeys FKBP51 has been shown to be 
the cause of glucocorticoid resistance, but this has yet to be shown 
using a genetic in vivo model (Denny et al., 2005; Westberry et al., 
2006). 
 While the causes of major depressive disorders are unknown, 
there is an emerging genetic diathesis for its occurrence within genes 
regulating the HPA axis; however few animal models have been 
developed or utilized for aetiologic validation studies. Genetic variation 
in FKBP51 appears to be one factor that facilitates liability to anxiety 
and mood disorders.  Thus, the goal of this study was to determine 
whether decreasing FKBP51 expression could make mice less 
susceptible to inducible “depression-like” states through a 
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corticosterone-dependent mechanism in vivo in well established 
models with high predictive value (Frazer and Morilak, 2005). Indeed, 
aged FKBP5-deficient mice were resistant to stress-induced 
depressive-like behavior. Moreover, despite robust hippocampal and 
forebrain expression patterns, deletion of FKBP5 did not result in 
cognitive impairment or other behavioral abnormalities. Circulating 
levels of corticosterone in the same FKBP5-/- mice were also reduced 
after stress, confirming the proposed mechanism previously described 
(Binder, 2009). These data suggest that not only is FKBP51 a valid 
therapeutic target, but targeting this protein may also have minimal 
consequences for other behavioral characteristics. 
Materials & Methods
 Generation of FKBP5-/- mice
  By PCR screening the 129SvJ mouse BAC library (Genome 
Systems, St. Louis, MO), bacterial artificial chromosome (BAC) clones 
that contained genomic regions for FKBP5 were isolated. Restriction 
fragments were subcloned into pBluescript (pBS; Stratagene, La Jolla, 
CA) or pZero (Invitrogen, Carlsbad, CA) cloning vectors. The PCR 
products were amplified from the BAC clones and were then used to 
construct a targeting vector in the pPGKneo vector (a generous gift of 
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James Lee, Mayo Clinic Scottsdale). The targeting vector contained a 
beta-galactosidase/neomycin cassette flanked by regions homologous 
to the FKBP5 gene and was recombined to remove all of exon 2, which 
is the first coding exon. ES cells were isolated from the 129SvJ mouse 
and cultured in Knockout DMEM media (Invitrogen) supplemented with 
10% FBS, penicillin/streptomycin, essential amino acids, and ESGRO 
(103 U/ml; Chemicon, Temecula, CA) with irradiated embryonic 
fibroblast feeder cells. The ES cells were then electroporated at 0.2 kV, 
950µF (Gene Pulser II; Bio-Rad, Hercules, CA) with linearized targeting 
vectors and selected with G418. DANN from G418-resistant clones was 
isolated for Southern blot analysis. A DNA probe was used to 
distinguish PstI restriction fragments from wild-type (~7.5 kb) and 
mutant (~10 kb) alleles. Appropriate homologous recombination in ES 
cell clones was confirmed by PCR using primers complementary to 
sequences within the neomycin cassette and to 3’ FKBP5 sequences 
downstream from the recombination site. ES cell clones containing a 
mutant FKBP5 allele were injected into C57BL/6 blastocysts and 
implanted into pseudopregnant 129SvJ females. Chimeric offspring 
were identified by coat patterns and mated to C57BL/6 mice to obtain 
germline transmission of the mutant allele. For colony maintenance 
mice were crossed from C57BL6 onto Swiss-Webster for purposes of 
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fecundity and genetic diversity to be more representative of a human 
population.
 Brain tissue fractionation and western blot analysis
 Brain tissue fractionation and western blot analysis were done as 
previously described (Dickey et al., 2006). 
PCR. mRNA was isolated and purified from the brain of four wild type 
and four FKBP5-/- mice using RNAeasy kit (QIAGEN, Valencia, CA). 
cDNA was synthesized from isolated mRNA by reverse transcription 
using Super Script III First-Strand cDNA Sythesis Kit (Invitrogen, 
Carlsbad, CA) from 50ng of isolated mRNA. PCR was performed with 
synthesized cDNA and FKBP5 specific primers to confirm presence or 
absence of FKBP5 gene.
 Antibodies
 Horseradish peroxidase conjugated secondary antibodies 
(Southern Biotech, Birmingham, AL), Glyceraldehyde-3-phosphate 
dehydrogenase antibody (Meridian Life Science, Saco, ME), Anti-
FKBP51 was provided by Drs. David F. Smith and Marc Cox (Mayo 
Clinic, Scottsdale, AZ).
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 Immunohistochemistry
 Fixed mouse brains were processed for sectioning as previously 
described (Gordon et al., 2002). β-galactosidase staining was 
performed using the in situ β-gal staining kit (Stratagene, La Jolla, 
CA).
 Behavior
 N=9 unless otherwise noted. Video tracking software was used in 
several tests (ANY-Maze, Stoelting, Illinois).
Open Field. Animals were monitored for 15 min in an open field with 
video tracing software. 
 Rotorod test
 Testing started at an initial rotation of 4 rpm accelerating to 40 
rpm over 5 min.  Mice were tested for 4 trials per day, for 2 
consecutive days with a 30-min intertrial interval. Latency to fall from 
the rod onto a spring-cushioned lever was measured.
Morris water maze (MWM). Mice were trained to locate an escape 
platform hidden beneath the water (3 centimeter).  Each mouse was 
given 4 trials per day with an intertrial interval of 1 hour for 
6 consecutive days.  Each animal was given 60 seconds to find the 
platform. Afterwards the mice were placed on the platform for 30 s. On 
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day 7, mice were subjected to a trial in which the platform was 
removed, and had 60 s to search for it. 
 Associative fear conditioning 
 Two mild foot shocks (0.5 milliamps) were paired with an 
auditory conditioned stimulus (CS, white noise, 70 decibels) within a 
novel environment. The CS was given for 30 s before each foot shock 
(2 s). Twenty-four hours later, the mice were placed in the chamber 
and monitored for freezing for 3 min (no shocks or CS). Immediately 
after the test, mice were placed into a novel context for 3 min without 
CS and then exposed to the CS for 3 min (cued). 
Prepulse Inhibition (PPI). Mice were placed in a restrainer (Panlab, 
Barcelona Spain) and placed inside a sound attenuation chamber.  The 
test consisted of 7 trial types in pseudorandom order: 1) 40 ms, 120 
decibels sound burst (startle); 2-6) 5 different acoustic prepulses 100 
ms in length, a 20 ms duration at 74, 78, 82, 86, and 90 dB; 7) no 
stimulus for baseline measurement .  The intertrial interval was 15 s. 
The startle response peak was measured within a second after the 
stimulus.
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 Elevated plus maze (EPM)
 EPM consisted of 2 open arms facing each other and two 
enclosed arms also facing each other.  Each arm is attached to the 
center platform and elevated 40 centimeters off the floor.  The mouse 
was placed on the platform and allowed to explore for 5 min.  Video 
tracking software measured movement. 
 Porsolt forced swim test (FST)
 Each mouse was placed in a 45 centimeters high and 20 
centimeters diameter clear Plexiglas cylinder filled with room 
temperature water to a depth of 12 centimeters for 6 min.  Amount of 
time spent immobile was recorded.
 Tail suspension test (TST)
 Mice were suspended from their tail for 6 min. Amount of time 
spent immobile was recorded.
 Novel object
 Mice were placed in an area with two objects similar in scale to 
the mouse. Each animal was given 3 acclimation trials of 5 min with a 
5-min intertrial interval. Then one acclimated object was replaced with 
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a novel object. Animals were given a 5-min exploratory trial monitored 
by video recording. 
 Y-maze
 Animals were started at the center of the Y and allowed to 
explore for 8 min. Each session was video-monitored. The number of 
arm entries was recorded. The percent of spontaneous alternation was 
calculated as the number of triads containing entries into all three 
arms divided by the maximum possible of alternations (total number 
of entries minus 2).
 Corticosterone assay, blood collection and stress paradigm
 The levels of corticosterone were measured using an ELISA kit 
(Enzo Life Sciences, Plymouth Meeting, PA). Blood from mice was 
collected in the morning one hour after the light cycle began and 30 
min after a 10-min tube restraint using the submandibular vein 
puncture method.  
 Statistics
 The student’s t-test was used to compare 2 groups. The paired t-
test was used to compare paired observations within 2 groups. The 2-
way RMANOVA was used to compare the interaction between two 
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dependent variables and an independent variable. All error bars 
represent standard error of the mean.
 All animal procedures were approved by the Institutional Animal 
Care and Use Committee (IACUC).
Results 
 FKBP5-/- mice were used to determine the effect of gene 
deletion on behavior. The mice contain a β-galactosidase reporter 
cassette, which expresses wherever the FKBP5 gene is normally 
expressed. To confirm gene knockout and establish cerebral 
distribution of FKBP51, tissue from 5.5 and 20-month-old FKBP5-/- 
mice was stained using an X-gal kit that produces a blue product when 
β-galactosidase is present. An age-dependent increase in β-gal 
expression was observed particularly in the upper cortical layers of the 
forebrain (Figure 3.1 A). This was consistent with the age-dependent 
increase in FKBP51 expression that had been previously reported in 
normal mice (Jinwal et al., 2010). To confirm the absence of FKBP51 
protein, whole brain homogenates were analyzed by immunoblot and 
probed using an FKBP51 antibody. No detectable FKBP51 was observed 
(Figure 3.1 B). To verify that FKBP51 mRNA was absent, oligo d(T) RT-
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PCR was performed using reverse transcriptase to produce cDNA. No 
FKBP5 PCR product was detected in the FKBP5-/- mice, confirming that 
no FKBP51 mRNA was present (Figure 3.1 C). 
 FKBP5-/- mice aged 17-20 months were submitted to two 
behavioral models of depressive-like activity; the classical forced swim 
test (FST) and the tail suspension test (TST) (Porsolt et al., 1977; 
Steru et al., 1985).  Results from these tests are based on the total 
time spent immobile over a 6-minute period, interpreted as despair. 
These tests are typical for assessing antidepressant efficacy (Steru et 
al., 1985). Aged FKBP5-/- mice displayed a shorter immobility time 
than their wild type counterparts (Figure 3.1 D&E). The weight, 
activity, and physical fitness of the mice were evaluated to account for 
possible confounding factors, but these variables did not contribute to 
the effect  (Figure 3.1 F-H). 
 Stress causes increased levels of cortisol in humans and 
depressed patients have higher-than-normal levels of cortisol in the 
blood (Burke et al., 2005). The dexamethasone-corticotropin releasing 
hormone (DEX-CRH) test, a commonly used tool to detect HPA system 
changes, has been used to link depressive behavior with glucocorticoid 
receptor (GR) insensitivity (Holsboer et al., 1987). To determine if 
FKBP5 deletion was altering glucocorticoid levels, circulating 
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corticosterone levels were assessed in the same aged cohort of 
FKBP5-/- mice that were used for behavioral analyses. Early morning 
blood draws were collected from both FKBP5-/- and wild type 
littermates before and 30 minutes after being placed in a restrainer for 
10 minutes. Levels of basal corticosterone were predictably low, 
consistent with previous reports showing low levels of corticosterone 
production in the earliest part of the murine diurnal cycle (Kakihana 
and Moore, 1976)(Figure 3.1 I).  After stress corticosterone levels rose 
in both wild type and FKBP5-/- mice, but this induction was attenuated 
in the FKBP5-/- mice.  These findings suggest that the lack of FKBP51 
permits unrestrained GR transcription activity, which decreases HPA-
axis activity and corticosterone levels, improving resilience to 
depressive-like behavior. 
 However, untoward consequences of FKBP51 ablation were a 
distinct possibility given the ubiquitous expression of FKBP51 
throughout the brain. Given the high levels of expression of FKBP5 in 
the hippocampus (Figure 3.1 A) memory formation was assessed. 
Therefore, short-term memory in the FKBP5-/- mice was tested with 
the use of the novel object recognition and Y-maze paradigms. Both 
tests are performed in a short period of time to capture the working 
memory ability of the mice. Neither test showed statistically significant 
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differences between FKBP5-/- and wild type littermates (Figure 3.2 
A&B). Long-term spatial memory function was then tested using the 
Morris water maze (MWM). Memory retention was tested 24 hours 
after the training was completed.  The training phase of the MWM 
displayed that wild type and FKBP5-/- mice were equally capable of 
learning the location of a hidden platform (Figure 2C). Moreover wild 
type and FKBP5-/- mice displayed an equivalent capacity to locate the 
hidden platform 24 hours after training (Figure 2D-2E). 
 The amygdala controls emotional learning in the brain and 
FKBP5 expression can be upregulated by GR activation (Scharf et al., 
2011). As a consequence, function of the amygdala could be affected 
by FKBP5 deletion. To test the impact of FKBP5-/- on emotionally 
derived memory function, a fear-conditioning paradigm was employed. 
In this test, a tone played for 30 seconds is followed by a small foot 
shock. Thus the animal learns to associate the tone with the shock. 
The amygdala-associated fear response caused by the tone is able to 
bypass the hippocampus once the association is made, allowing for 
assessment of emotionally driven memory formation. Surprisingly, no 
differences between wild type and FKBP5-/- mice were observed in 
either contextual (environmentally-based) or cued (tone-based) fear 
conditioning paradigms (Figure 2F-2H). These findings suggest that 
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neither spatially nor emotionally driven long-term memory is affected 
by FKBP5 deletion. In addition to these learning and memory tasks, no 
observable differences between wild type and FKBP5-/- mice were 
noted in tasks designed to assess activity, motor performance, motor 
coordination, motor learning, hearing, or prepulse inhibition, which 
measures startle response inhibition (Figure 3.3). 
 Brain-specific knockout of GR in mice reduces anxiety (Tronche 
et al., 1999). Also, FKBP51 expression was recently correlated to 
anxious behavior (Attwood et al., 2011).  Based on this and the novel 
link now established between FKBP51, GR activity and glucocorticoid 
production, the effects of FKBP5 deletion on anxiety were tested. The 
longitudinal impact of FKBP5 deletion on anxiety was assessed in mice 
aged 11-14 months and then again in the same mice aged 18-22 
months using the elevated plus maze (EPM).  A repeated measures 
two-way analysis of variance was conducted to examine the effect of 
time and genotype on anxiety. The behavioral correlates of anxiety in 
the EPM were significantly affected by age, and this change depended 
on the genotype at FKBP5 as reflected by a significant age*genotype 
interaction, F(1,14)=6.71, p=0.02 (Figure 3.4 A&B). Indeed, in wild 
type mice behavioral correlates of anxiety decreased with age, 
whereas they appeared to increase in FKBP5-/- mice. To further 
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examine whether anxiety was indeed being modified in these mice, the 
18-22 month-old mice were subjected to the light-dark chamber 
paradigm, which is another standard measure of anxiety. The mice 
were allowed to explore between a well-lit and unprotected area and a 
dark covered area that the mice had access to through a small 
opening. Normal mice typically move to the dark chamber. The light-
dark maze did not reveal any statistical differences between the 
groups (Figure 3.4 C-E). These data suggest that suppression of 
FKBP51 may have a differential effect on anxiety depending on the 
developmental stage; however, the effect is not pervasive enough to 
manifest itself through several indices of anxiety.
Discussion 
 Major depression is a devastating disease with a course that is 
frequently chronic or recurrent and affects millions of people. 
Research in the last decade has shown that variation in the FKBP5 
gene is associated with depression and several other mood and anxiety 
disorders. And although in vitro data suggests the possibility of a 
causal relationship between FKBP5 expression levels and depression, 
this has never been tested in vivo. Here we show for the first time that 
ablation of FKBP5 in mice led to reduced immobility in two behavioral 
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models that are routinely used to assess anti-depressant efficacy. This 
behavioral effect coincided with attenuation of corticosterone 
production after a stressful episode. Moreover, no defects in 
locomotion, somato-sensation or learning and memory were observed.
Thus, therapies developed to reduce FKBP51 levels may be highly 
efficacious as next generation anti-depressants. Furthermore, because 
FKBP51 ablation results in reduced anxiety-like behavior in mice 
(Attwood et al., 2011), we provide experimental support for the notion 
that genetically-driven variations in expression of FKBP51 may underlie 
susceptibility to anxiety and mood disorders, as suggested by 
association studies in humans (Binder et al., 2004; Binder, 2009).
FKBP51 is a peptidyl-prolyl cis-trans isomerase (PPIase) enzyme that 
also associates with the chaperone Hsp90 and is distributed 
ubiquitously throughout the brain. This isomerase activity is thought to 
be important for structural rearrangements and phosphorylation 
dynamics of client proteins bound by Hsp90. Several diseases in 
addition to psychiatric conditions have implicated FKBP51 as having a 
role in their pathogenesis. These include prostate cancer (Ni et al.), 
and neurodegenerative diseases, specifically tauopathies (Jinwal et al., 
2010). In fact, these effects on tau may somehow be tied to the 
manifestation of these psychiatric conditions. Indeed, depleting 
FKBP51 levels was shown to also reduce tau levels, while inhibiting its 
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PPIase activity actually lead to increased stability of phosphorylated 
tau. Thus it is certainly possible that FKBP51 is involved in Alzheimer’s 
disease progression, since one of its earliest clinical features is 
depression. More recently, the extracellular protease neuropsin was 
shown to mediate anxiety-like behavior via an FKBP51 dependent 
mechanism (Attwood et al., 2011). Thus, an important role for FKBP51 
in maintaining proper brain function is emerging. Its relationship with 
major depressive disorder in HIV, bipolar disorder and possibly anxiety 
and Alzheimer’s disease further underlie its significance.
Current treatment for depression includes the use of medications that 
extend the amount of time neurotransmitters are present in the 
synaptic cleft including serotonin, norepinephrine, and dopamine.  It is 
estimated that 60-70% of patients reach remission with the use of 
anti-depressant drugs (Rush et al., 2006).  These low rates of efficacy 
have prompted research into other potential therapeutic targets in the 
HPA axis, particularly GR. However, there are many different isoforms 
of GR, making selective targeting with compounds challenging. 
Therefore, the results presented here show that FKBP51 may be the 
most appropriate target for treating depression via the modulation of 
the HPA axis in terms of its risk/benefit equation and potential 
therapeutic window.  Also, and most noteworthy, because FKBP51 may 
act on the genetic liability to abnormal mood and anxiety states, it 
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may provide a much needed treatment tool for secondary prophylaxis 
of depression recurrence and relapse.
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Figure 1. FKBP5-/- mice display resistance to depression 
inducing stimulus. (A) Representative images of β-gal staining in 
horizontal brain slices of 5.5 and 20 month old FKBP5-/- mice. (B) 
Western blot analysis of wild type and FKBP5-/- whole brain 
homogenates. (C) FKBP5 primer-specific PCR of cDNA synthesized 
from brain-isolated mRNA by reverse transcription. (D) Total time 
immobile in the tail suspension test. (E) Total time immobile in the 
forced swim test. (F) No significant difference was observed between 
mass measurements of groups. (G) Latency to fall from a gradually 
accelerating rotorod apparatus displays no difference between groups. 
(H) Activity levels in the open field display no differences between 
groups. (I) Levels of corticosterone in serum right before a 10-minute 
tube restraint and 30 minute after (wt n=5, FKBP5-/- n=6). * p<0.05, 
** p<0.01. 
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Figure 2. Deletion of the FKBP5 gene does not alter learning 
and memory despite robust expression of FKBP5 in the 
hippocampus. (A) Discrimination index between familiar and novel 
object in the novel object recognition test. (B) Percent of spontaneous 
alternation shows no difference between the groups. (C) Learning of 
the location of the hidden platform in the MWM (interaction 
F(5,80)=0.14, p=0.98; genotype F(1,16)=0.0, p=0.98; time 
F(5,80)=12.71, p<0.0001) . (D) Percent time spent in quadrant during 
the probe trial of MWM. (E) Software generated heat plot representing 
amount of time spent in an area. (F) Percent freezing during training 
portion of fear conditioning (interaction F(6,90)=1.32, p=0.26; 
genotype F(1,15)=0.01, p=0.92; time F(6,90)=14.35, p<0.0001). (G) 
Percent freezing during contextual exposure to fear-conditioning 
chamber. (H) Percent freezing during the cued fear-conditioning test.
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Figure 3.3. Behavioral characterization of FKBP5-/- mice. (A) 
Distance traveled in the open field test. (B) Assessment of motor 
learning from comparison between the average of all four trials of 
rotorod from day one with those of day two. (C) Latency to fall from 
the rotorod apparatus. (D) Percent inhibition of startle response by 
increasing prepulse intensity. (E) Comparison of no pulse (no tone) 
with a 120 dB pulse (tone) to test hearing.
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Figure 3.4. Age-associated changes in anxious behavior in 
FKBP5-/- mice. (A) Time spent in the arms of the EPM as a 
percentage of the control group (wt and FKBP5-/- 11-14 mo. n=9, wt 
and FKBP5-/- 18-21 mo. n=8). (B) Number of entries into the arms of 
the EPM as a percentage of control. (C) Time spent in the areas of the 
dark-light chamber (wt n=8, FKBP5-/- n=8). (D) Number of entries 
into the areas of the dark-light chamber (wt n=8, FKBP5-/- n=8). (E) 
Software generated heat plot representing amount of time spent in 
area. *p<0.05, **p<0.01, ***p<0.001.
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CHAPTER FOUR:
FKBP5-/- Enhances Cognitive Flexibility, and Protects From Age 
and Genotype Dependent Loss of Resilience.
Abstract
 The ability to respond effectively to, and recuperate from 
stressful events is a key aspect of survival, and emotional health. 
However, it is not clear if there is a reduction in stress resiliency with 
age, and particularly, how age-related changes in gene expression in 
the Hypothalamic-Pituitary-Adrenal axis modulate the response to 
stress. Moreover, there is a relationship between memory and 
resiliency, but it is not known how. In particular, it is not known if 
there are proteins that regulate resiliency and memory. Here we show 
that wild type mice display decreased stress resiliency with age in the 
tail suspension test, a behavioral pattern of resignation and loss of 
effort that can be modulated with antidepressants. They also display 
greater serum corticosterone levels after stress with age. The FKBP5 
99
gene, which codes for a hypothalamic-pituitary-adrenal-axis regulating 
protein, may be partly responsible for this age-dependent decrease in 
resiliency, as FKBP5-/- mice display protection from stress and age 
induced despair. Deletion of this protein provides wild type mice with 
greater cognitive flexibility in the reversal of the 6 radial arm water 
maze. In addition, the absence of this protein is not deleterious to the 
lifespan or healthspan of the mice, suggesting that this gene is a 
possible therapeutic target for stress and aging induced psychiatric 
disease.
Introduction
 Resilience is the ability to recover and to spring back into shape 
after difficulties, to have elasticity (Russo et al., 2012). Although there 
are myriad environmental factors that have been shown to help 
patients recover from traumatic events, like strong social networks 
(Ozbay et al., 2007; Ozbay et al., 2008), positive outlook (Black and 
Lobo, 2008; Schmiege et al., 2011), and access to mental health 
professionals (Dowrick et al., 2009), several biological factors have 
also been found to be involved in resiliency, like patterns of brain 
activity (Shin et al., 2005), signaling molecules (Morgan et al., 2000), 
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genes (Binder et al., 2008), and epigenetic mechanisms (Klengel et al., 
2012). 
 Several genes have been singled out for their effect on stress 
resiliency in animals and humans, and one of them is the FK506-
Binding Protein 5 (FKBP5) (O'Leary et al., 2011; Touma et al., 2011; 
Hartmann et al., 2012). People who experience childhood trauma, like 
physical and sexual abuse, who carry certain FKBP5 single nucleotide 
polymorphisms (SNPs), are predisposed to develop PTSD (Binder et 
al., 2008), major depressive disorder (MDD) (Zimmermann et al., 
2011), and suicide (Brent et al., 2010; Roy et al., 2010; Supriyanto et 
al., 2011; Roy et al., 2012). One particular SNP, rs1360780, has been 
shown to increase the levels of FKBP5 in the cell and cause long-
lasting epigenetic effects that further increase FKBP5 levels, providing 
a plausible mechanism for gene x environment interactions (Binder et 
al., 2004; Klengel et al., 2012). In mice, knockdown of FKBP5 in the 
amygdala produces an anxiolytic effect after stress (Attwood et al., 
2011), and global knockout of this gene increases resiliency to the 
forced swim, tail suspension (O'Leary et al., 2011; Touma et al., 
2011), and chronic social defeat stress (Hartmann et al., 2012). FKBP5 
is expressed widely throughout the brain, but its role has been mostly 
studied within the Hypothalamic-Pituitary-Adrenal (HPA) axis (Barik, 
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2006). It is a regulator of the glucocorticoid receptor (GR), as it 
reduces the affinity of glucocorticoids for the GR, negatively impacting 
its activity (Reynolds et al., 1999; Denny et al., 2000; Scammell et al., 
2001; Denny et al., 2005; Wochnik et al., 2005). GR activity is 
extremely important protein, as global knockout of the gene is lethal 
perinatally (Cole et al., 1995). In particular, GR is responsible for the 
shut-off of the HPA-axis (Tasker and Herman, 2011). Consequently, by 
inhibiting the GR, FKBP5 allows for the HPA-axis to be turned on for a 
longer period of time, producing greater amounts of glucocorticoids. 
Hyperglucocorticoidism is common in depression (Herbert, 2013), and 
it is also linked to the perception of anguish during stress. A study that 
subjected active duty personnel to 24 hours of U.S. Navy survival 
school stress, revealed that distress perception was significantly 
correlated to cortisol expression (Morgan et al., 2002).
 However, what happens to our emotional elasticity as we age? 
Although very little is known about the longitudinal effects of 
resiliency, research in the aging brain suggests that it is more 
susceptible to neurodegenerative and psychiatric diseases, with 
Alzheimer’s and depression in particular (Sibille, 2013). This leads to 
the speculation that the brain has reduced resiliency with age. 
Moreover, several of the disease processes involved in aging, 
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neurodegeneration, and mental il lness, share pathological 
commonalities like inflammation, dysfunction in the HPA axis, and 
metabolic syndrome. This makes it conceivable that age-dependent 
gene expression may play an important role. 
 Memory, like resilience, is also modulated by age, emotion, and 
stress, and may play a role in resilience. An overactive amygdala has 
been shown as a feature of PTSD (Shin et al., 2011). Presumably, 
excessive amygdaloid activity enhances emotional memory formation, 
increasing the effect of a traumatic event. Another protein involved in 
resiliency, anxiety, and psychiatric disorders, NPY, has also been 
implicated in the acquisition, consolidation and extinction of memory 
(Lach and de Lima, 2013). Conceivably, memory strength is important 
for emotional processing of events. FKBP5 is expressed in virtually all 
of the brain regions involved with memory. In particular, the 
hippocampus, the amygdala, and prefrontal cortex (O'Leary et al., 
2011; Scharf et al., 2011). However, a previous study showed no 
impact in the ability to form new memories in the FKBP5-/- mice 
(O'Leary et al., 2011). 
 FKBP5 has recently been found to be expressed age-dependently 
in humans and mice. This, in combination with its stress inducement 
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and the clinical studies implicating it with disease, places FKBP5 in a 
unique position to be capable of being an age-dependent enabler for 
reduced stress resiliency. In addition, its role in resiliency and its 
topography in the brain indicate a possibility of altered memory 
processing, since FKBP5 is present in all the regions of the brain that 
handle memory. Here, we aged C57BL/6 mice and longitudinally tested 
their ability to respond to the forced swim and tail suspension tests. 
We found that wild type mice display reduced resiliency in the tail 
suspension test with age, and the FKBP5-/- mice display increased 
resiliency due to genotype and aging. Moreover, the FKBP5-/- display 
reduced serum corticosterone after stress at all ages, and the wild 
type mice produce increased serum corticosterone after stress with 
age. Additionally, the FKBP5-/- mice display greater cognitive 
flexibility, as they learn the reversal of the hidden platform faster than 
the wild type mice. Moreover, the FKBP5-/- mice have equal rates of 
survival as wild type mice up to 800 days. These data suggest that 
FKBP5-/- is beneficial for resiliency and cognitive flexibility, and that 
reduction of FKBP5 is a promising therapeutic strategy. 
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Materials & Methods
 FKBP5-/- mice
 The mice have been generated as previously described (O'Leary 
et al., 2011) (Touma et al., 2011). Briefly, by PCR screening, the 
129SvJ mouse BAC library (Genome Systems, St. Louis, MO), and the 
bacterial artificial chromosome (BAC) clones that contained genomic 
regions for FKBP5 were isolated. Restriction fragments were subcloned 
into pBluescript (pBS; Stratagene, La Jolla, CA) or pZero (Invitrogen, 
Carlsbad, CA) cloning vectors, and the PCR products were amplified 
from the BAC clones, which were then used to construct a targeting 
vector in the pPGKneo vector (a generous gift of James Lee, Mayo 
Clinic Scottsdale). The targeting vector contained a beta-
galactosidase/neomycin cassette flanked by regions homologous to the 
FKBP5 gene. Due to the size of the protein it is more practical to 
partially delete the gene. Consequently, when the targeting vector 
integrates into the chromosome through homologous recombination it 
removes all of exon 2, which is the first coding exon. Since the only 
deleted portion of the gene is exon 2, the expression of the beta-
galactosidase protein is dependent on the FKBP5 promoter and 
transcription machinery, and expresses in frame with the initiation 
codon. ES cells were isolated from the 129SvJ mouse and cultured in 
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Knockout DMEM media (Invitrogen) supplemented with 10% FBS, 
penicillin/streptomycin, essential amino acids, and ESGRO (103 U/ml; 
Chemicon, Temecula, CA) with irradiated embryonic fibroblast feeder 
cells. The ES cells were then electroporated at 0.2 kV, 950 µF (Gene 
Pulser II; Bio-Rad, Hercules, CA) with linearized targeting vectors and 
selected with G418. DNA from G418-resistant clones was isolated for 
Southern blot analysis, and a DNA probe was used to distinguish PstI 
restriction fragments from wildtype allele (~7.5 kb) and targeting 
vector (~10 kb). Appropriate homologous recombination in ES cell 
clones was confirmed by PCR using primers complementary to 
sequences within the neomycin cassette and to 3′ FKBP5 sequences 
downstream from the recombination site. ES cell clones containing the 
targeting vector were injected into C57BL/6 blastocysts and implanted 
into pseudopregnant 129SvJ females. Chimeric offspring were 
identified by coat patterns and mated to C57BL/6 mice to obtain 
germline transmission of the targeting vector. For colony maintenance 
mice were crossed from C57BL6 onto Swiss-Webster for purposes of 
fecundity and genetic diversity to be more representative of a human 
population.
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 Porsolt forced swim test (FST)
 This test was performed as previously published (O'Leary et al., 
2011). Each mouse was placed in a tall (45 centimeters high and 20 
centimeters diameter) clear Plexiglas cylinder filled with room 
temperature water to a depth of 12 centimeters for a total of 6 
minutes. The total time immobile was measured. Any immobility 
episode below two seconds was not used towards the total.
 Tail suspension test (TST)
 Each mouse was suspended from the tail for 6 minutes. The total 
time spent immobile was measured. Any immobility episode below two 
seconds was not used towards the total.
 Radial arm water maze
 A six arm apparatus was placed inside a black painted pool, filled 
with 10 cm of water. The pool was close to the room’s walls for queue 
visibility. The hidden platform was located in a different arm for each 
mouse (goal arm), and the arm in which they were placed at the 
beginning of each trial (start arm) was changed every trial. Each 
mouse had 60 seconds to find the hidden platform in any given trial. 
The number of incorrect arm entries and the escape latencies were 
recorded. An entry is considered as such when all four limbs have 
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entered the arm. An error was also scored when the mouse did not 
choose an entry for 15 sec. If the mouse did not find the platform after 
1 minute, the mouse was gently guided to and placed on it. 
Afterwards, the mouse was kept on the platform for 15 seconds. The 
mice were towel dried and placed under a heat lamp to dry completely. 
On day one, trial one through twelve alternated between visible and 
hidden platforms, and trial thirteen through fifteen were performed 
using the hidden platform only. A total of fifteen trials a day were 
performed. On day two, only the hidden platform was used. On day 
four, a goal arm reversal was performed, where the hidden platform 
was placed in the directly opposite arm. The same procedure was 
repeated for the revearsal, for a total of six days of training: three 
days for initial platform training and three days for retraining. This 
protocol is based on a previously published one (Alamed et al., 2006).
 Corticosterone assay, blood collection and stress paradigm
 The levels of corticosterone were measured using an ELISA kit 
(Enzo Life Sciences, Plymouth Meeting, PA). Blood from the mice was 
collected in the morning one hour after the light cycle began and 30 
min after a 10-min tube restraint using the submandibular vein 
puncture method.
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 Glucose challenge
 Mice were fasted overnight. The next morning they were injected 
with a 2g/kg dose of sucrose (Sigma) into the peritoneum. Blood drops 
were collected and analyzed in a standard glucometer at baseline, 30, 
75, and 120 minutes after injection. 
 Western blotting and tissue processing
 Western blotting was performed as previously described (Dickey 
et al., 2006). Briefly, mouse brain samples were homogenized in lysis 
buffer containing 50 mM Tris-HCl pH 8.0, 274 mM NaCl, 5 mM KCl, 
phosphatase inhibitor cocktail I (Sigma), phosphatase inhibitor cocktail 
II (Sigma), mammalian protease inhibitor cocktail (Sigma), and 1 mM 
PMSF (Sigma). Protein concentration was determined using a 
bicinchoninic acid protein assay (Peirce). Samples were heated for five 
minutes in Laemmli’s buffer and 5% B-mercaptoethanol (Sigma). 
Equal amounts of protein were loaded onto 10% Tris-glycine SDS-
PAGE gels. Afterwards, the gels were transferred onto polyvinalidene 
fluoride membranes (Millipore) using the Biorad transfer system, and 
blocked for 1 hour in 5% non-fat dry milk diluted in Tris buffered 
Sailne and 0.2% Triton-X 100 (Fischer). 
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 Complete blood count
 Complete blood count measurements were performed with a 
blood analyzer (Heska).
 Size measurements
 Size measurements were performed using a standard digital 
caliper. 
 Cytokine measurements
 Cytokine levels were measured using the Bioplex system from 
Biorad with the Biorad 8-panel cytokine kit.
 Long-term potentiation
 LTP was performed as previously described (Abisambra et al., 
2010). For the stress experiment, mice were restrained in their cages 
for 1 hour.  
 Statistics and chance levels
  Assuming that the mice can adjust their performance to make 
no more than 6 errors, only entering an arm once, we can determine 
the chance level using a a negative hypergeometric distribution with 
the following equation, (α(n + 1)/(α + 1)) - α. “α” is the total number 
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of arms with an escape (platform), and “n” is the total number of 
arms. This results in 2.5. This was previously published (Diamond et 
al., 1996; Diamond et al., 1999).
Results
 FKBP5-/- mice have been shown to display stress resiliency 
(O'Leary et al., 2011; Hartmann et al., 2012). At three months of age 
the amount of stress required to precipitate this phenotype was much 
greater than at 21 months of age, since they required prior restraint 
stress to display a phenotype in the forced swim test, and 21 month 
old mice do not. However, age also increases the levels of FKBP5 (Blair 
et al., In Press)(Jinwal et al., 2010; O'Leary et al., 2011). 
Consequently, we wanted to investigate if there is a relationship 
between age and behavior due to FKBP5. We subjected two cohorts of 
FKBP5-/- mice and their wild type littermates ages 6, and 21 months 
to the tail suspension and forced swim tests. In the tail suspension 
test, analysis by a two-way ANOVA revealed that there was a strong 
genotype (F(1,30)=13.30, ***p=0.001), and aging effect 
(F(1,30)=10.33, *p=0.00031) for increased resilience in the FKBP5-/- 
mice (Figure 4.1 A). In the forced swim test, there was a strong 
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genotype effect (F(1,33)=14.12, p=0.0007), but no aging effect 
(F(1,33)=0.70, p=0.4102) (Figure 4.1 B). 
 
 Due to the strong inhibition FKBP5 confers on GR we also 
measured serum corticosterone levels after stress longitudinally 
(Figure 4.2). There is a strong genotype effect for the FKBP5-/- mice 
to produce less corticosterone after stress (F(1,50)=13.26, 
***p=0.0006). There is also a significant effect for the increase in 
corticosterone with age (F(1,50)=4.46, *p=0.0397) which the 
FKBP5-/- mice are protected from. 
 Glucocorticoids are very important for general metabolic 
processes and immune system function. They are known to promote 
fat deposition and glucose metabolism (Lee et al., 2013). 
Glucocorticoids are given routinely to reduce inflammation (Barnes, 
1998).  Since these mice produce less glucocorticoids during stress, 
we tested their weight, and size. There were no significant changes 
between these (Table 4.1). To test for glucose metabolism we 
challenged these mice with a 2g/kg of sucrose injected into the 
peritoneum after an overnight fast. We tested blood levels at 0 (before 
injection), 30, 75 and 120 minutes after injection. There was no 
significant change in glucose metabolism in these mice (Figure 4.3). 
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FKBP5 is actually primarily known as an immune protein, since it is 
part of a family of proteins that provide immunosuppressive properties 
to FK506 and cyclosporine. Because of this and the corticosterone 
phenotype, we also tested for changes in the number of white blood 
cells, and there were no differences between the groups (Table 4.1). 
 Glucocorticoids also have important immunosuppressive 
properties. Since FKBP5-/- mice produce less corticosterone after 
stress, we tested the effect of this hypoglucocorticoid phenotype on 
the levels of serum cytokines at different ages (Figure 4.4). We found 
that at 7 months FKBP5-/- mice display a reduction in IL-1β, and IL-5. 
However, this difference is not present at 10 and 22 months old. 
 We, and others, have previously shown that FKBP5 is highly 
expressed in the hippocampus (O'Leary et al., 2011; Scharf et al., 
2011). Consequently, we previously performed the Morris water maze 
on the FKBP5-/- mice to test if the ablation of the gene had any effect 
on learning and memory. Despite its robust expression in this highly 
important memory center, there were no changes. Even so, It may be 
that the absence of FKBP5 has an effect in other regions of the brain 
involved with memory. The radial arm water maze offers an advantage 
for this question, since the mice are forced to make a decision as to 
which arm they should enter. Decision-making requires a group of 
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brain regions working together (Clark et al., 2004). Using a reversal 
experiment, where the platform is changed to an alternative arm, the 
mice have to relearn the position of the platform. Consequently, we 
can test for cognitive flexibility and the ability to relearn. We did not 
observe any changes between the initial acquisition of the of RAWM 
training (Figure 4.5 A). When we reversed the location of the platform, 
however, the FKBP5-/- mice were better able to relearn (Figure 4.5 B). 
They quickly reached the learning criteria. This criteria consists of 
committing fewer errors than chance, which is 2.5 errors per trial in 
this paradigm, as established previously (Diamond et al., 1996). The 
FKBP5-/- mice achieved this on trial 18 (day four), but the wild type 
mice did not cross this threshold until trial 21 (day five). The total 
number of errors per day shows no change in the first three days 
(Figure 4.5 C), but the reversal displays a significant genotype effect 
(F(1,16)=4.9, p=0.0417), as the knockout mice learn the new location 
faster, and make fewer errors (Figure 4.5 D). Despite the greater 
ability to display cognitive flexibility, there is no change in hippocampal 
long-term potentiation (Figure 4.6 A), suggesting this could be an 
enhancement from another brain region, perhaps the prefrontal 
cortex. There is also no significant difference between the slopes of the 
amplitude of the fiber volley and the slopes of the field excitatory post-
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synaptic potential, which indicates a normal relationship between the 
presynaptic and postsynaptic response (Figure 4.6 B).
 
 One potential role for FKBP5 is to protect from GR activity, since 
the hippocampus is very sensitive to glucocorticoids (Popoli et al., 
2012). To test for this we challenged 12 month old wild type and 
FKBP5-/- mice to acute restraint stress for one hour prior to the 
performance of long term potentiation. We found that FKBP5-/- mice 
display reduced potentiation and do not maintain long term 
potentiation as compared to the wild type mice (Figure 4.7 A). There is 
a significant genotype effect F(1,624)=75.47, ***p<0.0001), and time 
effect (F(29,624)=3.95, ***p<0.0001). The last five minutes are also 
significantly different F(1,105)=39.24, ***p=0.0001). This difference 
is not altered due to an altered postsynaptic response due to a 
presynaptic stimulus(Figure 4.7 B).
 Due to the strong genotype effect in resilient behavior and 
corticosterone signaling, FKBP5 is a promising therapeutic target for 
the treatment of psychiatric disease and emotional endurance. As a 
result, it is important to study the effect of longterm FKBP5 ablation on 
the lifespan. We aged wild type and FKBP5-/- mice up to ~800 days 
and both populations displayed 50% survival of the cohort (Figure 
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4.8). There was no statistical significance between the groups (Log-
rank, Mantel-Cox, test, χ2=0.001354, p=0.9707). 
Discussion
 Here we show that FKBP5 has an effect in resiliency with aging 
and genotype and that its ablation is beneficial in responding to 
emotionally stressful situations. We also show that the lack of FKBP5 
allows for greater cognitive flexibility in non-emotional memory, as the 
FKBP5-/- mice quickly adapt to the reversal of the hidden platform in 
the 6 radial arm water maze. Moreover, the lack of FKBP5 does not 
affect the lifespan or healthspan of these mice. 
 One interesting observation from these data is that there is an 
age dependent increase in immobility in the tail suspension test that is 
not present in the forced swim test. From observation of the videos of 
the mice in these tests, it is plausible that the tail suspension test is a 
more uncomfortable test than the forced swim test, as they seem to 
struggle more. In the forced swim test the water is at room 
temperature, ~23-25 , and although the mice do not like swimming, 
they are very good swimmers. Thus, the level of discomfort may be 
less than the tail suspension test. This could explain the discrepancy 
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between the two tests. However, there is still a strong genotype effect 
regardless of aging. 
 Because glucocorticoids promote anti-inflammation, and the 
FKBP5-/- mice display hypoglucocorticoidism after stress, we expected 
the levels of basal cytokines to increase in these mice with age. 
However, this did not occur. In fact, the exact opposite was observed 
for the 7-month old cohort. One possible explanation is that the 
chronic absence of FKBP5 causes the activation of a compensatory 
mechanism for inflammation. 
  Previously, the FKBP5-/- mice did not exhibit any hippocampal 
memory deficits (O'Leary et al., 2011), and here we show no change in 
hippocampal LTP, proving that there is no abnormalities to the 
hippocampus in the FKBP5-/- mice. As a result, we tested these mice 
in the radial arm water maze, as the mice are required to make a 
decision. Decision-making is dependent on several brain regions 
working together (Clark et al., 2004; Euston et al., 2012). This may be 
better able to show if there is a change in memory processing as a 
whole. The results here show that FKBP5 reduces cognitive flexibility. 
Interestingly, it has been shown that in depression, patients also 
display reduced cognitive flexibility (Deveney and Deldin, 2006; 
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Murphy et al., 2012). The prefrontal cortex has been identified as an 
important brain region for cognitive flexibility (Clark et al., 2004; 
Armbruster et al., 2012). This area has also been identified as under 
active in patients with PTSD (Shin et al., 2006), and it is also involved 
in resilience, since its activity is enhanced in people who experience 
trauma, but do not develop PTSD (Fani et al., 2012). These resilient 
subjects also display stronger physical connections in the circuitry 
connecting the hippocampus with the anterior cingulate cortex, an 
area of the prefrontal cortex. PTSD-subjects also display greater 
amygdaloid activity (Shin et al., 2006). In context with these data, 
FKBP5 deletion may manifest its effects by reducing amygdaloid 
activity and increasing prefrontal cortex activity during or even after a 
stressful event. Mice treated with an shRNA virus against FKBP5 in the 
amygdala display reduced anxiety in the elevated plus maze, after six 
hours of restraint stress (Attwood et al., 2011). In the same study, N-
methyl-D-aspartate receptor activity in the Amygdala resulted in a 
massive increase in FKBP5, which led to anxious behavior. 
 
 Astonishingly, in all the literature regarding FKBP5, we have 
found only a few benefits to having this protein. Patients with the 
FKBP5 SNP rs1360780 display a more rapid response to antidepressant 
treatments compared to other depressed patients without this FKBP5 
118
allele (Binder et al., 2004). This includes treatment with selective 
serotonin reuptake inhibitors, tricyclic antidepressants, and 
mirtazapine. However, these same patients have a greater number of 
depressive episodes throughout their life. The aging data in this study 
further presses the point that the lack of this gene is not damaging, 
and may even be beneficial. 
However, it has been shown that acute stress enhances memory 
(Shors, 2001; Spyrka et al., 2011). Here, we show that FKBP5-/- mice 
are not able to display enhanced LTP due to acute stress. As a result, it 
is possible that FKBP5 protects the hippocampus from damage due to 
excessive glucocorticoid receptor activity. It may be that chronic stress 
given to the FKBP5-/- mice may damage the hippocampus to a greater 
extent than wild type mice. This would be a good future study.
Conclusion
 In conclusion, this study shows that FKBP5 knockout animals are 
protected from an age and genotype dependent reduction in resilience, 
and increased corticosterone production. Moreover, FKBP5 knockout 
provides greater cognitive flexibility, and does not reduce lifespan. As a 
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result, FKBP5 may be an excellent target for the treatment of 
psychiatric diseases of the elderly. 
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Table 4.1. FKBP5-/- mice display no changes in body weight, 
size, or white blood cell counts.
  Wild type   FKBP5-/-    
 Units Value S.D. N Value S.D. N P value
Mass g 43.04 11.6 12 38.82 8.382 13 0.3043
Width mm 26.78 7.674 12 24.35 4.294 13 0.3338
Depth mm 23.94 6.734 12 21.57 3.88 13 0.2868
WBC 10^3/uL 4.155 2.282 11 3.3 2.854 12 0.4394
WBC, white blood cells; S.D., standard deviation; N, sample size. P-
value was derived by t-test comparing wild type with FKBP5-/- 
animals.
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Figure 4.1. FKBP5-/- mice display a protection from FKBP5-
induced decrease in resiliency. (A) Amount of time spent immobile 
in the tail suspension test in three separate cohorts of mice at two 
different ages. Analysis by 2-way ANOVA revealed a genotype effect 
(F(1,30)=13.30, ***p=0.001), aging effect (F(1,30)=10.33, 
*p=0.00031). (B) Amount of time spent immobile in the forced swim 
test in three separate cohorts of mice at three different ages. Analysis 
by 2-way ANOVA revealed a genotype effect (F(1,33)=14.12, 
p=0.0007), but no aging effect (F(1,33)=0.70, p=0.4102). 
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Figure 4 .2 . FKBP5-/- mice exhib i t reduced serum 
corticosterone after stress, which is exacerbated with age. 
Several cohorts of mice were tested in this experiment, n=25 wt, 
n=29 FKBP5-/-. Post hoc, the mice were plotted by groups according 
to the age of 10 months. Serum corticosterone after stress shows a 
strong genotype effect (F(1,50)=13.26, ***p=0.0006). Serum 
corticosterone after stress also increases with age, (F(1,50)=4.46, 
*p=0.0397).
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Figure 4.3. FKBP5-/- mice display normal glucose processing. 
Glucose challenge of wild type and FKBP5-/- mice. Mice were fasted 
overnight and challenged the next morning with a 2 g/kg dose of 
sucrose and their glucose levels were monitored for two hours (F 
(1,15)=0.17, p=0.6855).
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Figure 4.4. IL-1β and IL-5 are reduced in the FKBP5-/- mice at 
7 months of age. (A) FKBP5-/- mice of 7 months of age display 
reduced levels of basal serum IL-1β, and IL-5 as compared to wild type 
mice. (B) FKBP5-/- mice do not show statistical difference in the levels 
of basal serum cytokines at 10 months of age. (C) FKBP5-/- mice do 
not show a statistical difference in the levels of basal serum cytokines 
at 22 months of age. *p<0.05, **p<0.01. 
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Figure 4.5. FKBP5 ablation increases cognitive flexibility. (A) 
Acquisition phase of the six radial arm water maze. Each number is a 
group of three trials. (B) Reversal of the location of the hidden 
platform. (C) Total number of errors per day in the initial acquisition 
phase of learning the location of the escape platform. (D) Total number 
of errors per day in the reversal of the escape platform (F(1,16)=4.9, 
*p=0.0417). Dashed line represents the probability of the number of 
errors per day by chance. Chance is accepted as 2.5 errors per trial, 
and there are 15 trials per day.
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Figure 4.6. Knockout of FKBP5 gene does not affect long term 
potentiation. (A) 30 minutes of long term potentiation does not show 
a deficit between wild type and FKBP5-/- mice. (B) Equal presynaptic 
stimulus does not produce differential postsynaptic response.
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Figure 4.7
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Figure 4.7. Long-term potentiation is enhanced in wild type 
mice after acute restraint stress, but not in FKBP5-/- mice. (A) 
Hippocampal long-term potentiation of mice after 1 hour of acute 
restraint stress displays FKBP5-/- mice do not potentiate or maintain 
LTP to the extent of wild type mice. (B) Equal presynaptic stimulus 
does not produce differential postsynaptic response.
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Figure 4.8. Ablation of the FKBP5 gene does not alter lifespan. 
Survival curve of wild type and FKBP5-/- mice. Approximately 50% of 
both cohorts are still alive at 800 days (2= 0.0014, p=0.9707).
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CHAPTER FIVE:
Discussion & Conclusions
Hsp70 and Methylene Blue
 In the introduction we outlined that the targeting of soluble tau 
is a promising therapeutic avenue for the treatment of AD. In “Chapter 
Two” we tested this hypothesis with methylene blue, due to its ability 
to inhibit Hsp70 ATPase activity and reduce tau levels in various 
neuronal and non-neuronal cell models. Methylene blue was able to 
reduce tau when found in large concentrations in the brain. It was also 
able to rescue neuronal death. Interestingly, cognition was only 
restored in animals where tau levels were lowered. Mice with low 
levels of methylene blue displayed robust neuroprotection, but no 
reduction in tau. As a result, there was no improvement in cognition, 
suggesting that protection from tau-induced neuronal malfunction 
came from lessening the tau burden. Keeping more neurons alive was 
only beneficial when tau was reduced. This indicates that keeping 
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neurons alive is not sufficient for the treatment of AD. Removing tau, 
however, allows neurons to communicate properly to establish 
function, in this case memory. This idea is further discussed in 
Appendix C.
 Methylene blue is a tau fibril inhibitor?
 Despite its success in clinical trials and in animal models, there is 
some controversy as to the mechanism(s) of methylene blue. In vitro, 
methylene blue displays an inhibition of tau fibrillization, potentially 
through the oxidation of cysteine residues (Wischik et al., 1996; 
Miyata et al., 2012; Akoury et al., 2013). However, there is yet to be a 
study where methylene blue treatment retards, prevents or reduces 
tau tangles in vivo, including the study in this dissertation, “Chapter 
Two.” Here, there were no differences in tangle load in mice treated 
with methylene blue in their water at 165 µM, or direct injection to the 
brain at 1 mM concentration. But as has been previously established, a 
change in tangle load may not be necessary to improve cognition. 
Others have also found methylene blue treatment to be beneficial in 
other AD, tau, and other neurodegenerative mouse models (Deiana et 
al., 2009; Medina et al., 2010; Congdon et al., 2012; Hosokawa et al., 
2012).
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 Future work
 Although we do not know the precise mechanism of how 
methylene blue affects tau, it is important to note that it has shown 
positive effects in phase 2 clinical trials (Gura, 2008; Wischik and 
Staff, 2009). TauRxⓡ, the company that put methylene blue through 
the trials, has patented an analog of the compound called leuco-
methylthioninium, LMTX™, and has begun enrolling patients into phase 
three clinical trials (Yan, 2012). This is the most exciting part, to think 
that soon a new therapeutic option may be available. However, further 
work into the Hsp70 chaperone network has revealed that different 
Hsp70 proteins have differential effects on tau levels (Jinwal et al., 
2013). In fact, there are 11 human Hsp70 genes, according to one 
article (Tavaria et al., 1996). However, an extensive discussion on 
these genes argues that 5 of these are not real, and thus there are 
really 7 Hsp70 genes that make a protein (Moran). The HSPA1L gene 
is specific to the testis, the HSPA5 is specific to the ER, and the 
HSPA9B is specific to the mitochondria. The rest are cytosolic, the 
HSPA1A and he HSPA1B, are inducible, and HSPA2 and HSPA8, are 
constitutively expressed.The work of Dr. Chad Dickey and Dr. Umesh 
Jinwal suggest that there is a chaperone “code,” which helps create 
proteostasis in the cell (Jinwal et al., 2010; Jinwal et al., 2011; Jinwal 
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et al., 2013). Future work must elucidate which genes are good for tau 
degradation and which ones promote tau accumulation. Then, we have 
to develop strategies to fine tune the activities of these genes to 
promote tau clearance. 
 Implications
 This study on methylene blue goes beyond the ability of 
methylene blue to affect cognition in Alzheimer’s disease. It is part of a 
fuselage of work from Dr. Dickey’s laboratory showing the potential 
that chaperone proteins have as targets from which therapies can be 
developed for the treatment of neurodegenerative diseases. This study 
is also important for the tau field, as these data support the previous 
work showing that reducing the levels of soluble tau is beneficial 
(Santacruz et al., 2005) (de Calignon et al., 2010) . The reduction of 
the tau burden in these mice was not detrimental to their locomotion 
or motor skills, as suggested it would be by the study showing tau 
knockout mice having motor issues with age. On the contrary, mice 
regained cognitive function from tau removal. Tau tangles were not 
removed and the number of tangles remained steady, and the result 
was not affected by this. 
151
FKBP5 and Stress Disorders
 FKBP5 levels are elevated in people with SNPs in the FKBP5 
gene. These people are overrepresented in the population of those 
who have experienced severe trauma and develop mood disorders. In 
“Chapter Three” and “Chapter Four,” we tested the hypothesis that the 
absence of FKBP5 would protect from developing disease. The 
FKBP5-/- mice were protected from an increase in age-related 
corticosterone levels, and displayed increased resilience and cognitive 
flexibility, both due to stress and age. Natural resilience decreased 
with age in wild type mice, but the FKBP5-/- mice were protected from 
this. Moreover, global knockout of this gene was not deleterious in any 
measurements done in these studies. 
 
 Future work
 Several experiments need to be done to further validate the 
results in this dissertation. First, we performed these experiments on a 
permanent knockout mouse line. Accordingly, we need to test if the 
transient knockout of this gene is as effective in treating disease. 
Moreover, this mouse line is a global knockout, thus the transient 
knockout mouse should be a brain only knockout as well. After this 
validation, therapeutic strategies need to be developed to reduce the 
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levels of FKBP5 in the brain, and then translated into human clinical 
trials. 
 Implications
 There has been a lack of development of new therapies in the 
realm of mood and anxiety disorders from the use of hypothesis driven 
science (2007). As a result, these studies are very exciting, as we 
have a good general understanding of the mechanism of how the 
environment is changing our genetic regulation, thus making us more 
susceptible to disease. Traditionally, the ideas are first developed in 
animal models and then tested in humans. Here, it has been the 
opposite. Since FKBP5 is ubiquitous in the human body, mRNA levels 
can be tested in blood cells, and these highly correlate with brain 
mRNA levels (Sullivan et al., 2006). As a result, we know that chronic 
elevation of FKBP5 levels is bad for people. Armed with this knowledge 
we can develop therapies aimed at decreasing the levels of FKBP5.
 Very little work has been done with resilience and the genetic 
causes of resilience, but even less on the resilience of the elderly. This 
work shows that the absence of FKBP5 provides mice with an 
enhancement in resilience that extends on to old age. There is also a 
very strong correlation between elevated cortisol levels and psychiatric 
disease (Pariante and Miller, 2001). As a result, the reduced cortisol 
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phenotype observed in these mice has the potential to alleviate the 
risk of developing different types of mood and anxiety disorders. 
Conclusion
 Chaperone proteins are very important in the cell. They are 
responsible for folding, transporting, receptor function, assisting 
endocytic vesicles, decreasing levels of reactive oxygen species, 
vesicle fusion, protein degradation, preventing protein aggregation, 
and ER associated degradation, among others (Muchowski and Wacker, 
2005). Despite this, their function is not always sufficient to prevent 
disease. Because of their multiple talents, though, we can modulate 
them to restore health, and prevent disease.
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APPENDIX A:
Chapter Two Supplementary Material
 Appendix A consists of the supplementary material from 
“Chapter 2: Phenothiazine-mediated rescue of cognition in tau 
transgenic mice requires neuroprotection and reduced soluble tau 
burden.”
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Figure A1. Chronic MB treatment does not cause abnormal 
changes in mice behavior. (A) Mice were assessed in the open field 
task for abnormal locomotion and exploratory behavior for 30 minutes. 
No statistical differences were observed. (B) Mice were evaluated for 
anxiety in the elevated plus maze task. The amount of time spent in 
the open and closed arms, and the center area was evaluated and at 
least one mean was indicated to be significant (F (3,36) = 3.414, 
p<0.05). Post-hoc evaluation shows that MB treated wild type mice 
displayed significantly more time in the closed arms and significantly 
less time in the open arms than both cohorts of transgenic mice. (C) 
Mice were subjected to the rotorod apparatus for 4 trials a day for 2 
days. No overt differences were observed. (D) Mice positive for human 
P301L tau transgene expression and their wild type littermates were 
grouped based on genotype and MB treatment. On the 14th week of 
chronic MB treatment they were subjected to the water maze 
paradigm. Learning was evaluated by the latency of the mice to find 
the hidden platform. The mice were trained until the wild type mice 
plateaued. Wild Type animals learned significantly better than 
transgenic animals (n=10 per group, F (3, 236) = 19.71, p<0.0001). 
(E) Graphic representation of the mean latency of all mice in all trials 
of plot d.
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Figure A2. Differences in parenchymal drug concentrations 
could not be attributed to gender or weight. (A) All drug treated 
mice (both transgenic and wild type) separated by gender show no 
statistical difference between the means, p=0.7197 (males n=10, 
females n=9). (B) Linear regression and correlation between weight 
and drug concentration show that slope is not significantly non-zero 
and correlation is not statistically significant, p=0.7778 (n=19).
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Figure A3. Mice treated with methylene blue display normal 
vision and swim speed. (A) Visible trial in the Morris water maze 
displays no significant difference between groups. (B) Swim speed in 
the Morris water maze shows no significant difference between the 
groups. 
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APPENDIX B3:
Hsc70 Rapidly Engages Tau after Microtubule Destabilization
Abstract
 The microtubule-associated protein Tau plays a crucial role in 
regulating the dynamic stability of microtubules during neuronal 
deve lopment and synapt ic t ransmiss ion. In a group of 
neurodegenerative diseases, such as Alzheimer disease and other 
tauopathies, conformational changes in Tau are associated with the 
initial stages of disease pathology. Folding of Tau into the MC1 
conformation, where the amino acids at residues 7–9 interact with 
residues 312–342, is one of the earliest pathological alterations of Tau 
in Alzheimer disease. The mechanism of this conformational change in 
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Chemistry (Jinwal, U. K., O'Leary, J. C., Borysov, S. I., Jones, J. R., Li, 
Q., Koren, J., ... & Dickey, C. A. (2010). Hsc70 rapidly engages tau 
after microtubule destabilization. Journal of Biological Chemistry, 
285(22), 16798-16805.), and is used here with permission of the 
publisher. The permissions are available in Appendix F. © the American 
Society for Biochemistry and Molecular Biology.
Tau and the subsequent effect on function and association to 
microtubules is largely unknown. Recent work by our group and others 
suggests that members of the Hsp70 family play a significant role in 
Tau regulation. Our new findings suggest that heat shock cognate 
(Hsc) 70 facilitates Tau-mediated microtubule polymerization. The 
association of Hsc70 with Tau was rapidly enhanced following 
treatment with microtubule-destabilizing agents. The fate of Tau 
released from the microtubule was found to be dependent on ATPase 
activity of Hsc70. Microtubule destabilization also rapidly increased the 
MC1 folded conformation of Tau. An in vitro assay suggests that Hsc70 
facilitates formation of MC1 Tau. However, in a hyperphosphorylating 
environment, the formation of MC1 was abrogated, but Hsc70 binding 
to Tau was enhanced. Thus, under normal circumstances, MC1 
formation may be a protective conformation facilitated by Hsc70. 
However, in a diseased environment, Hsc70 may preserve Tau in a 
more unstructured state, perhaps facilitating its pathogenicity.
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Introduction
 Deposition of Tau after its sequestration from microtubules is a 
neuropathological hallmark of a group of diseases termed tauopathies. 
This family of diseases includes Alzheimer disease (AD),3 hereditary 
frontotemporal dementia with parkinsonism linked to chromosome 17, 
progressive supranuclear palsy, and corticobasal degeneration (1,–4). 
The Tau protein is normally expressed in the cytoplasm of neurons and 
performs the critical function of stabilizing and maintaining the 
microtubule networks that are essential for axonal transport. During 
the development of Tau pathology, Tau dissociates from microtubules, 
and unknown factors converge to cause abnormal polymerization of 
Tau into highly insoluble paired helical filaments (PHF) and forms 
neurofibillary tangles. The number of neurofibillary tangles directly 
correlates with the degree of dementia seen in the progressing stages 
of AD (5, 6); however, it is now speculated that it is intermediate 
species of Tau rather than the pathologically visible tangles that are 
the most toxic (7, 8). It has been hypothesized that in disease, 
hyperphosphorylation and conformational changes lead to the loss of 
function and pathogenic assembly of Tau (9,–11). This idea of Tau 
adopting a conformation, or “fold,” is somewhat paradoxical because 
Tau is almost entirely an unstructured protein. However, evidence for a 
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folded Tau species emerged from studies that used paired helical 
filaments from AD brain as haptens for monoclonal antibody 
production (10,–12). Several antibodies were generated that had 
discontinuous epitopes within the Tau molecule. One of these 
antibodies, MC1, recognizes Tau when its N terminus is positioned near 
residues of the ninth exon. Pathological studies with this antibody 
revealed that formation of this species was an early event in Tau 
pathology in AD (10,–12). Thus, detection of Tau in the MC1 
conformation could result from either folding of a single Tau molecule, 
or it could be due to anti-parallel stacking/filament formation of Tau.
The emergence of molecular chaperones as key regulators of Tau 
processing suggests that conformational changes to the structure of 
Tau may indeed be key events in the pathogenesis of AD and other 
tauopathies (13,–17). Aggregation of Tau in vitro is negligible and 
typically requires accelerants such as heparin (18, 19), an indication 
that conformation plays an important role in its assembly. In a cellular 
environment, post-translational processing of Tau is likely essential for 
facilitating its aggregation, and certainly this could be regulated by the 
chaperone network. One of the first described chaperone regulators of 
Tau is the Hsp70 chaperone family. This family is comprised of 13 
members; however, the cytoplasm is predominated by two members, 
the constitutive heat shock cognate (Hsc) 70 protein and the inducible 
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Hsp70. Hsc70 and Hsp70 share 92% primary sequence homology. 
Both have highly conserved N-terminal ATPase domains as well as 
substrate-binding domains located just upstream of a more variable/
regulatory domain (20). The cyto-protective role of Hsc70 may be 
particularly relevant in neurons where an attenuated Hsp70 response 
has been correlated with aging. Hsc70 and Hsp70 can each bind Tau in 
the nervous system, but endogenous Hsc70 is typically in much higher 
abundance than Hsp70 in the cytosol (21, 22). Based on previous 
work, we hypothesized that the highly abundant Hsc70 protein would 
be the most likely member of the Hsp70 family to regulate Tau 
processing. We also speculated that the time when Hsc70 would be 
most engaged with Tau would be following its release from 
microtubules (17). Lastly, we investigated what affect Hsc70 might 
have on Tau in distinct cellular environments. For the first time, we 
have connected microtubule dysfunction with chaperone-mediated 
regulation of Tau, as well as conformational changes to and 
hyperphosphorylation of Tau in a comprehensive way. These findings 
could be useful for implementing therapeutic strategies based on 
Hsc70, given its apparent early involvement in Tau pathogenicity. 
These studies may also point to a mechanism of how Tau dysfunction 
begins in AD and other tauopathies.
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Materials & Methods
 Antibodies and chemicals
 MC1 and PHF1 (anti-S396/S404 p-Tau) were provided by P. 
Davies (Albert Einstein College of Medicine, Yeshiva University, New 
York, NY). Anti-Hsc70 was obtained from Stressgen Biotechnologies 
(Ann Arbor, MI). Anti-actin was obtained from Sigma-Aldrich. Anti-Tau 
(total Tau) was obtained from Santa Cruz Biotechnology Inc. (Santa 
Cruz, CA). Secondary antibodies were obtained from Southern Biotech 
(Birmingham, AL). All of the antibodies were used at a 1:1,000 dilution 
with the exception of PHF1, which was used at a dilution of 1:200. 
Secondary antibodies conjugated to fluorophore were purchased from 
AlexaFluor (Molecular Probes). Albendazole, colchicine, paclitaxel, 
okadaic acid, and phenothiazine (methylene blue) were purchased 
from Sigma. Nocodazole was purchased from Tocris Bioscience.
 Recombinant protein purification
 Wild type 4R Tau and Hsc70 gene sequences cloned into pET28 
vector with His tag and were transformed into the Escherichia coli 
strain BL21 (DE3) codon Plus. Bacterial culture condition and protein 
purification protocol were followed as described earlier (23). The purity 
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of all proteins was verified on a Coomassie Brilliant Blue-stained SDS-
polyacrylamide gel.
 Xenopus oocytes
 S phase Xenopus egg extracts were prepared according to a 
standard protocol (24) and supplemented with 5% Me2SO to stimulate 
microtubule polymerization as described (23). Purified recombinant 
wild type Tau and Hsc70 proteins were added at a final concentration 
of 80 ng/µl. The extracts were treated with nocodazole and incubated 
for 30 min at room temperature, and newly formed microtubule 
structures were visualized by fluorescence of incorporated rhodamine-
tubuline. Image quantification was performed as previously described 
(25). Briefly, tubulin-positive signal was detected using the same 
threshold for each image in ImageJ (26, 27), and the fraction of the 
total area of the field covered by the tubulin signal was collected for 
statistical analysis.
 Cell culture and western blot analysis
 HeLa cells stably transfected with V5-tagged 4R0N Tau were 
generated using G418 selection. HeLa cells were grown in Opti-Mem 
plus 10% fetal bovine serum (complete media; Invitrogen) and 
passaged every 3–5 days based on 90% confluence. IMR32 cells were 
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maintained in Opti-Mem plus 10% fetal bovine serum and 2% of 200 
mm l-glutamine (Cellgro, Mediatech, Inc., Herndon, VA). The cells 
were harvested in M-PER buffer (Pierce) containing 1× protease 
inhibitor mixture (Calbiochem), 1 mm phenylmethylsulfonyl fluoride, 
and 1× phosphatase inhibitor I and II cocktails (Sigma). The 
measurements of Tau levels in cell culture were performed by Western 
blot analysis. Plasmid transfections were done utilizing Lipofectamine 
2000 reagent from Invitrogen. HeLa cells stably transfected with V5-
tagged 4R human Tau were transfected with 3 µg of DNA. The cells 
were incubated for 4 h with the Lipofectamine/plasmid mixture in Opti-
MEM medium, and this was replaced with fresh complete medium for 
an additional 44–48 h. For the immunoprecipitation (IP) studies, cell 
culture lysates were incubated with 2 µg of antibody for 2–3 h at 4 °C 
with rocking. Then 50 µl of protein G were added and rocked at 4 °C 
for overnight. The protein G beads were pelleted and washed five 
times with phosphate-buffered saline.
 Drug preparations
 All of the drugs for the cell culture experiments were solubilized 
in Me2SO to get a 20 mm stock. For the in vivo study in mice, 
albendazole used in the hippocampal injections in Figure B3 panel C 
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were prepared by dissolving 3 g of albendazole in 40% hydroxypropyl-
β-cyclodextrin in water.
 Immunocytochemistry
 IMR32 cells were plated onto a chamber slide (Fisher) and 
maintained in the medium described above. The cells were treated 
with nocodazole for 30 min and were fixed in high pressure liquid 
chromatography grade methanol for 15 min. Blocking and 
permeabilization were done by incubating samples with Tris-buffered 
saline containing 5% normal goat serum, 0.1% Tween 20, and 0.03 
NaN3 for 60 min at 25 °C. Primary antibodies rabbit anti-Tau and rat 
anti-Hsc70 (1:100) were added and incubated overnight at 4 °C. The 
slide was washed five times for 5 min in 1× Tris-buffered saline. 
Secondary antibodies AlexaFluor 488 (anti-rabbit; 1:1000) and 594 
(anti-rat; 1:1000) were added to the slides and incubated for 60 min 
at 25 °C. The slides were washed and coverslipped. A Leica confocal 
microscope was used to take images. Significance was assessed by 
Pearson's correlation coefficient.
 Albendazole injections in mouse brains
 All of the procedures using mice were done in accord with the 
guidelines set forth by the University of South Florida's Institutional 
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Animal Care and Use Committee. The wild type FVB/N background 
mice brain hippocampus were injected with 2 µl of vehicle and 3 mg/
ml albendazole. The surgical procedure was performed as previously 
described by Carty et al. (28) with some modifications. The mice were 
anesthetized using isofluorane, and the cranium was exposed with a 
small incision along the skin covering the medial sagittal plane. Holes 
were drilled through the cranium over the desired injection sites as 
measured with a stereotaxic apparatus. Burr holes were drilled using a 
dental drill bit (SSW HP-3; SSWhiteBurs) or a 21-gauge needle (BD). A 
2-µl total volume of vehicle or albendazole were dispensed into the 
each injection site. The animals were recovered within 10 min of post-
surgery and were singly housed. 24 h after the injections, the brains 
were harvested as described earlier (29) and processed for 
immunoprecipitation as described above.
 Enzyme-linked immunosorbent assay
 Tau and HSP complex containing Hsc70, DNAJB2, and ATP were 
preincubated for 30 min. Paraformaldehyde was added into the 
samples and coated on to 96-well plate for 1 h at 37 °C followed by 
washing five times with wash buffer containing 0.45% NaCl and 0.05% 
Tween 20. Blocking of plate was done for 1 h at 37 °C by using 
starting blocking solution (Pierce and Thermo Fisher Scientific), 
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followed by a wash. MC1 antibody was added at 1:50 dilutions and 
incubated at 37 °C for 1 h, and the plate was washed again. 
Horseradish peroxidase-linked secondary antibody was added and 
incubated at 37 °C for 1 h. The plate was washed. 3,3′,5,5′-
Tetramethylbenzidine dihydrochloride (Sigma) solution was added, and 
the reaction was stopped by adding 2 m H2SO4. The plate was read at 
450 nm in spectrophotometer.
Results
 Hsc70 facilitates tau-mediated microtubule stabilization
 Previous work from our lab and others suggested that the Hsp70 
chaperone network plays a critical role in Tau biology and could be 
used as a therapeutic target for tauopathies (13, 14, 17, 30, 31). Of 
the Hsp70 family members, the Hsc70 protein expression level was 
found to be highest in the neurons from adult brain (21, 32,–34). 
Based on this evidence, we investigated the role of Hsc70 on Tau-
mediated microtubule polymerization. We used our recently optimized 
assay for the analysis of microtubule polymerization in oocyte extract 
(23). Using purified recombinant Hsc70 and Tau, we incubated 
Xenopus oocyte extracts with Tau, Hsc70, or a combination of both Tau 
and Hsc70 for 30 min. These extracts were then treated with 20 µm 
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nocodazole or vehicle for an additional 30 min. Microtubule formation 
was analyzed using fluorescent microscopy (Figure B1). Tubulin-
positive signal was detected using the same threshold for each image 
as determined by ImageJ software (26, 27), and the fraction of the 
total area of the field covered by the tubulin signal was collected for 
statistical analysis (Figure B1 B). The extracts incubated with Tau 
alone and Hsc70 alone showed similar levels of microtubule formation 
(Figure B1). However, we observed a significant increase in 
microtubule formation when Tau was supplemented with Hsc70. 
Nocodazole was able to abrogate microtubule formation under all the 
previously mentioned conditions as seen in the representative image 
(Figure B1 A). These findings suggest that Hsc70 could be a potent 
enhancer of Tau-mediated microtubule polymerization, suggesting that 
microtubule dynamics could be critical for facilitating the Tau/Hsc70 
interface.
 
 Tau associates with Hsc70 upon microtubule destabilization
 Although Hsc70 facilitated Tau-mediated microtubule assembly in 
normal cellular oocyte extracts, we found that microtubule 
destabilization with nocodazole overrode this activity (Figure B1). 
Based on this result, we wanted to determine how microtubule 
destabilization may impact the association of Hsc70 with endogenous 
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Tau in an intact cellular environment. First, we performed fluorescent 
immunostaining on neuroblastoma cells (IMR32) following microtubule 
destabilization to determine whether colocalization of these two 
proteins was increased. The cells were grown on chamber slides and 
treated with nocodazole for 30 min and then fixed, and the levels of 
Tau and Hsc70 were assessed by immunofluorescent confocal 
microscopy. Image analysis showed no significant colocalization 
between Tau and Hsc70 in the vehicle-treated cells as determined by 
Pearson's correlation coefficient; however, Hsc70 and Tau were found 
to be colocalized by Pearson's correlation coefficient after nocodazole 
treatment (Figure B2). These data suggested that Hsc70 and Tau do 
have a greater propensity to interact following microtubule 
destabilization. However, we wanted to further confirm these data 
using coimmunoprecipitation studies.
 We tested whether the interaction of Tau with Hsc70 could be 
enhanced with microtubule destabilization in cells overexpressing Tau, 
as well as cells with endogenous Tau levels. We treated IMR32 cells 
that have endogenous levels of Tau with three microtubule-
destabilizing drugs: albendazole, nocodazole, and colchicine. These 
compounds did not increase Hsc70 levels; however, consistent with our 
colocalization data, they did increase the binding of Tau with HSc70 
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(Figure B3, A and B). A similar result was found with HeLa cell 
overexpressing wild type human Tau (Figure B3 C). As a control in this 
overexpressing cell model, we also treated with the microtubule 
stabilizer, paclitaxel, and saw no increase in Tau association to Hsc70 
(Figure B3 C). We then tested whether the association of Hsc70 with 
Tau could be increased by microtubule destabilization in the brain. We 
injected albendazole and vehicle control into the hippocampal region of 
mice. Brain tissue was harvested 24 h after injection, and 
homogenates were analyzed by an IP with Tau antibody followed by 
Western blot probing with Hsc70 antibody. Again, we found that 
microtubule destabilization increased the association of Tau with Hsc70 
(Figure B3 D).
 ATPase activity of Hsp70/Hsc70 regulates tau upon microtubule 
destabilization
 Based on these findings and our previous work with Hsp/Hsc70 
chemical inhibitors (14), we speculated that chemically inhibiting 
Hsc70 activity when the number of Hsc70·Tau complexes is highest 
(after microtubule destabilization) would lead to enhanced efficacy for 
reducing Tau levels. To determine this, we performed dose-response 
studies with an Hsp70 ATPase inhibitor (methylene blue) in the 
presence or absence of a 30-min pretreatment with albendazole. 
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Indeed we found that reductions in both endogenous and 
overexpressed Tau by Hsc70 inhibition were enhanced following 
microtubule destabilization in IMR32 cells and HeLa cells, respectively 
(Figure B4). These findings provide further evidence that the 
association of Hsc70 with Tau is rapidly enhanced following 
microtubule destabilization, which forms more Hsc70·Tau complexes 
that can be targeted by inhibitors.
 Hsc70 folds tau into MC1 conformation
 Based on our results, we hypothesized that Hsc70 could be 
contributing to some of the early pathological modifications to Tau 
depending on the cellular environment. Because Hsc70 largely 
functions as a protein “foldase” (35), and Tau folding is thought to be 
an early event in disease progression (11, 12, 36), we investigated 
what impact Hsc70 could be having on Tau folding.
 We first tested whether the folding of Tau into the MC1 
conformation coincided with Hsc70 binding to Tau. Again we treated 
two cell models, one with endogenous Tau and the other with 
overexpressed Tau, with microtubule destabilizers for 30 min and 
performed IPs with the MC1 antibody, which recognizes folded Tau, 
and a total Tau antibody. We found that MC1-reactive Tau was 
180
increased within 30 min in both cell models, similar to the time frame 
of Hsc70 binding to Tau (Figure B5, A and B); however, this effect was 
more pronounced in cells overexpressing Tau (Figure B5 B). Although 
this suggested that Hsc70 and Tau folding were occurring in a similar 
time frame, we still were not certain that Hsc70 was facilitating the 
MC1 conformation for Tau. To test this more directly, we performed an 
in vitro enzyme-linked immunosorbent assay experiment using purified 
recombinant proteins to look for the amount of MC1 reactive Tau in the 
presence and absence of Hsc70. Impressively, we found more MC1-
reactive Tau species when Tau was incubated with Hsc70 versus bovine 
serum albumin (Figure B5 C). Based on our findings that the MC1 Tau 
conformation could be rapidly facilitated by Hsc70, we speculated that 
Tau hyperphosphorylation might be impacted as well when 
microtubules are destabilized.
 Microtubule destabilization affects tau phosphorylation pattern
 We first investigated the phosphorylation of Tau within the first 
24 h following microtubule destabilization. Again we investigated this 
for both endogenous Tau and overexpressed Tau. Interestingly, we 
observed an initial decrease in Tau phosphorylation at 30 min, the 
same time that MC1 Tau formation and Hsc70 binding to Tau were 
increased. Tau phosphorylation then began to recover over the next 
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several hours and eventually was increased by 24 h in both cell lines 
(Figure B6). Total Tau levels remained largely unaffected. Thus, 
microtubule destabilization decouples Tau phosphorylation from MC1 
formation and Hsc70 binding. Perhaps more importantly, MC1 
formation and Hsc70 actually preceded endogenous phosphorylation of 
Tau following microtubule destabilization. This led us to consider what 
would happen to both the MC1 conformation of Tau and Hsc70 binding 
to Tau if microtubules were destabilized in the face of aberrant kinase 
activation.
 A hyperphosphorylating environment blocks folding of tau but 
enhances Hsc70 binding
 Although we have demonstrated that Hsc70 associates to Tau 
upon microtubule destabilization, we wanted to determine how this 
association is affected in a hyperphosphorylating environment. Tau 
protein can be phosphorylated by a number of proline-directed serine/
threonine kinases at several sites. The prevalence and chronology of 
these phosphorylation events have been rigorously correlated with AD 
tangle pathology (5, 6). GSK3β is a primary kinase for several key 
sites that are associated with Tau pathology, and it can lead to Tau 
hype rphospho ry l a t i on (37 ) . He re , we have c r ea t ed a 
hyperphosphorylating environment for Tau by overexpressing a 
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constitutively active form of GSK3β. Lysates from cells overexpressing 
either the constitutively active form of GSK3β or empty vector treated 
with nocodazole for 30 min were analyzed by IP as described above. 
Although we found that phosphorylation of Tau (as measured by 
increased immunoreactivity to PHF1 antibody) did increase its 
associat ion with Hsc70, we were surprised to f ind that 
hyperphosphorylation of Tau actually blocked MC1 formation (Figure 
B7). Thus, when microtubule destabi l ization occurs in a 
hyperphosphorylating environment, MC1 formation is blocked, but 
Hsc70 binding goes up. In this way, Hsc70 may be preserving 
hyperphosphorylated Tau in a more exposed, linear conformation that 
may be more prone to toxic intracellular interactions than it would be 
in the condensed MC1 conformation.
Discussion
 Apart from the known association of the members of the Hsp70 
family of chaperones with Tau in the brain, their role in the initiation 
and progression of AD and other tauopathies is not clear. Here, we 
aimed to explore the role of the most prevalent cytosolic member of 
the Hsp70 family, Hsc70, in the early events of Tau pathogenesis. We 
developed a model using microtubule-destabilizing compounds to 
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explore the consequences of loss of function for Tau and then coupled 
t h i s w i t h a t ox i c g a i n o f f un c t i o n by p r omo t i ng Tau 
hyperphosphorylation with GSK3β overexpression (14, 38, 39). Our 
results were surprising: we found that the MC1 conformation of Tau 
can be decoupled from Tau hyperphosphorylation. Moreover, Hsc70 
facilitated MC1 formation while also enhancing Tau-mediated 
microtubule polymerization. Although MC1 has indeed been shown to 
be an early pathological structure of Tau pathology, as assessed by 
post-mortem tissue analysis (10) and a conformation that emerges 
during fibrillarization (11), our results suggest that there might be 
multiple phases of MC1 formation: one at the onset of Tau dysfunction, 
as described here, and others after Tau tangles have been seeded and 
become self-perpetuating (29, 40).
 Based on our results, we speculate that Tau folding into the MC1 
conformation after microtubule destabilization could be a protective 
mechanism facilitated by Hsc70 to control the disordered nature of Tau 
and prevent its self-assembly in the neuron. In fact, this would be 
expected given the known “foldase” functionality of Hsc70 and 
previous work showing that it prevents disordered proteins from 
aggregating (41,–44). However, when microtubules are destabilized in 
a hyperphosphorylating environment, Hsc70 still binds to Tau, but this 
phospho-Tau can no longer be protectively folded into the MC1 
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conformation. In this way, Hsc70 may be a double-edged sword; when 
Tau loses its function, Hsc70 can hold it in a labile folded state, 
returning it to the microtubule once the insult on microtubule stability 
has resolved. But when Tau loses its function and gains a toxic 
modification such as aberrant phoshorylation, Hsc70 still holds Tau but 
fails to protect it, perhaps inadvertently contributing to the 
preservation of hyperphosphorylated Tau in the cell (Figure B8). This 
notion that unfolded proteins are intrinsically prone to aggregation is 
an emerging principle for the field of protein chemistry, as recently 
reviewed (45).
 This necessity for Tau to both lose its function and gain toxic 
post-translational modifications could be precisely why single 
mechanisms linking amyloid accumulation to Tau pathogenesis have 
been challenging to prove. The Tau dysfunction seen in AD might 
require a pleiotropic activation strategy, where a number of pathways 
activated by the pluripotency of amyloid must converge to promote 
Tau pathogenesis. In fact, amyloid is known to destabilize microtubules 
and activate kinases (37, 46). Thus, our model may recapitulate some 
aspects of amyloid-induced Tau pathogenesis and describe the very 
earliest part of this cascade.
185
 Our study also shows that regardless of the neuronal 
environment, Hsc70 is engaged with Tau when microtubule stability is 
altered. Thus, inhibitors of Hsc70 ATPase activity that facilitate the 
release and degradation of Tau, such as those that we have recently 
described (14, 35), could be broadly applicable throughout the Tau 
pathogenic cycle. Although not investigated here, we would anticipate 
that Hsp90 and other chaperone proteins would also be involved in Tau 
processing when it disengages from the microtubule. Therefore 
developing diverse therapeutic strategies aimed at modulating distinct 
chaperone functions could be highly applicable for AD.
 In summary, our data suggest that the dissociation of Tau from 
microtubules enhances its association with the chaperone network, 
specifically with Hsc70. This association, as our data suggest, seems to 
be crucial for Tau folding and restoration of Tau function. However, 
abnormal phosphorylation of Tau, coupled with its loss of function, 
circumvents the protective surveillance of Hsc70, and Hsc70 may 
actually become an unwitting accomplice to Tau pathogenesis by 
holding onto abnormal Tau. Based on these data, pharmacological 
manipulation of the Hsp70 family of proteins may prevent the disease 
progression in certain Tau-related neurodegenerative diseases where 
microtubule disruption has occurred in a hyperphosphorylating 
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environment, a likely scenario in AD. However, in circumstances where 
disease arises only from a loss of function for Tau, then inhibiting 
Hsc70 may accelerate pathogenicity by subverting the attempts of 
Hsc70 to restore Tau to the microtubule. By understanding the 
mechanisms involved in Tau pathogenesis, we can continue to identify 
therapeutic targets and strategies that may be customizable based on 
disease etiology.
Acknowledgments
 We thank Dr. Huntington Potter for providing invaluable insights 
through discussions. We thank Dr. Peter Davies (Albert Einstein College 
of Medicine) for PHF1 (pS396/S404) and MC1 Tau antibodies. We 
thank Dr. Benjamin Wolozin for providing the GSK3β expression 
plasmid. This work was supported, in whole or in part, by National 
Institutes of Health Grants NS059690 (to J. E. G.) and AG031291. This 
work was also supported by the Rosalinde and Arthur Gilbert 
Foundation/American Federation for Aging Research and CurePSP.
187
Abbreviations
AD: Alzheimer disease
Hsp: Heat shock protein 
Hsc: Heat shock cognate
PHF: Paired helical filaments
IP: Immunoprecipitation
GSK3β: Glycogen synthase kinase 3β.
References
1. Hutton, M., Lendon, C.L., Rizzu, P., Baker, M., Froelich, S., 
Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., 
Grover, A., Hackett, J., Adamson, J., Lincoln, S., Dickson, D., 
Davies, P., Petersen, R. C., Stevens, M., de Graaff, E., Wauters, 
E., van Baren, J., Hillebrand, M., Joosse, M., Kwon, J. M., 
Nowotny, P., Che, L. K., Norton, J., Morris, J. C., Reed, L. A., 
Trojanowski, J., Basun, H., Lannfelt, L., Neystat, M., Fahn, S., 
Dark, F., Tannenberg, T., Dodd, P. R., Hayward, N., Kwok, J. B., 
Schofield, P. R., Andreadis, A., Snowden, J., Craufurd, D., Neary, 
D., Owen, F., Oostra, B. A., Hardy, J., Goate, A., van Swieten, J., 
Mann, D., Lynch, T., and Heutink, P. (1998) Nature 393, 702–705
188
2. Goedert, M., Spillantini, M. G., Crowther, R. A., Chen, S. G., 
Parchi, P., Tabaton, M., Lanska, D. J., Markesbery, W. R., 
Wilhelmsen, K. C., Dick- son, D. W., Petersen, R. B., and 
Gambetti, P. (1999) Nat. Med. 5, 454 – 457
3. Spillantini, M. G., Murrell, J. R. ,Goedert, M., Farlow ,M.R., Klug, 
A., and Ghetti, B. (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 7737–
7741 
4. Hardy, J., andOrr, H.(2006) J. Neurochem. 97,1690–1699 
5. Braak,H.,and Braak, E.(1991) Acta Neuropathol. 82,239–259 
6. Grundke-Iqbal, I., Iqbal, K., Tung, Y.C., Quinlan, M., Wisniewski, 
H.M., and Binder, L. I. (1986) Proc. Natl. Acad. Sci. U.S.A. 83, 
4913– 4917 
7. Spires-Jones, T.L., de Calignon, A., Matsui, T., Zehr, C., Pitstick, 
R., Wu, H. Y., Osetek, J. D., Jones, P. B., Bacskai, B. J., Feany, M. 
B., Carlson, G. A., Ashe, K. H., Lewis, J., and Hyman, B. T. 
(2008) J. Neurosci. 28, 862– 867 
8. Wolfe, M. S.(2009) J. Biol. Chem. 284,6021–6025 
9. Uboga,N. V., and Price,J. L.(2000) Neurobiol. Aging 21, 1–10
10. Weaver, C. L., Espinoza, M., Kress, Y., and Davies, P. (2000) 
Neurobiol. Aging 21, 719 –727
11. Carmel, G., Mager, E.M.,Binder,L.I., and Kuret, J.(1996) 
J.Biol.Chem. 271, 32789 –32795 
189
12. Jicha, G.A., Bowser,R., Kazam, I.G., and Davies,P.(1997) J. 
Neurosci. Res. 48, 128 –132 
13. Dickey,C.A.,Kamal,A.,Lundgren,K.,Klosak,N.,Bailey,R.M.,Dunmore
, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C. B., Patterson, 
C., Dickson, D. W., Nahman, N. S., Jr., Hutton, M., Burrows, F., 
and Petrucelli, L. (2007) J. Clin. Invest. 117, 648 – 658 
14. Jinwal,U.K.,Miyata,Y.,Koren,J.,3rd,Jones,J.R.,Trotter,J.H.,Chang,L., 
O’Leary, J., Morgan, D., Lee, D. C., Shults, C. L., Rousaki, A., 
Weeber, E. J., Zuiderweg, E. R., Gestwicki, J. E., and Dickey, C. 
A. (2009) J. Neurosci. 29, 12079 –12088 
15. Tortosa, E., Santa-Maria, I., Moreno, F., Lim, F., Perez, M., and 
Avila, J. (2009) J. Alzheimer’s Dis. 17, 319 –325 
16. Sev c i k , J ., S k rabana ,R ., Kon t s ekova , E ., andNovak ,M .
(2009)ProteinPept. Lett. 16, 61– 64 
17. Dou, F., Netzer, W. J., Tanemura, K., Li, F., Hartl, F. U., 
Takashima, A., Gouras, G. K., Greengard, P., and Xu, H. (2003) 
Proc. Natl. Acad. Sci. U.S.A. 100, 721–726 
18. Pe ́rez,M.,Arrasate,M.,MontejoDeGarcini,E.,Mun ̃oz,V.,andAvila,J. 
(2001) Biochemistry 40, 5983–5991 
19. Barghorn, S., Davies, P., and Mandelkow, E. (2004) Biochemistry 
43, 1694 –1703 
190
20. Mayer, M. P., and Bukau, B. (2005) Cell Mol. Life Sci. 62, 670 – 
684 
21. Manzerra, P., Rush, S. J., and Brown, I. R. (1997) J. Cell. Physiol. 
170, 130 –137 
22. Sarkar, M., Kuret, J., and Lee, G. (2008) J. Neurosci. Res. 86, 
2763–2773 
23. Jinwal, U. K., Koren, J., 3rd, Borysov, S. I., Schmid, A. B., 
Abisambra, J. F., Blair, L. J., Johnson, A. G., Jones, J. R., Shults, 
C. L., O’Leary, J. C., 3rd, Jin, Y., Buchner, J., Cox, M. B., and 
Dickey, C. A. (2010) J. Neurosci. 30,591–599
24. Desai, A., Verma, S., Mitchison, T. J., and Walczak, C. E. (1999) 
Cell 96, 69 –78
25. Abisambra, J. F., Fiorelli, T., Padmanabhan, J., Neame, P., Wefes, 
I., and Potter, H. (2010) PLoS One 5, e8556
26. Bolte,S.,andCordelie`res,F.P.(2006)J.Microsc.224,213–232
27. Rasband,M.N.(2009)PLoSGenet5,e1000340
28. Carty, N. C., Nash, K., Lee, D., Mercer, M., Gottschall, P. E., 
Meyers, C., Muzyczka, N., Gordon, M. N., and Morgan, D. (2008) 
Mol. Ther. 16,1580 –1586
29. Dickey,C.,Kraft,C.,Jinwal,U.,Koren,J.,Johnson,A.,Anderson,L.,Lebs
on, L., Lee, D., Dickson, D., de Silva, R., Binder, L. I., Morgan, D., 
and Lewis, J. (2009) Am J. Pathol. 174, 228 –238
191
30. Dickey, C. A., Koren, J., Zhang, Y. J., Xu, Y. F., Jinwal, U. K., 
Birnbaum, M. J., Monks, B., Sun, M., Cheng, J. Q., Patterson, C., 
Bailey, R. M., Dun- more, J., Soresh, S., Leon, C., Morgan, D., 
and Petrucelli, L. (2008) Proc. Natl. Acad. Sci. U.S.A. 105, 3622–
3627
31. Petrucelli, L., Dickson, D., Kehoe, K., Taylor, J., Snyder, H., 
Grover, A., De Lucia, M., McGowan, E., Lewis, J., Prihar, G., Kim, 
J., Dillmann, W. H., Browne, S. E., Hall, A., Voellmy, R., Tsuboi, 
Y., Dawson, T. M., Wolozin, B., Hardy, J., and Hutton, M. (2004) 
Hum. Mol. Genet. 13, 703–714
32. D’Souza, S.M., and Brown, I.R.(1998) Cell Stress Chaperones 
3,188–199 
33. Chen, S., and Brown, I.R.(2007) J. Neurosci. Res. 85, 402–409
34. Tohgi, H., Utsugisawa, K.,Yoshimura,M., Yamagata, M., and 
Nagane,Y.(1995) Neurosci. Lett. 196, 89 –92
35. Koren, J.3rd, Jinwal,U.K., Jin, Y., O’Leary, J., Jones, J.R., 
Johnson, A.G., Blair, L. J., Abisambra, J. F., Chang, L., Miyata, Y., 
Cheng, A. M., Guo, J., Cheng, J. Q., Gestwicki, J. E., and Dickey, 
C. A. (2010) J. Biol. Chem. 285, 2498 –2505
36. Jeganathan, S., von Bergen, M., Mandelkow, E. M., and 
Mandelkow, E. (2008) Biochemistry 47, 10526 –10539
192
37. Hernandez,F.,GomezdeBarreda,E.,Fuster Matanzo, A., Lucas, J.J., 
and Avila, J. (2009) Exp. Neurol. 10.1016/j.expneurol.
2009.09.011
38. Khalilzadeh, A., Wangoo, K. T., Morris, D. L., and Pourgholami, M. 
H. (2007) Biochem. Pharmacol. 74, 407– 414
39. Liang, Z., Liu, F., Iqbal, K., Grundke-Iqbal, I., Wegiel, J., and 
Gong, C.X. (2008) J. Alzheimer’s Dis. 13, 295–302
40. Clavaguera, F., Bolmont, T., Crowther, R.A., Abramowski,D., 
Frank,S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., 
Staufenbiel, M., Jucker, M., Goedert, M., and Tolnay, M. (2009) 
Nat. Cell Biol. 11, 909 –913
41. Morano, K.A.(2007)Ann. N. Y. Acad. Sci. 1113,1–14
42. Meriin, A. B., Zhang, X., He, X., Newnam, G. P., Chernoff, Y. O., 
and Sherman, M. Y. (2002) J. Cell Biol. 157, 997–1004
43. Ryu, K., Kim, C. W., Kim, B. H., Han, K. S., Kim, K. H., Choi, S. 
I., and Seong, B. L. (2008) Biochem. Biophys. Res. Commun. 
373, 74 –79
44. Ben-Zvi, A. P., and Goloubinoff, P. (2001) J. Struct. Biol. 135, 
84–93
45. Hartl, F. U., and Hayer-Hartl, M. (2009) Nat. Struct. Mol. Biol. 
16, 574 –581
193
46. King, M. E., Kan, H. M., Baas, P. W., Erisir, A., Glabe, C. G., and 
Bloom, G. S. (2006) J. Cell Biol. 175, 541–546
194
Figure B1
195
Figure B1. Hsc70 facilitates Tau-mediated microtubule 
stabilization. A, in vitro microtubule assembly assays were 
performed using Xenopus oocyte extracts supplemented with 
rhodamine-labeled tubulin. Recombinant proteins, Tau, Hsc70, or both 
in combination, were added to the Xenopus extracts, and microtubules 
were detected with fluorescent microscopy. Control indicates no 
protein added. As a negative control, microtubules were disrupted 
using nocodazole in the presence of Hsc70 and Tau. B, microtubules 
were quantified as the percentage of area distributed throughout the 
total area of the field; see details under “Materials and Methods” (n = 
19; **, p (hsc70 versus both) < 0.001; and ***, p (Tau versus both) 
< 0.0001).
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Figure B2
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Figure B2. Dramatic increase in Tau colocalization with Hsc70 
upon microtubule destabilization. IMR32 cells were treated with 20 
µM nocodazole or vehicle control for 30 min. Immunofluorescent 
staining of Tau (green) and Hsc70 (red) in cells shows enhanced 
colocalization of these two proteins upon treatment with microtubule 
destabilize nocodazole.
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Figure B3
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Figure B3. In vitro and in vivo enhanced association of Hsc70 to 
microtubule-destabilized Tau. A, IMR32 cells treated with 
microtubule-destabilizing agents albendazole, nocodazole, colchicine or 
vehicle Me2SO as a control for 30 min. Treated cell lysates were 
immunoprecipitated (IP) with total Tau antibody and immunoblotted 
with Hsc70 antibody. B, quantitation of immunoblot from A after 
normalization to corresponding inputs shows increased binding of 
Hsc70 to Tau upon destabilization of microtubules by various drugs 
compared with vehicle control. The values are presented as Hsc70 
association to Tau as a percentage of vehicle-treated cells ± S.D. C, In 
HeLa cells stably transfected with Tau were treated with microtubule 
stabilizer paclitaxel and destabilizer albendazole or nocodazole for 30 
min. An IP with total Tau antibody followed by immunoblotting with 
Hsc70 antibody, showed only increased association of Hsc70 with Tau 
upon treatment with microtubule destabilizer not with stabilizer 
treatment. D, in vivo study was performed in mice. Brain hippocampus 
of mice (n = 4) were injected with albendazole or vehicle as a control. 
24 h after injection, the mouse brains were homogenized. An IP with 
total Tau antibody followed by immunoblot analysis showed significant 
increased of Tau association to Hsc70 upon treatment with albendazole 
compared with vehicle-injected animals.
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Figure B4
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Figure B4. Tau released from microtubules is regulated by 
ATPase activity of Hsc70. A, IMR32 cells were treated with 20 µM 
albendazole or vehicle for 30 min, followed by 1 h of treatment with 
various doses of methylene blue (MB). B, a similar experiment as in A 
was performed in HeLa cells stably transfected with Tau. Quantitation 
plots of the Western blots after actin normalization illustrates 
microtubule destabilization favors further reduction of Tau by the 
Hsc70 ATPase inhibitor methylene blue. The gray lines depict the 
efficacy of the Hsp70 complex ATPase modulators alone, and black 
lines depict the efficacy of the ATPase modulators in conjunction with 
albendazole treatment. The values are presented as Tau levels as 
percentages of vehicle-treated cells ± S.D. *, p < 0.05; **, p < 0.001 
by Student's t test.
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Figure B5
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Figure B5. Hsc70 folds Tau into MC1 conformation. A, IMR32 
cells having endogenous Tau were treated with 20 µM albendazole or 
nocodazole for 30 min prior to an IP using a MC1 (folded) Tau 
antibody. An increased binding of Hsc70 to folded Tau was observed 
upon treatment with drugs. B, HeLa cells stably transfected with Tau 
(overexpressing Tau) were treated with 20 µM albendazole or 
nocodazole for 30 min prior to an IP using a MC1 (folded) Tau 
antibody. An increased binding of Hsc70 to folded Tau was observed 
upon treatment with drugs. C, an enzyme-linked immunosorbent 
assay (ELISA) for folding of Tau (folded, MC1) was performed using 
recombinant Tau and Hsc70 in a buffer containing ATP. The plate was 
read at 450 nm, and the data are represented as black bars. A 
significant increase in Tau folding by Hsc70 suggests that Hsc70 folds 
Tau. The values are presented as Tau levels as percentages of vehicle 
(Veh)-treated cells ± S.D. ***, p < 0.0001 by Student's t test.
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Figure B6
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Figure B6. Microtubule destabi l izat ion affects Tau 
phosphorylation pattern. A, IMR32 cells were treated with 
nocodazole for 0, 0.5, 1, 3, 6, and 24 h. Tau phosphorylation was 
found to be reduced initially and in later on phosphorylation was 
increased. B, HeLa cells stably transfected with Tau were treated with 
nocodazole for 0, 0.5, 1, 3, 6, and 24 h. Tau phosphorylation was 
found to be reduced initially, and later on phosphorylation was 
increased. Quantitation plots of the Western blots after actin 
normalization illustrates a time-dependent initial reduction and later on 
up-regulation of Tau phosphorylation. The gray bars represent 
phospho-Tau, and the black bars represent total Tau. The values are 
presented as Tau levels as percentages of vehicle-treated cells ± S.D.
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Figure B7
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Figure B7. A hyperphosphorylating environment reduces 
folding of Tau but enhances Hsc70 binding. A, HeLa cells stably 
expressing Tau were transfected with and without constitutively active 
GSK-3β followed by a treatment with nocodazole for 30 min. Two 
separate IPs were performed: one with total Tau antibody and another 
with MC1 antibody (folded Tau). B–D, quantitation of the immunoblots 
from A was performed after input normalization. The values are 
presented as percentages of vehicle (veh)-treated cells ± S.D. for 
Hsc70 binding to total Tau (B), total Tau following MC1 IP (C), and 
Hsc70 binding to MC1 Tau (D).
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Figure B8
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Figure B8. A hyperphosphorylating environment reduces 
folding of Tau but enhances Hsc70 binding. A, HeLa cells stably 
expressing Tau were transfected with and without constitutively active 
GSK-3β followed by a treatment with nocodazole for 30 min. Two 
separate IPs were performed: one with total Tau antibody and another 
with MC1 antibody (folded Tau). B–D, quantitation of the immunoblots 
from A was performed after input normalization. The values are 
presented as percentages of vehicle (veh)-treated cells ± S.D. for 
Hsc70 binding to total Tau (B), total Tau following MC1 IP (C), and 
Hsc70 binding to MC1 Tau (D).
210
APPENDIX C4:
Neuronal Life Span Versus Health Span 
Principles of Natural Selection at Work in the Degenerating 
Brain
Abstract
 Impaired nutrient delivery to the brain due to decreased blood 
flow contributes to cognitive decline and dementia in Alzheimer’s 
disease (AD). Considering this, many studies have suggested that 
neuroprotective agents like those used in stroke could prevent AD 
onset or progression by promoting cell survival. However, research in 
the past decade suggests that the culprit behind the cognitive loss in 
AD models is actually the soluble tau accumulating inside of surviving 
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neurons. In fact, tau reductions improve cognition in mouse models of 
AD, even those that only deposit amyloid plaques. There is emerging 
evidence that neuroprotection alone in these AD models may be 
insufficient to restore neuron function and cognition. Only when 
soluble tau is reduced on a neuroprotective background could memory 
be rescued. Thus, once a neuron begins to accumulate tau, it may 
survive in a malfunctioning capacity, leading to impaired electrical 
signaling and memory formation in the brain. These data imply that 
multiple drugs may be necessary to ameliorate the different disease 
components. In fact, strategies to preserve neurons without affecting 
the soluble protein burden within neurons may accelerate the disease 
course.
Review
 Cerebral angiopathy and blood flow dysregulation in AD
 Current research in Alzheimer’s disease (AD) suggests that 
cerebral angiopathy (CA) can occur from excess neuronal secretion of 
amyloid beta (Aβ) and from preexisting vascular disease (Iadecola 
2004; Zlokovic 2008). Aβ can be cleared from the brain by vascular 
transport across the blood–brain barrier. This free Aβ can bind to 
different transport-binding proteins like apolipoprotein J (Ghiso et al. 
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1993) and E (Yang et al. 1997), transthyretin (Schwarzman et al. 
1994), lipoprotein receptors (Matsubara et al. 1999), and several 
others. Vascular smooth muscle cells (VSMC) have recently been an 
intense area of focus due to their ability to internalize and clear Aβ and 
contract the capillary (Urmoneit et al. 1997). Thus, modulation of 
VSMC could provide a cellular and molecular link between vascular 
disorders and AD. The VSMC can clear Aβ by using lipoprotein 
receptor-related protein-1 to sequester it (Shibata et al. 2000; 
Urmoneit et al. 1997). It is speculated that when the neuron begins 
secreting excess amyloid, the VSMC becomes saturated, allowing Aβ to 
accumulate. Aβ is also capable of potentiating the cell’s constriction 
capability (Niwa et al. 2001; Paris et al. 2002). In fact, when Aβ 1–40 
peptide is administered to wild-type mice by topical superfusion, the 
subjects display reduced resting cerebral blood flow (Niwa et al. 2001). 
Also, it has been found that serum response factor and myocardin are 
upregulated in AD tissue (Chow et al. 2007). They are transcription 
factor proteins that facilitate the VSMC-differentiated phenotype. 
Hence, AD patients may have a hypercontractile phenotype that can be 
further potentiated by Aβ. The amyloid cascade hypothesis is further 
supported by studies showing that the overexpression of amyloid 
precursor protein (APP) in mice is capable of causing pathologic 
changes before the detectable appearance of amyloid plaques. In the 
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PDAPP mice, dentate gyrus volume is reduced before plaque formation 
(Redwine et al. 2003). Mice overexpressing the Swedish APP mutation 
exhibit a reduction in hyperemia (Niwa et al. 2000). On the other 
hand, vascular disease on its own is also capable of reducing blood 
flow across the blood–brain barrier, creating a hypoxic state. Hypoxia 
has been shown to decrease the ability of VSMC to clear Aβ (Bell et al. 
2009). Another complication arising from CA is that reduced blood flow 
leads to energy deprivation, which in turn potentiates beta-secretase 1 
(BACE1) levels (O’Connor et al. 2008). Since BACE1 is the rate-limiting 
step of Aβ production, more BACE1 proteins create more Aβ peptide. 
Ultimately, a cascade can arise from CA that becomes self-
perpetuating, manifesting in dementia.
 Neuroprotective agents for AD
 Because of the strong vascular component in AD, there has been 
a search for compounds that can elongate the life of neurons. Many 
drugs have been proposed to have possible neuroprotective effects in 
AD based on their ability to scavenge antioxidants and free radicals. 
Examples of these drugs are indole-3-propionic acid (IPA), vitamin E, 
and resveratrol.
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 IPA is an inhibitor of Aβ fibril formation, an antioxidant, and 
neuroprotectant. To assess its ability to protect neurons from ischemic 
damage, it was administered for 15 days at a 10 mg/kg dose to mice. 
Tissue was collected, and IPA was shown to spare neurons from 
ischemic damage ~300% (Hwang et al. 2009). IPA has also been 
shown to inhibit Aβ fibril formation, but other indole derivatives like 
indole 3-acetic acid, indole 3-carbinol, and tryptophol were more 
effective (Morshedi et al. 2007).
 Vitamin E is currently in phase III of clinical trials to treat AD. 
However, beneficial effects of vitamin E in patients with moderate to 
severe AD have been modest (Brewer 2010). Vitamin E treatment of 
2,000 IU slowed the functional deterioration of patients, improving 
their daily living, but failing to improve the mini-mental exam score 
(Grundman 2000; Petersen et al. 2005).
 Resveratrol can promote antioxidant activity, has neuroprotective 
effects, and activates sirtuins and their positive effect on aging (Albani 
et al. 2010). This compound, derived from grapes, improves cognition 
and reduces p laque pathology in animal models of AD 
(Karuppagounder et al. 2009; Kim et al. 2007; Wang et al. 2006). 
215
Resveratrol is one of the more promising compounds that have entered 
clinical trials.
 Pharmacological agents like resveratrol and IPA may indeed be 
neuroprotective, but questions about a strategy designed to spare sick 
neurons are beginning to emerge. In some sense, this is in direct 
violation of Darwinian principles: Culling of the weak or sick from the 
herd is better for the species population as a whole. This same 
principle may be in play in the brain. Perhaps, sparing neurons that 
harbor aberrantly accumulated proteins could worsen brain function. 
Thus, extending the life of neurons that have already begun to 
accumulate tau may not be an effective strategy. Perhaps, the brain is 
able to adapt when a neuron dies, as has been shown in stroke and 
occlusion diseases; the plasticity in the brain can reroute processes to 
perform essential functions. However, when a neuron is chronically 
sick, but surviving, the brain may continue to route information 
through it, but that neuron may simply be unable to propagate the 
signal (Figure C1).
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 Pathologically visible tau or invisible soluble intermediates; what 
should we be targeting?
 Although there are strong data demonstrating the adverse 
effects of vascular dysfunction and amyloid accumulation in AD, 
research in the last decade suggests that tau may be a better 
therapeutic target. Recent work has demonstrated a critical role for tau 
in amyloid-induced deficits of the human amyloid precursor protein 
(hAPP) mice (Roberson et al. 2007). Since these mice do not develop 
tau pathology, it was long assumed that tau did not have a role in their 
cognitive deficits. However, when the hAPP transgenic mice were 
crossed onto a tau null background, the cognitive deficits induced by 
amyloid accumulation were ameliorated. Moreover, tau depletion 
protected against both kainate- and GABAA receptor antagonist 
(pentylenetetrazol)-induced seizures. Furthermore, tau reduction did 
not change Aβ deposition, neuritic dystrophy, or aberrant sprouting. 
This study suggests that tau may be a better therapeutic target 
because it is necessary for Aβ-mediated cognitive deficits and 
excitotoxicity. Also, it suggests that cognition can be improved despite 
amyloid pathology.
 Another piece of evidence that supports tau-induced cognitive 
decline is the creation of the rTg4510 mouse model (Santacruz et al. 
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2005), which is doubly transgenic for the tetracycline operator driven 
by the CamKII promoter and human P301L tau driven by the PrP 
promoter and regulated by the tetracycline-responsive element. These 
mice accumulate tau tangles and develop severe neurodegeneration 
and cognitive deficits. A large group of rTg4510 mice were trained to 
find the hidden escape platform in the Morris water maze (MWM) at 
2.5 months of age. It was found that tau was not affecting all mice 
equally. As a result, the mice were split into two cohorts. To test the 
effect of tau reduction and pathology on cognition in a suboptimally 
performing cohort, tau expression was shut off at 2.5 months of age in 
half of the mice, while the other half received control diet. The mice 
were retrained and tested at 4.5 months, an age prior to onset of 
neurodegeneration. Suppressing tau expression for 2 months enabled 
mice that had previously performed poorly in the MWM to now learn 
and recall the location of the escape platform, while the performance 
of the vehicle-treated rTg4510 mice continued to decline. Next, the 
higher-performing cohort had doxycycline treatment initiated at 
5.5 months, a point when neurodegeneration and frank tangle 
pathology begin in this model. These mice had improved cognitive 
function despite increasing tangle formation. These two studies 
showed that not only is soluble tau able to impair learning and 
memory but tangles failed to correlate with memory improvement.
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A role for soluble tau in altering cognitive function was reemphasized 
in a subsequent study using the rTg4510 model (O’Leary et al. 2010). 
Seven-month-old rTg4510 mice were treated with the pleiotropic 
compound, methylene blue (MB), which is currently in clinical trials for 
AD. Direct hippocampal infusion of MB improved learning and memory 
in the rTg4510 mice, but neither pathology nor neuronal morphology 
was altered: Only soluble tau was extensively reduced.
 In a more recent study, the role of caspase cleavage of tau was 
tested in the rTg4510 model. Caspase activation was shown to occur 
before tangle formation, tangle-bearing neurons were long lived, and 
aggregated tau was able to suppress caspase activity (de Calignon et 
al. 2010). Conversely, injection with a virus expressing wild-type 
human tau induced caspase cleavage of tau, suggesting that soluble 
cytosolic tau could activate caspase. This work suggests that tau 
tangles may protect the neuron from apoptosis, while soluble tau can 
induce caspase activation and possibly neurotoxicity.
 There is still more evidence for the importance of soluble tau in 
disrupting neuronal function. Mice overexpressing wild-type human tau 
show no tau insolubility or neuronal loss, yet these mice have memory 
deficits and synaptic dysfunction. Conversely, mice overexpressing the 
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P301L variant of human tau did develop neuronal loss and tau 
insolubility, but these mice were cognitively intact and synapses were 
functional (Kimura et al. 2010). This concept provides further support 
to the notion that accumulation of soluble tau essentially clogs the 
neuron, but does not kill it, leading to reduced overall brain function. 
In fact, neuronal death and insolubility of tau are less deleterious 
compared to soluble tau accumulation and survival of suboptimally 
performing neurons.
 There are several mechanisms through which soluble tau might 
accumulate and take on a deleterious function. Pre-fibrillar Aβ can 
cause microtubule disassembly, resulting in a loss of function for tau 
and an increased cytosolic burden of free tau (King et al. 2006; 
Rapoport et al. 2002). Aberrant phosphorylation and mutations 
associated with some tauopathies also reduce tau’s affinity for the 
microtubules (Wagner et al. 1996), possibly enlarging the pool of tau 
that is not microtubule bound (Dayanandan et al. 1999). Another 
possible way that soluble tau becomes enriched in the cytosol would 
be by overexpression. Indeed, this occurs naturally in sporadic 
Parkinson’s disease (Simon-Sanchez et al. 2009). It has been shown 
that overexpression of wild-type human tau leads to excess free tau in 
the cytosol (Andorfer et al. 2003), providing a greater opportunity for 
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tau to interact with itself and aggregate into a soluble nonfunctioning 
intermediate. Thus, perhaps when tau loses its microtubule function, it 
can gain a toxic function. For example, tau can mediate Aβ 
excitotoxicity by allowing fyn to phosphorylate the NMDA receptor 
subunit 2 (Ittner et al. 2010). In this study, crossing the APP23 
transgenic mouse line with tau null mice disrupted the dendritic 
targeting of fyn. Interestingly, the same result was achieved by 
overexpressing a truncated form of tau that lacks the microtubule-
binding domains of tau. Again, this suggests that soluble, free tau 
without the capacity to interact with microtubules may be even more 
deleterious to neuronal function.
 All of these evidences strengthen the rationale for developing 
strategies to deplete free, soluble tau to treat AD. While reducing all 
tau has been thought likely to be harmful, there are several findings 
that suggest that the brain may be more tolerant of such a strategy 
than first imagined. In particular, tau knockout mice are functionally 
intact, due in part to compensation by MAP1a (Harada et al. 1994; 
Tucker et al. 2001). Moreover, fast axonal transport is not affected in 
tau knockout mice (Yuan et al. 2008). Considering this evidence and 
that many of the patients who would receive anti-tau therapies would 
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be elderly, reducing tau may indeed be a well-tolerated strategy to 
ameliorate AD symptoms and modify disease course.
 Life span versus health span for neurons: do Darwinian 
principles apply in a degenerating brain?
 The phenothiazine class of compounds includes the controversial 
compound, methylene blue (MB). The pleiotropy of MB has raised a 
number of concerns about its clinical application. More than a decade 
passed between the time that MB was first reported to prevent tau 
aggregation in solution and the time that the first reports emerged 
describing successful use of MB in the clinic (Wischik and Staff 2009; 
Wischik et al. 1996). Since then, a number of studies have begun to 
dissect the mechanisms contributing to the efficacy of this drug. MB 
was shown to reduce Aβ levels in the 3xTg-AD mouse model and 
improve learning and memory (Medina et al. 2011). In this study, MB 
treatment was given for 4 months, beginning at the age of 6 months. 
MB treatment ameliorated learning and memory deficits in this mouse 
model and reduced Aβ levels, but failed to alter tau.
 Other studies have ascribed one mechanism of MB action to its 
ability to inhibit the molecular chaperone Hsp70. Indeed, this activity 
was shown to destabilize tau in cells and mice (Jinwal et al. 2009). MB 
treatment was recently shown to improve cognitive function in rTg4510 
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mice, but only when sufficiently high doses were present in the brain 
(O’Leary et al. 2010). Interestingly, tau tangle pathology as assessed 
by histology was unchanged in these mice compared to those treated 
with vehicle. When stereological analyses were performed on tissues 
from these mice, MB facilitated neuroprotection in all treated mice; 
however, this neuroprotection did not correlate with cognitive function. 
Biochemical analyses of tissue from these mice showed that soluble 
tau levels were reduced by MB treatment, but only in mice with high 
concentrations in their brain. Surprisingly, reduced soluble tau burden 
correlated with improved cognitive function in this study.
 An additional report recently showed that reducing soluble tau 
burden with a purely genetic approach could improve neuronal 
function in the rTg4510 mice, as measured by long-term potentiation 
(Abisambra et al. 2010). Moreover, overexpression of wild-type human 
tau in mice does not beget tau insolubility or neuronal loss, but does 
cause cognitive dysfunction, while overexpression of mutant tau 
causes neuronal loss and insolubility of tau, but does not lead to 
memory deficits (Kimura et al. 2010). These results allow for several 
conclusions to be drawn. First, neuroprotection alone is insufficient to 
rescue memory function in tau transgenic mice, decoupling two 
processes that have always been intertwined. Secondly, reductions in 
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tau tangle pathology are not necessary for neuroprotection or 
cognitive improvement. Lastly, reducing soluble tau levels is necessary 
for cognitive improvement in this model, but it is not required for 
neuroprotection.
 This work has several important implications regarding classical 
paradigms about the relationship of neuronal survival, neuronal health, 
and overall brain function. When soluble proteins accumulate in the 
cytosol, the endgame may be neuronal death, but there are likely 
many neurons that continue to survive for long periods of time in a 
suboptimal, or functionally impaired, state. This is likely due to the 
intracellular accumulation of “sticky” proteins. Strategies aimed at only 
protecting these sick neurons may ultimately be deleterious to brain 
function. Instead, focusing on amelioration of the protein accumulation 
in these neurons to restore their function may prove more therapeutic. 
Simply prolonging the life of nonfunctioning neurons may prevent 
compensatory brain plasticity mechanisms from being triggered to 
overcome the loss of function of a discreet circuit (Figure C1). While 
neuroprotective strategies may indeed be beneficial, it might be critical 
to couple such agents with a treatment that can reduce the soluble 
protein accumulation that burdens neurons in many neurodegenerative 
diseases. Neuroprotection has proven successful in stroke; however, 
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these neurons do not have toxic soluble proteins accumulating within. 
In neurodegenerative diseases resulting from proteotoxicity, 
neuroprotection without reducing the toxic protein burden may be 
harmful.
Conclusions
 The population with AD is expected to grow tremendously within 
the next 20 years as the first wave of baby boomers reaches 65 years 
of age this year. In addition to AD, there are more than 15 other 
neurodegenerative diseases where tau is pathogenic. Research from 
the most recent decade suggests that ameliorating soluble tau protein 
accumulation may provide patients with greater cognitive 
improvement and behavioral health. This, coupled with neuroprotective 
agents, may be an even more effective clinical strategy. However, 
neuroprotection without also rescuing the soluble proteotoxic burden in 
neurons may be unsuccessful, essentially allowing malfunctioning 
neurons to evade the “survival of the fittest” principle. Thus, the brain 
may be unable to recognize a need to reconfigure damaged circuitry. 
Strategies aimed at only neuroprotection may ultimately accelerate the 
course of these disorders.
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Figure C1
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Figure C1. Suboptimally function- ing neurons surviving with 
pro- teotoxic tau accumulation subvert brain plasticity that 
nor- mally occurs in response to neuronal death. (A) Neuronal 
transmission in normal brain. (B) Suboptimally performing neu- rons 
due to tau accumulation cannot transmit a signal to the postsynaptic 
neuron, and the brain fails to reroute connectiv- ity since the neuron is 
not dead. (C) Neuronal death facilitates net- work rerouting, allowing 
the plastic brain to adapt and rees- tablish downstream connectivity.
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APPENDIX D:
The Role of FKBP5 in Mood Disorders:
 Action of FKBP5 on Steroid Hormone Receptors Leads to 
Questions About its Evolutionary Importance
Abstract
 Research on the FKBP5 gene and FKBP51 protein has more than 
doubled since the discovery that polymorphisms in this gene could 
alter treatment outcomes and depressive behavior in humans. This 
coincided with other data suggesting that the stress hormone axis 
contributes to the development of numerous mental illnesses. As a 
result, FKBP51 now lies at the heart of the research of many stress 
related psychiatric disorders, which has led to advances in the 
understanding of this protein and its role in humans and in animal 
models. Specifically, FKBP5-/- mice and a naturally existing 
overexpression of FKBP5 in 3 genera of new world monkeys have 
helped understand the effects of FKBP5 in vivo. This review will 
235
highlight these finding as well as discuss the current evolutionary need 
for the FKBP5 gene. 
Introduction
 Mood disorders are characterized by feelings of sadness, 
frustration, loss, anger, anxiety, fear, or panic that in disease become 
chronic and interfere with normal life. Research in the last decade has 
found that dysregulation of steroid hormone receptors can cause mood 
disorders. The hypothalamus-pituitary-adrenal (HPA) axis, for 
example, which produces glucocorticoids and releases them into the 
blood stream, has been linked to depression (Holsboer, 2000; de Kloet 
et al., 2005).
 Steroid hormones, produced in the periphery by endocrine 
glands (Belelli and Lambert, 2005), can cross the blood-brain-barrier 
and bind to steroid hormone receptor complexes that produce changes 
at the cellular level and global level, such as acting as transcription 
factors for gene expression upregulation, altering neuronal excitability, 
and modifying mood and behavior. Steroid hormone receptors are 
ubiquitously expressed in almost all human tissues including the brain, 
and are especially abundant in the parts of the brain that control mood 
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and emotion: the hypothalamus, hippocampus, amygdala, and 
prefrontal cortex (de Kloet et al., 2005). As a result, the brain is 
susceptible to mood disorders generated by aberrant function of 
steroid hormone receptors (De Kloet et al., 1998).  
 To this end, researchers have looked for genetic and 
environmental factors that increase the risk of psychiatric disease. 
Genome wide association studies for single nucleotide polymorphisms 
(SNPs) have revealed significant associations between allelic variants 
of the FKBP5 gene and depression (Binder et al., 2004; Tatro et al., 
2010), post-traumatic stress disorder (PTSD) (Xie et al., 2010), bipolar 
disorder (Willour et al., 2009), peritraumatic dissociation (Koenen et 
al., 2005), suicide (Brent et al., 2010; Roy et al., 2010; Supriyanto et 
al., 2011; Roy et al., 2012), negative personality traits (Shibuya et al., 
2010), and aggression (Bevilacqua et al., 2012). An environmental 
factor found to interact with this gene is stress (Binder, 2009; Lupien 
et al., 2009). The current primary biological role of FKBP51 is thought 
to be with the protein heterocomplex of steroid hormone receptors 
within the HPA axis, where it helps regulate receptor sensitivity 
(Jaaskelainen et al., 2011).
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 Due to the overwhelming evidence that stress and the FKBP5 
gene are involved in psychiatric diseases, studying how this gene 
works is imperative to understanding the mechanisms of mood 
disorders and finding therapies.
Review
 HPA-axis and stress
 A general definition for stress is a disruption of homeostasis due 
to a real or perceived threat to the well-being of the organism 
(Chrousos and Gold, 1992; de Kloet et al., 2005). For example, upon 
the perception of threat, the amygdala immediately activates the 
autonomic nervous system and the HPA-axis.
 The hypothalamic-pituitary connection provides the brain with 
endocrine function (Ulrich-Lai and Herman, 2009). This system 
evolved to allow the brain to turn the production of hormones that are 
made distally in the periphery off and on. These hormones travel 
through the blood, cross the blood brain barrier and bind to their 
specific receptors in distinctive brain areas. 
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 The brain uses multiple hormones to trigger the synthesis of 
cortisol, which is the most abundant stress hormone. The 
Hypothalamic neurons synapse at the pituitary where they release 
corticotropin-releasing hormone (CRH), also known as corticotropin-
releasing factor (CRF) (Lupien et al., 2009). The pituitary will then 
respond by producing adrenocorticotropic hormone (ACTH), and 
releasing it into the blood stream. ACTH will bind to its receptor in the 
adrenal gland, which is located above the kidneys, and trigger the 
adrenal cortex to synthesize glucocorticoids, including cortisol, and 
release them into the blood stream (Lupien et al., 2009). 
  Glucocorticoids have two main receptors in the brain, the 
mineralcorticoid receptor (MR) and the glucocorticoid receptor (GR). At 
low concentrations, the MR is the main active receptor, while at high 
concentrations the GR is the main active receptor since all MRs are 
occupied (Reul and de Kloet, 1985; Arriza et al., 1988). 
 The MR and GR are cytoplasmic receptors that translocate to the 
nucleus upon hormone binding (Datson et al., 2001). There, they 
activate as well as suppress transcription of many genes. The system 
is also self-regulating, such that activation of GR triggers a negative 
feedback loop that attenuates the axis and consequently stress-
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hormone production (Lupien et al., 2009). Thus the rate of feedback 
inhibition can have dramatic impact on the length of time that the 
stress hormone system is active. GR is in virtually every tissue of the 
body, helping to coordinate the body’s response to stress; however the 
feedback inhibition primarily occurs in the amygdala, hypothalamus, 
and the pituitary to shut down production. Some systemic functions of 
GR activation other than those affecting mood, decision-making or 
memory function, include increased metabolism and inhibition of 
inflammation (Sapolsky et al., 2000). 
 Cellular role and biochemistry of FKBP51 with focus on steroid 
hormone receptors
 FKBP51 (FK506 binding protein 51) is part of the immunophilin 
family, a superfamily of highly conserved proteins first characterized 
by their ability to bind to immunosuppressant drugs (Barik, 2006). The 
superfamily is divided into two sequence families by the type of 
immunosuppressant to which it binds.  FKBPs are able to bind to 
FK506 and rapamycin, two immunosuppressants of fungal origin. In 
addition to their drug-binding capability, some FK506-binding 
immunophilins are also protein chaperones, with the related but 
apparently separate ability to isomerize proline residues (Barik, 2006).
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FKBP51 (FK-506 Binding Protein 51kDa, p54, FKBP54) was originally 
identified as a novel FK-506 binding protein capable of peptidyl-prolyl 
cis-trans isomerization (PPIase) activity (Wiederrecht et al., 1992). 
PPIases, like FKBP51, are able to change the conformation of proline 
residues, a unique amino acid with the capability of existing in cis and 
trans conformations (Barik, 2006). Proline cis-trans transitions are 
important for proper protein folding (Barik, 2006), yet deletion of the 
N-terminal PPIase domain (FK1) had little effect on FKBP51’s efficacy 
as a chaperone. Instead, the C-terminus of FKBP51, which includes 
three highly degenerate 34-amino-acid repeats known as 
tetratricopeptide repeats (TPRs),  has been found to exhibit 
independent protein-folding activity.
 Up until recently, however, FKBP51 was relatively unstudied, 
particularly because its function in cellular processes was not well 
known.  In fact, it is not understood whether PPIase activity in general 
is necessary for cell viability.  But studies have begun to elucidate its 
role in the biology of the cell. For example, FKBP51 was recently found 
to regulate the phosphorylation of the microtubule associating protein 
tau (MAPT, tau), a protein whose aggregates are a hallmark of 
Alzheimer’s disease (Jinwal et al., 2010). FKBP51, and other 
immunophilins, have also been found to interact with steroid hormone 
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receptor heterocomplexes, an interaction mediated by the chaperone 
heat shock protein 90 (Hsp90) (Chen et al., 1996), (Davies et al., 
2005). 
 Three hormone receptor complexes that interact with FKBP51 
are the glucocorticoid receptor (GR), progesterone receptor (PR), and 
androgen receptor (AR). Each, are transcriptionally active steroid 
hormone receptor complexes whose activation leads to a change in the 
transcription rate of many genes, one of which is FKBP5. Paradoxically, 
FKBP51 also inhibits the activation of GR (Denny et al., 2000) and PR 
(Hubler et al., 2003). These receptors thus have a short negative 
feedback loop built into their activity, while AR, on the other hand, is 
positively regulated by FKBP51 (Denny et al., 2005). Two questions 
arise from the effect of FKBP51 on GR, PR and AR. Is PPIase activity 
necessary? Is binding to Hsp90 necessary?
 The exact mechanism of action within the steroid hormone 
receptor heterocomplex has been difficult to piece together, since the 
importance of PPIase activity of immunophilins is questionable. One 
study analyzing the relative importance of the PPIase and TPR domains 
in squirrel monkey FKBP51 rendered each of the protein domains 
inactive via site-directed mutagenesis and showed that while only the 
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TPR domain was required for FKBP51 to bind to the GR and PR 
complex with Hsp90, both PPIase and TPR domains were required for 
the FKBP51 inhibitory effect on GR to be effective (Denny et al., 2005). 
Other studies, however, showed that PPIase activity is not necessary 
for its inhibitory action on GR(Wochnik et al., 2005) but is necessary 
for its activating action on AR (Ni et al.). All three complexes do 
require Hsp90 for FKBP51 to have an effect, as Hsp90 was found 
necessary to be bound to FKBP51 for it to have its inhibitory action on 
GR (Denny et al., 2005), PR (Hubler et al., 2003), and its activating 
action on AR (Ni et al.). The data indicate that, perhaps due to 
structural reasons, the physical presence of FKBP51 may be more 
important than its PPIase enzymatic activity.
 SNPs and FKBP51 mechanism of action
 Genome-wide association studies (GWAS) have enabled 
scientists to look at small changes in DNA and the effects of single 
base pair variations called single nucleotide polymorphisms (SNPs) on 
gene expression and function. SNPs in FKBP5 have been associated 
with mood disorders and an increased risk for PTSD, suicide, and overt 
aggressive behavior. One particular SNP in the FKBP5 gene, 
rs1360780, was associated with an increased number of depressive 
episodes (Binder et al., 2004). A closer look at the SNP revealed three 
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different polymorphisms possible at the site:  TT homozygotes, CT 
heterozygotes, and CC homozygotes. Association of these SNP 
variations with episodes of depression and responses to antidepressant 
treatment showed that individuals with TT homozygosity had more 
frequent episodes of depression but also a faster recovery from 
antidepressant therapy. SNP association studies were performed with 
FKBP51 and other psychiatric disorders, with findings that FKBP51 
SNPs are also associated with mood disorders, many of which were 
formed in conjunction with childhood trauma. Increased risks of 
developing PTSD (Xie et al., 2010), suicide (Roy et al., 2010; Roy et 
al., 2012), and overt aggressive behavior were also associated with 
certain FKBP51 polymorphisms (Bevilacqua et al., 2012). 
 Mechanistically, the effect of FKBP5 polymorphisms on mood 
disorders is elusive.  One particular area of study is the HPA axis, as 
FKBP51 is a known regulator of HPA-axis activity. The HPA-axis has 
major roles in both PTSD and depression, albeit with opposite 
phenotypes. Patients with Major Depressive Disorder (MDD) have a 
hyperactive HPA-axis, where an increased stimulation of adrenal 
corticotropic hormone (ACTH) and GR desensitization cause high 
amounts of cortisol to be released and retained in the bloodstream. 
PTSD patients, on the other hand, have hypersensitive GR and a 
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hypersuppression of cortisol (Binder, 2009). The SNP rs1360780 is 
thus of great interest here, as it is associated with increased risks of 
both PTSD and depression, despite these diseases having different GR 
sensitivities. For example, the TT genotype may provide mechanistic 
evidence on how FKBP51 could cause HPA-axis dysregulation, as it was 
shown that individuals with TT had higher basal levels of FKBP51 and 
thus very likely a greater inhibition effect on GR activity. However 
Depressed patients with TT genotypes had greater decreases of ACTH 
and cortisol levels in response to the DEX/CRH test than depressed 
patients with CC and TC genotypes. The study did not, however, 
compare the FKBP51 levels of healthy controls with the TT genotype 
versus depressed patients with the same genotype, and so it is unclear 
if FKBP51 levels are higher due to depression or if all people with the 
genotype exhibit increased levels of FKBP51.  Nevertheless healthy 
individuals with the TT genotype were shown to lack a normalization of 
cortisol levels after stress as compared to the CC and CT genotypes; 
TT individuals had higher cortisol levels for a longer period of time 
(Ising et al., 2008). The data from the healthy controls resembled 
those having high FKBP51 levels, and the data of the depressed 
patients resembles those having low FKBP51 levels. 
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 How do we make sense of the fact that people with the same 
genotype had different GR phenotypes depending on the disease 
state? It may be that healthy individuals only have high levels of 
FKBP51 in the short term, but the chronic stress state may increase 
FKBP51 levels in the long term, which could drive adaptive changes in 
GR activity. However, if FKBP51 protein levels were elevated in this 
genotype irrespective of disease state, it may be that another risk 
factor is interacting with FKBP51 to promote depression. In individuals 
with this genotype with probable PTSD, baseline cortisol activity was 
not elevated as compared to healthy controls (Binder et al., 2008), 
while it was in depressed patients (Binder et al., 2004). Thus it is clear 
that while genotypes do not consistently affect GR in the same way, 
the risk for mood disorders is clearly elevated by the rs1360780 SNP. 
This suggests that factors other than just GR must be responsible for 
the differential disease phenotypes. 
 FKBP5 animal models
 Studies of FKBP51 in animal models have proven helpful in 
determining endogenous and stress-response levels of FKBP51 
expression in different regions of the brain. A study of FKBP5 mRNA 
levels in the murine brain discovered that under basal conditions, the 
highest levels occurred in the hippocampus (Scharf et al., 2011), 
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especially the dentate gyrus, and the premammillary nucleus, the 
motor nuclei of the nervus trigeminus and the nervus facialis. 
Interestingly, lower levels of FKBP5 mRNA were found in the amygdala 
and the hypothalamic paraventricular nucleus (PVN), the latter of 
which is a part of the HPA axis and a stress response mediator. 
Stressing the mice, however, showed a marked increase in FKBP5 
mRNA levels in these two regions. Both moderate and short-term 
stress and strong and long-lasting stress caused FKBP5 mRNA levels to 
rise in dose-dependent fashion. Moderate stress was caused through a 
4-hour restrain, and a 1-day food deprivation paradigm was used as 
the long-lasting stressor. Upregulation of FKBP5 mRNA was observed 
in the central amygdala, the hypothalamic PVN, and the hippocampus 
after both conditions, with a stronger response after food deprivation 
in all regions. Injecting the mice with dexamethasone, a corticosteroid 
analog and GR agonist, also increased the levels of FKBP51 mRNA, 
supporting the hypothesis that the stress response and FKBP5 mRNA 
levels are linked to the GR.
 However, while all three regions showed increased levels of 
FKBP5 mRNA, the relative increase differed based on the baseline 
levels already observed in the mouse brain. The hypothalamic PVN and 
the central amygdala, which had low endogenous FKBP5 mRNA levels, 
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had average FKBP5 mRNA increases of over 600% from baseline, while 
the hippocampus, which has a relatively high basal level of FKBP5 
mRNA, had average increases of less than 200%. It appears that 
higher endogenous levels of FKBP5 mRNA caused the GR in those 
particular brain regions to become less responsive to corticosteroid 
stimulation. In cases of chronic stress, constant high levels of stress 
could result in potentially long-term elevated corticosteroid levels, and 
induce high levels of FKBP5 mRNA expression, in turn causing GR 
activity to become resistant.
 Two additional models have been studied intensively, FKBP5-/- 
mice and new world monkeys. Three genera of new world monkeys 
have been discovered to have naturally occurring GR resistance due to 
excess production of FKBP51 (Scammell et al., 2001).  This begs the 
question of whether this affects the behavior of the monkeys. An 
induced model of depression in monkeys exist (Clark and Gay, 1980), 
and extreme social stress causes coronary artery disease (Petticrew 
and Davey Smith, 2012), presumably due to hypercortisolemia, but it 
is not clear whether it is FKBP5 dependent. However, it does suggest 
that the hypercortisolemia seen in humans with depression could be 
aided by a reduction in the levels of FKBP51.
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 The function of the HPA axis was studied in the FKBP51-/- mice. 
The mice displayed a moderate GR hypersensitivity, as they produced 
less corticosterone (the main murine glucocorticoid) and recovered 
faster after dexamethasone (DEX) and stress treatment (Touma et al., 
2011). The DEX/CRH test was compared between FKBP51-/- mice and 
healthy humans of the rs1360780 SNP. Healthy humans with the TT 
genotype displayed GR hyposensitivity to dexamethasone while the 
FKBP51-/- mice displayed GR hypersensitivity, showing that reduction 
in levels of FKBP51 may be a successful therapy for GR insensitivity.
In terms of protein levels and protein expression, FKBP51-/- mice 
exposed to chronic social defeat stress produced equal amounts of 
CRH mRNA as compared to wild type before and after stress, although 
levels did increase after stress (Hartmann et al., 2012). This 
demonstrated that corticosterone levels were not reduced in the 
FKBP51-/- mice due to the lack of HPA activation, but rather due to the 
FKBP51-GR negative feedback mechanism that has been characterized 
so well. It was found, on the other hand, that the lack of FKBP51 alters 
the levels of GR. In wild type mice, GR levels decreased during a 1 hr 
restraint stress experiment, yet  in FKBP5-/- mice they increased at 15 
minutes then went down slightly, but remained significantly higher 
than wild type. It is also possible that FKBP51 may actually be 
regulating the levels of GR, particularly since Hsp90 is intimately linked 
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to proteasomal degradation (Ballatore et al.) and Hsp90 is a part of 
the GR complex.
 Surprisingly, general behavior was not changed in 10-16 week 
old (young) FKBP5-/- mice. As a result, changes in behavior after 
stress were studied. Young FKBP5-/- mice showed significantly less 
time immobile in the forced swim test than wild type mice after 
restraint stress (Touma et al., 2011). Moreover, FKBP51 is a protein 
whose expression increases with age (Jinwal et al., 2010), and young 
mice have low basal levels in the hypothalamus and amygdala. It may 
be that the young mice needed FKBP51 to be expressed after stress to 
modulate behavior, since basal FKBP51 levels were low. Twenty-two 
month old mice (old), however, displayed this phenotype in the forced 
swim test without prior stress (O'Leary et al., 2011). General behavior 
in the old mice was also unchanged, especially in learning and 
memory, implying that FKBP51 may have a role limited to the biology 
of the stress response. But this role may be protective, as stress and 
its related molecules are known to cause cognitive impairment 
(Diamond et al., 1992; de Quervain et al., 1998; Diamond et al., 1999; 
Diamond et al., 2004; Sandi, 2004; Diamond et al., 2005; Diamond et 
al., 2006). 
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 FKBP5 and neuropsin-mediated effects in the amygdala
 Recently, FKBP51 was found to be involved in stress response in 
the amygdala. FKBP51 was found to be upregulated by NMDA 
activation and caused anxiety in mice after stress (Attwood et al., 
2011).  This effect was dependent on the cleavage of EphB2 by 
neuropsin, causing EphB2 to disassociate from the NR1 subunit of the 
NMDA receptor and enhancing NMDA receptor current. Neuropsin is an 
extracellular serine protease and EphB2 is a receptor tyrosine kinase, 
and both are heavily expressed in the amygdala and hippocampus, 
with higher basal expression in the hippocampus, similar to FKBP51. 
After stress, neuropsin is dramatically upregulated in the amygdala. 
This data was not shown in the hippocampus; it would be interesting 
to find out if neuropsin had a similar expression profile to FKBP51 and 
to see the basal and stress-induced expression of FKBP51 in neuropsin 
knockout mice. In amygdala neuronal cell cultures, the majority of 
FKBP51 expression was found to be due to the activity of neuropsin 
and not by corticosterone, and it may be that FKBP51 has a primary 
role in stress behavior in a neuropsin dependent mechanism, and that 
its role with GR is secondary to that. Additionally, despite FKBP51 
expression upregulation by NMDA receptor activation, no effects are 
shown in learning and memory. It may be that a large threshold of 
NMDA receptor activation is needed to trigger the upregulation of 
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FKBP51, and the large threshold would only be reached during 
extreme situations like stress, and thus FKBP5 would be activated to 
promote behavioral signatures of anxiety.
 The need of the FKBP51 gene in the brain is unclear, as it seems 
to be extremely problematic, and its absence does not seem to have 
negative effects. A posited theory for the development of FKBP51 may 
be within the fear response. Evolutionary genetics suggest that these 
genes arose early in development; analysis of phylogenetic 
relationships among 100 FKBP domains show a clustering pattern that 
suggests the emergence of the FKBP genes early in eukaryotic 
evolution (Patterson et al., 2002), and another study suggests that 
FKBP proteins arose even before the divergence of prokaryotes from 
eukaryotes (Trandinh et al., 1992). As a result, FKBP5 may have 
played an important role in the evolution of the stress response.  In 
the past we needed to exhibit a proper response to fear, since the 
reaction was critical to survival. The problem is, we no longer have the 
same life or death triggers.
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Conclusion
 It is clear that FKBP51 is a significant player in the human 
response to stress. It has a dramatic effect on the biology of steroid 
hormone receptors, and is upregulated in the amygdala as part of a 
stress response. SNPs within the FKBP5 gene are associated with 
mood disorders, but the mechanism of how this happens is not well 
understood.  Surprisingly, the lack of FKBP51 does not appear to have 
deleterious side effects in mice and its presence causes steroid 
hormone receptor hypersensitivity. This not only makes FKBP51 an 
excellent drug target, but it also suggests that FKBP5 may be genetic 
baggage that no longer provides a competitive advantage for natural 
selection. As successful adaptation allows for a species to age, genes 
like FKBP5, which at one point during the evolutionary process were 
necessary for their survival and propagation, may actually become 
deleterious to the aging process. Furthermore, societal success no 
longer follows Darwinian principles. As a result, it may be the role of 
society to combat these processes; in the same way that bacteria 
adapt to antibiotic pressure, society may need to develop ways to 
suppress or even remove these genetic leftovers. 
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List of Abbreviations
ACTH: Adrenocorticotropic hormone
AR: Adrogen receptor
CRH/CRF: Corticotropin releasing hormone/factor
FKBP5: Gene name for FKBP51 protein
FKBP51: FK506-binding protein 51
GR: Glucocorticoid receptor
GWAS: Genome-wide association studies
HPA-axis: Hypothalamic-pituitary-adrenal-axis
MDD: Major depressive disorder
MR: Mineralocorticoid receptor
NMDA: N-methyl-D-aspartate
PPIase: Peptydil-prolyl cis-trans Isomerase activity
PR: Progesterone receptor
PTSD: Post-traumatic stress disorder
PVN: Paraventricular nucleus of the hypothalamus
TPR: Tetratricopeptide repeat
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Figure D1. FKBP5 genotype as a modulator of GR phenotype. 
Everyone may be vulnerable to mood disorders involving depression 
following stress. However, the length of time that an individual remains 
vulnerable can be dramatically affected by FKBP51 levels due to its 
ability to decrease GR activity. FKBP51 may widen the length of time 
after stress that a person is susceptible to stress, while individuals with 
low FKBP51 levels may be in this state for a shorter period of time. 
While the magnitude of the acute GR response to stress following an 
insult may be higher in individuals with low FKBP51 levels, the length 
of time that an individual with high levels of FKBP51 spends in a 
susceptible state is longer. As a result, SNP’s in the FKBP5 gene may 
increase the likelihood of developing psychiatric disorders by altering 
the levels of FKBP51. This in turn changes the responsiveness of the 
GR, whose balance appears to be critical for normal function. Thus, in 
MDD, chronic stress may have a greater effect on those individuals 
with too much FKBP51. 
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APPENDIX E:
Sequence of FKBP5 Gene
 It is often that one underestimates the power of that which is 
small. Similarly, we commonly underestimate our potential for great 
achievement, precisely because we are small. Ironically, small things 
can have tremendous impact. Single nucleotide polymorphisms in the 
FKBP5 gene enlarge the size of the stress response, and interact with 
traumatic stress in childhood to dramatically increase the risk of major 
depressive disorder, and post-traumatic stress disorder. Some of these 
polymorphisms are also overrepresented in people who commit 
suicide, and develop bipolar disorder. To appreciate the size of a single 
nucleotide change, I have included the DNA sequence of mRNA 
transcript 1 from the Homo Sapiens FK506 binding protein 51. If a 
single nucleotide can have so much impact, maybe we can too.
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Origin      
GATTCGGGCC GGCTCGCGGG CGCTGCCAGT CTCGGGCGGC 
GGTGTCCGGC GCGCGGGCGG CCTGCTGGGC GGGCTGAAGG 
GTTAGCGGAG CACGGGCAAG GCGGAGAGTG ACGGAGTCGG 
CGAGCCCCCG CGGCGACAGG TTCTCTACTT AAAAGACAAT GACTACTGAT 
GAAGGTGCCA AGAACAATGA AGAAAGCCCC ACAGCCACTG 
TTGCTGAGCA GGGAGAGGAT ATTACCTCCA AAAAAGACAG GGGAGTATTA 
AAGATTGTCA AAAGAGTGGG GAATGGTGAG GAAACGCCGA 
TGATTGGAGA CAAAGTTTAT GTCCATTACA AAGGAAAATT GTCAAATGGA 
AAGAAGTTTG ATTCCAGTCA TGATAGAAAT GAACCATTTG TCTTTAGTCT 
TGGCAAAGGC CAAGTCATCA AGGCATGGGA CATTGGGGTG 
GCTACCATGA AGAAAGGAGA GATATGCCAT TTACTGTGCA AACCAGAATA 
TGCATATGGC TCGGCTGGCA GTCTCCCTAA AATTCCCTCG AATGCAACTC 
TCTTTTTTGA GATTGAGCTC CTTGATTTCA AAGGAGAGGA TTTATTTGAA 
GATGGAGGCA TTATCCGGAG AACCAAACGG AAAGGAGAGG 
GATATTCAAA TCCAAACGAA GGAGCAACAG TAGAAATCCA CCTGGAAGGC 
CGCTGTGGTG GAAGGATGTT TGACTGCAGA GATGTGGCAT 
TCACTGTGGG CGAAGGAGAA GACCACGACA TTCCAATTGG AATTGACAAA 
GCTCTGGAGA AAATGCAGCG GGAAGAACAA TGTATTTTAT ATCTTGGACC 
AAGATATGGT TTTGGAGAGG CAGGGAAGCC TAAATTTGGC ATTGAACCTA 
ATGCTGAGCT TATATATGAA GTTACACTTA AGAGCTTCGA AAAGGCCAAA 
GAATCCTGGG AGATGGATAC CAAAGAAAAA TTGGAGCAGG CTGCCATTGT 
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CAAAGAGAAG GGAACCGTAT ACTTCAAGGG AGGCAAATAC 
ATGCAGGCGG TGATTCAGTA TGGGAAGATA GTGTCCTGGT TAGAGATGGA 
ATATGGTTTA TCAGAAAAGG AATCGAAAGC TTCTGAATCA TTTCTCCTTG 
CTGCCTTTCT GAACCTGGCC ATGTGCTACC TGAAGCTTAG AGAATACACC 
AAAGCTGTTG AATGCTGTGA CAAGGCCCTT GGACTGGACA 
GTGCCAATGA GAAAGGCTTG TATAGGAGGG GTGAAGCCCA 
GCTGCTCATG AACGAGTTTG AGTCAGCCAA GGGTGACTTT 
GAGAAAGTGC TGGAAGTAAA CCCCCAGAAT AAGGCTGCAA 
GACTGCAGAT CTCCATGTGC CAGAAAAAGG CCAAGGAGCA 
CAACGAGCGG GACCGCAGGA TATACGCCAA CATGTTCAAG 
AAGTTTGCAG AGCAGGATGC CAAGGAAGAG GCCAATAAAG 
CAATGGGCAA GAAGACTTCA GAAGGGGTCA CTAATGAAAA 
AGGAACAGAC AGTCAAGCAA TGGAAGAAGA GAAACCTGAG 
GGCCACGTAT GACGCCACGC CAAGGAGGGA AGAGTCCCAG 
TGAACTCGGC CCCTCCTCAA TGGGCTTTCC CCCAACTCAG GACAGAACAG 
TGTTTAATGT AAAGTTTGTT ATAGTCTATG TGATTCTGGA AGCAAATGGC 
AAAACCAGTA GCTTCCCAAA AACAGCCCCC CTGCTGCTGC 
CCGGAGGGTT CACTGAGGGG TGGCACGGGA CCACTCCAGG 
TGGAACAAAC AGAAATGACT GTGGTGTGGA GGGAGTGAGC 
CAGCAGCTTA AGTCCAGCTC ATTTCAGTTT CTATCAACCT TCAAGTATCC 
AATTCAGGGT CCCTGGAGAT CATCCTAACA ATGTGGGGCT GTTAGGTTTT 
ACCTTTGAAC TTTCATAGCA CTGCAGAAAC CTTTAAAAAA AAAATGCTTC 
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ATGAATTTCT CCTTTCCTAC AGTTGGGTAG GGTAGGGGAA GGAGGATAAG 
CTTTTGTTTT TTAAATGACT GAAGTGCTAT AAATGTAGTC TGTTGCATTT 
TTAACCAACA GAACCCACAG TAGAGGGGTC TCATGTCTCC CCAGTTCCAC 
AGCAGTGTCA CAGACGTGAA AGCCAGAACC TCAGAGGCCA 
CTTGCTTGCT GACTTAGCCT CCTCCCAAAG TCCCCCTCCT CAGCCAGCCT 
CCTTGTGAGA GTGGCTTTCT ACCACACACA GCCTGTCCCT GGGGGAGTAA 
TTCTGTCATT CCTAAAACAC CCTTCAGCAA TGATAATGAG CAGATGAGAG 
TTTCTGGATT AGCTTTTCCT ATTTTCGATG AAGTTCTGAG ATACTGAAAT 
GTGAAAAGAG CAATCAGAAT TGTGCTTTTT CTCCCCTCCT CTATTCCTTT 
TAGGGAATAA TATTCAATAC ACAGTACTTC CTCCCAGCAT TGCTACTGCT 
CAGCTTCTTC TTTCATTCTA ATCCTTGCTA TTAAGAATTT AAGACTTGTG 
CTTACAATAT TTTTGACCTG GAGTGGATCT ATTTACATAG TCATTTAGGA 
TCCATGCAGC TTTTTTTGTC TTTTTAAGAT TATTGGCTCA TAAGCATATG 
TATACTGGTT TATGGAACTT TATTTACACT CCTCTATCAT GCAAAAAAAT 
TTTGACTTTT TAGTACTAAG CTTAATTTTT AAAAACAAAA TCTGTAGGGT 
TGACAAATAA ATAGTTGCTC TTCTACACTA GGGGTTTCAC CTGCAGGTTT 
GACACGCAGT TGCTCGCTTT TCCTGCCCTG TCAAGCTTCT CTGTTCTGGC 
GTGAGTTGTG AAAGAGTTGA AGACAGCTTC CCATGCCGGT 
ACACAGCCAG TAGCCTAAAT CTCCAGTACT TGAGCTGACC ATTGAACTAG 
GGCAAGTCTT AAATGTGTAC ATGTAGTTGA ATTTCAGTCC TTACGGGTAA 
ACAGATTGAG CATGGCTCTC TATTCCCTCA GCCTAAGAAA CACTCATGGG 
AATGCATTTG GCAACCCAAG GAACCATTTG CTTAAACCTG GAACATCTCA 
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CCTTTTTAAA TCCTAAAAAA CACTGGCAGT TATATTTTAA ATTAGTTTTT 
ATTTTTATGA TGGTTTTATC AAAAGACTTT TATTATTAGA TTGGGACCCC 
CTTCAAACCT AAAAATCAAG TTATTTCCTT TTATAATACT TTTCTTCCCC 
ATGGAACAAA TGGGATCAAT TTGTGAGTTT TTTCCTTTAA TGATAACTAA 
AATCCCTCTA ATTTCTCATT TATGCTTTTG TCTTTTTTAT GAAATATTTC 
TTTTAAAAGC CCCAGTCTCA CCTACGAAAT ATGAAGAGCA AAAGCTGATT 
TTGCTTACTT GCTAAACTGT TGGGAAAGCT CTGTAGAGCA TGGTTCCAGT 
GAGGCCAAGA TTGAAATTTG ATACTAAAAA GGCCACCTAG CTTTTTGCAG 
ATAACAAACA AGAAAGCTAT TCCAAGACTC AGATGATGCC AGCTGTCTCC 
CACGTGTGTA TTATGGTTCA CCAGGGGGAA CTGGCAAAAG 
TGTGTGTGGG GAGGGGAAGG GTGTGTGAGT GGTTCTGAGC 
AAATAACTAC AGGGTGCCCA TTACCACTCA AGAAGACACT TCACGTATTC 
TTGTATCAAA TTCAATAATC TTAAACAATT TGTGTAGAAG TCCACAGACA 
TCTTTCAACC ACCTTTTAGG CTGCATATGG ATTGCCAAGT CAGCATATGA 
GGAATTAAAG ACATTGTTTT TAAAAAAAAA AAATCATTTA GATGCACTTT 
TTTGTGTGTT CTTTAAATAA ATCCAAAAAA AATGTGACTT CCAAAAAAAA 
AAA
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APPENDIX F:
Permissions 
 This appendix contains the copyright permissions to use the 
material previously published in a journal. 
Chapter Two Permission
 BioMed Central copyright and license agreement
 In submitting a research article ('article') to any of the journals 
published by BioMed Central Ltd ('BioMed Central') I certify that:
1. I am authorized by my co-authors to enter into these 
arrangements.
2. I warrant, on behalf of myself and my co-authors, that:
a.  the article is original, has not been formally published in any 
other peer-reviewed journal, is not under consideration by 
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any other journal and does not infringe any existing copyright 
or any other third party rights;
b.  I am/we are the sole author(s) of the article and have full 
authority to enter into this agreement and in granting rights 
to BioMed Central are not in breach of any other obligation. If 
the law requires that the article be published in the public 
domain, I/we will notify BioMed Central at the time of 
submission upon which clauses 3 through 6 inclusive do not 
apply;
c.  the article contains nothing that is unlawful, libellous, or 
which would, if published, constitute a breach of contract or 
of confidence or of commitment given to secrecy;
d.  I/we have taken due care to ensure the integrity of the 
article. To my/our - and currently accepted scientific - 
knowledge all statements contained in it purporting to be 
facts are true and any formula or instruction contained in the 
article will not, if followed accurately, cause any injury, illness 
or damage to the user.
 And I agree to the following license agreement:
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 BioMed Central Open Access license agreement Brief summary of 
the agreement.
 Anyone is free:
• to copy, distribute, and display the work; 
• to make derivative works; 
• to make commercial use of the work; 
Under the following conditions: Attribution 
• the original author must be given credit; 
• for any reuse or distribution, it must be made clear to others 
what the license terms of 
this work are; 
• any of these conditions can be waived if the authors gives 
permission. 
Statutory fair use and other rights are in no way affected by 
the above. 
Full BioMed Central Open Access license agreement 
(Identical to the 'Creative Commons Attribution License') 
License 
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 THE WORK (AS DEFINED BELOW) IS PROVIDED UNDER THE 
TERMS OF THIS BIOMED CENTRAL OPEN ACCESS LICENSE 
("LICENSE"). THE WORK IS PROTECTED BY COPYRIGHT AND/OR 
OTHER APPLICABLE LAW. ANY USE OF THE WORK OTHER THAN AS 
AUTHORIZED UNDER THIS LICENSE IS PROHIBITED.
 BY EXERCISING ANY RIGHTS TO THE WORK PROVIDED HERE, 
YOU ACCEPT AND AGREE TO BE BOUND BY THE TERMS OF THIS 
LICENSE. THE LICENSOR GRANTS YOU THE RIGHTS CONTAINED HERE 
IN CONSIDERATION OF YOUR ACCEPTANCE OF SUCH TERMS AND 
CONDITIONS.
1. Definitions
a. "Collective Work" means a work, such as a periodical issue, 
anthology or encyclopedia, in which the Work in its entirety in 
unmodified form, along with a number of other contributions, 
constituting separate and independent works in themselves, 
are assembled into a collective whole. A work that constitutes 
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a Collective Work will not be considered a Derivative Work (as 
defined below) for the purposes of this License. 
b. "Derivative Work" means a work based upon the Work or 
upon the Work and other pre-existing works, such as a 
trans lat ion, musica l arrangement, dramat izat ion, 
fictionalization, motion picture version, sound recording, art 
reproduction, abridgment, condensation, or any other form in 
which the Work may be recast, transformed, or adapted, 
except that a work that constitutes a Collective Work will not 
be considered a Derivative Work for the purpose of this 
License. For the avoidance of doubt, where the Work is a 
musical composition or sound recording, the synchronization 
of the Work in timed-relation with a moving image 
("synching") will be considered a Derivative Work for the 
purpose of this License. 
c. "Licensor" means the individual or entity that offers the Work 
under the terms of this License. 
d. "Original Author" means the individual or entity who created 
the Work. 
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e. "Work" means the copyrightable work of authorship offered 
under the terms of this 
License. 
f. "You" means an individual or entity exercising rights under 
this License who has not previously violated the terms of this 
License with respect to the Work, or who has received express 
permission from the Licensor to exercise rights under this 
License despite a previous violation. 
 2. Fair Use Rights
 Nothing in this license is intended to reduce, limit, or restrict any 
rights arising from fair use, first sale or other limitations on the 
exclusive rights of the copyright owner under copyright law or other 
applicable laws.
 3. License Grant
 Subject to the terms and conditions of this License, Licensor 
hereby grants You a worldwide, royalty-free, non-exclusive, perpetual 
(for the duration of the applicable copyright) license to exercise the 
rights in the Work as stated below:
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a. to reproduce the Work, to incorporate the Work into one or 
more Collective Works, and to reproduce the Work as 
incorporated in the Collective Works; 
b. to create and reproduce Derivative Works; 
c. to distribute copies or phonorecords of, display publicly, 
perform publicly, and perform publicly by means of a digital 
audio transmission the Work including as incorporated in 
Collective Works; 
d. to distribute copies or phonorecords of, display publicly, 
perform publicly, and perform publicly by means of a digital 
audio transmission Derivative Works; 
e. For the avoidance of doubt, where the work is a musical 
composition: 
i. Performance Royalties Under Blanket Licenses. Licensor 
waives the exclusive right to collect, whether individually or 
via a performance rights society (e.g. ASCAP, BMI, SESAC), 
royalties for the public performance or public digital 
performance (e.g. webcast) of the Work. 
ii. Mechanical Rights and Statutory Royalties. Licensor waives 
the exclusive right to collect, whether individually or via a 
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music rights agency or designated agent (e.g. Harry Fox 
Agency), royalties for any phonorecord You create from the 
Work ("cover version") and distribute, subject to the 
compulsory license created by 17 USC Section 115 of the US 
Copyright Act (or the equivalent in other jurisdictions). 
f. Webcasting Rights and Statutory Royalties. For the avoidance 
of doubt, where the Work is a sound recording, Licensor 
waives the exclusive right to collect, whether individually or 
via a performance-rights society (e.g. SoundExchange), 
royalties for the public digital performance (e.g. webcast) of 
the Work, subject to the compulsory license created by 17 
USC Section 114 of the US Copyright Act (or the equivalent in 
other jurisdictions). 
 The above rights may be exercised in all media and formats 
whether now known or hereafter devised. The above rights include the 
right to make such modifications as are technically necessary to 
exercise the rights in other media and formats. All rights not expressly 
granted by Licensor are hereby reserved.
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 4. Restrictions
 The license granted in Section 3 above is expressly made subject 
to and limited by the following restrictions:
a. You may distribute, publicly display, publicly perform, or 
publicly digitally perform the Work only under the terms of 
this License, and You must include a copy of, or the Uniform 
Resource Identifier for, this License with every copy or 
phonorecord of the Work You distribute, publicly display, 
publicly perform, or publicly digitally perform. You may not 
offer or impose any terms on the Work that alter or restrict 
the terms of this License or the recipients' exercise of the 
rights granted hereunder. You may not sublicense the Work. 
You must keep intact all notices that refer to this License and 
to the disclaimer of warranties. You may not distribute, 
publicly display, publicly perform, or publicly digitally perform 
the Work with any technological measures that control access 
or use of the Work in a manner inconsistent with the terms of 
this License Agreement. The above applies to the Work as 
incorporated in a Collective Work, but this does not require 
the Collective Work apart from the Work itself to be made 
subject to the terms of this License. If You create a Collective 
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Work, upon notice from any Licensor You must, to the extent 
practicable, remove from the Collective Work any reference to 
such Licensor or the Original Author, as requested. If You 
create a Derivative Work, upon notice from any Licensor You 
must, to the extent practicable, remove from the Derivative 
Work any reference to such Licensor or the Original Author, as 
requested. 
b. If you distribute, publicly display, publicly perform, or publicly 
digitally perform the Work or any Derivative Works or 
Collective Works, You must keep intact all copyright notices 
for the Work and give the Original Author credit reasonable to 
the medium or means You are utilizing by conveying the 
name (or pseudonym if applicable) of the Original Author if 
supplied; the title of the Work if supplied; to the extent 
reasonably practicable, the Uniform Resource Identifier, if any, 
that Licensor specifies to be associated with the Work, unless 
such URI does not refer to the copyright notice or licensing 
information for the Work; and in the case of a Derivative 
Work, a credit identifying the use of the Work in the 
Derivative Work (e.g., "French translation of the Work by 
Original Author," or "Screenplay based on original Work by 
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Original Author"). Such credit may be implemented in any 
reasonable manner; provided, however, that in the case of a 
Derivative Work or Collective Work, at a minimum such credit 
will appear where any other comparable authorship credit 
appears and in a manner at least as prominent as such other 
comparable authorship credit.
 5. Representations, Warranties and Disclaimer
UNLESS OTHERWISE MUTUALLY AGREED TO BY THE PARTIES IN 
WRITING, LICENSOR OFFERS THE WORK AS-IS AND MAKES NO 
REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE 
WORK, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING, 
WITHOUT LIMITATION, WARRANTIES OF TITLE, MERCHANTIBILITY, 
FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR THE 
ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY, OR THE 
PRESENCE OF ABSENCE OF ERRORS, WHETHER OR NOT 
DISCOVERABLE. SOME JURISDICTIONS DO NOT ALLOW THE 
EXCLUSION OF IMPLIED WARRANTIES, SO SUCH EXCLUSION MAY 
NOT APPLY TO YOU.
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 6. Limitation on Liability
 EXCEPT TO THE EXTENT REQUIRED BY APPLICABLE LAW, IN NO 
EVENT WILL LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY 
FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR 
EXEMPLARY DAMAGES ARISING OUT OF THIS LICENSE OR THE USE 
OF THE WORK, EVEN IF LICENSOR HAS BEEN ADVISED OF THE 
POSSIBILITY OF SUCH DAMAGES.
 7. Termination
a. This License and the rights granted hereunder will terminate 
automatically upon any breach by You of the terms of this 
License. Individuals or entities who have received Derivative 
Works or Collective Works from You under this License, 
however, will not have their licenses terminated provided such 
individuals or entities remain in full compliance with those 
licenses. Sections 1, 2, 5, 6, 7, and 8 will survive any 
termination of this License. 
b. Subject to the above terms and conditions, the license 
granted here is perpetual (for the duration of the applicable 
copyright in the Work). Notwithstanding the above, Licensor 
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reserves the right to release the Work under different license 
terms or to stop distributing the Work at any time; provided, 
however that any such election will not serve to withdraw this 
License (or any other license that has been, or is required to 
be, granted under the terms of this License), and this License 
will continue in full force and effect unless terminated as 
stated above. 
 8. Miscellaneous
a. Each time You distribute or publicly digitally perform the Work 
or a Collective Work, the Licensor offers to the recipient a 
license to the Work on the same terms and conditions as the 
license granted to You under this License. 
b. Each time You distribute or publicly digitally perform a 
Derivative Work, Licensor offers to the recipient a license to 
the original Work on the same terms and conditions as the 
license granted to You under this License. 
c. If any provision of this License is invalid or unenforceable 
under applicable law, it shall not affect the validity or 
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enforceability of the remainder of the terms of this License, 
and without further action by the parties to this agreement, 
such provision shall be reformed to the minimum extent 
necessary to make such provision valid and enforceable. 
d. No term or provision of this License shall be deemed waived 
and no breach consented to unless such waiver or consent 
shall be in writing and signed by the party to be charged with 
such waiver or consent. 
e. This License constitutes the entire agreement between the 
parties with respect to the Work licensed here. There are no 
understandings, agreements or representations with respect 
to the Work not specified here. Licensor shall not be bound by 
any additional provisions that may appear in any 
communication from You. This License may not be modified 
without the mutual written agreement of the Licensor and 
You.
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Chapter Three Permission
PLoS One
Open-Access License 
No Permission Required
 PLOS applies the Creative Commons Attribution License (CCAL) 
to all works we publish (read the human-readable summary or the full 
license legal code). Under the CCAL, authors retain ownership of the 
copyright for their article, but authors allow anyone to download, 
reuse, reprint, modify, distribute, and/or copy articles in PLOS 
journals, so long as the original authors and source are cited. No 
permission is required from the authors or the publishers.
 In most cases, appropriate attribution can be provided by simply 
citing the original article (e.g., Kaltenbach LS et al. (2007) Huntingtin 
Interacting Proteins Are Genetic Modifiers of Neurodegeneration. PLOS 
Genet 3(5): e82. doi:10.1371/journal.pgen.0030082). If the item you 
plan to reuse is not part of a published article (e.g., a featured issue 
image), then please indicate the originator of the work, and the 
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volume, issue, and date of the journal in which the item appeared. For 
any reuse or redistribution of a work, you must also make clear the 
license terms under which the work was published.
 This broad license was developed to facilitate open access to, 
and free use of, original works of all types. Applying this standard 
license to your own work will ensure your right to make your work 
freely and openly available. Learn more about open access. For queries 
about the license, please contact us.
Appendix B Permission
 Copyright Permission Policy
 These guidelines apply to the reuse of articles, figures, charts 
and photos in the Journal of Biological Chemistry, Molecular & Cellular 
Proteomics and the Journal of Lipid Research.
 For authors reusing their own material:
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 Authors need NOT contact the journal to obtain rights to reuse 
their own material. They are automatically granted permission to do 
the following:
• Reuse the article in print collections of their own writing.
Present a work orally in its entirety.
Use an article in a thesis and/or dissertation.
Reproduce an article for use in the author's courses. (If the 
author is employed by an academic institution, that institution 
also may reproduce the article for teaching purposes.)
• Reuse a figure, photo and/or table in future commercial and 
noncommercial works. Post a copy of the paper in PDF that 
you submitted via BenchPress.
Link to the journal site containing the final edited PDFs 
created by the publisher.
 EXCEPTION: If authors select the Author’s Choice publishing 
option:
 The final version of the manuscript will be covered under the 
Creative Commons Attribution license (CC BY), the most 
accommodating of licenses offered. Click here for details.
The final version of the manuscript will be released immediately on the 
publisher’s website and PubMed Central.
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 Please note that authors must include the following citation when 
using material that appeared in an ASBMB journal: "This research was 
originally published in Journal Name. Author(s). Title. Journal Name. 
Year; Vol:pp-pp. © the American Society for Biochemistry and 
Molecular Biology."
 For other parties using material for noncommercial use:
Other parties are welcome to copy, distribute, transmit and adapt the 
work — at no cost and without permission — for noncommercial use as 
long as they attribute the work to the original source using the citation 
above.
 Examples of noncommercial use include: Reproducing a figure 
for educational purposes, such as schoolwork or lecture presentations, 
with attribution. Appending a reprinted article to a Ph.D. dissertation, 
with attribution.
 For other parties using material for commercial use:
Navigate to the article of interest and click the "Request Permissions" 
button on the middle navigation bar. (See diagram at right.) It will 
walk you through the steps for obtaining permission for reuse.
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Examples of commercial use by parties other than authors include:
Reproducing a figure in a book published by a commercial publisher. 
Reproducing a figure in a journal article published by a commercial 
publisher.
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SPRINGER LICENSE TERMS AND CONDITIONS
 This is a License Agreement between John C O'Leary ("You") and 
Springer ("Springer") provided by Copyright Clearance Center ("CCC"). 
The license consists of your order details, the terms and conditions 
provided by Springer, and the payment terms and conditions.
All payments must be made in full to CCC. For payment instructions, 
please see information listed at the bottom of this form.
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License Number: 3150350457452
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Licensed content publisher: Springer
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 The publisher for this copyrighted material is Springer Science + 
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